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Abstract 
Non-immune islet -cell susceptibility to failure 
in NODk mice 
NODk mice are congenic for the protective MHC H2k (Idd 1 locus) and unlike NOD 
mice do not develop autoimmune diabetes. The aim of the study was to determine if 
NODk β-cells have a non-immune islet -cell defect that may be revealed by stressing 
the islets with high fat diet (HFD). B10k (B10.Br mice with H2k haplotype) and Balb/c 
mice were used as comparator groups.  
Male NODk, B10k and Balb/c mice were fed chow or HF diets from 4 weeks of age for 
10 weeks (short-term study) and 20 weeks (long-term study). Body weight and 9 AM  
fed-state blood glucose levels were measured fortnightly. At 13 and 23 weeks of age 
intraperitoneal glucose tolerance tests (ipGTT) were performed for both studies. NODk 
mice were refreshed by backcrossing on to NOD mice (NODk-REF) and preliminary 
experiments were performed to determine the effects of HF-feeding. NODk-REF mice 
were also fed chow or HF-diet from weaning, with fortnightly body weight and fed-
state blood glucose measurements, and ipGTTs were performed after 9 and 20 weeks on 
diets. At sacrifice, the pancreases were harvested for histological assessment, including; 
islet morphology, islet inflammation, -cell apoptosis, insulin immunohistochemistry 
and -cell mass measurement.  
Despite excellent glucose tolerance at all ages on chow diet, HF-fed NODk mice 
developed diet-induced obesity, profound hyperinsulinemia and diabetes by 13 weeks of 
age. Severe hyperglycaemia caused several NODk mice to be euthanased prior to 
completing the long-term study. B10k mice had poor glucose tolerance on chow diet 
only, but despite some HF-diet induced excessive weight gain, they did not develop 
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severe hyperinsulinemia or progress onto diabetes. Balb/c mice maintained excellent 
glucose tolerance on both diets. Analyses of the pancreas histology does not indicate 
that diabetes in the HF-fed NODk mice is due to insulitis. Islet -cell mass initially 
increased in HF-fed NODk mice, but finally began to decrease in the long-term cohort, 
accompanied by the presence of occasional apoptosis in endocrine cells in the islets of 
these mice. 
The pancreas histological features of the B10k and Balb/c mice did not indicate failure 
of  -cell mass compensatory effects with HF-feeding.  
Many of the effects of HF-feeding of NODk mice were seen in the HF-fed NODk-REF 
mice, except for the development of diabetes. This suggests that the NODk mice have an 
additional islet -cell susceptibility to failure compared to the NODk-REF mice.        
These preliminary results indicate that a major diabetes susceptibility factor present in 
the NODk mice, important for type 2 diabetes (T2D) development, is not necessary for 
the development of type 1 diabetes (T1D). 
In conclusion, NODk mice are prone to a severe type 2 diabetes (T2D) phenotype when 
fed a HF-diet. Underlying non-immune islet susceptibility factors may contribute to the 
propensity of NOD mice to develop T1D and the NODk mice to develop T2D. These 
results are also consistent with the -cell overwork hypothesis in diabetes pathogenesis 
as seen in NODk mice. In addition, these results show that -cell underwork or “lazy” -
cells in B10k mice may protect them from more severe failure. 
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Ach:                     acetylcholine 
Ach-R: acetylcholine receptor. 
ADP: adenosine diphosphate 
ARC: Animal Resource Centre 
ATP: adenosine triphosphate 
B10k : B10.BR-H2K2H2-T18a/SgSnJArc 
B10k.insHEL: B10k transgenic 
BETA2: beta-cell E-box transactivator 2 
BSA:  BSA phosphate buffer 
CoA: coenzyme A 
C-peptide:  connecting peptide 
CTS:  cataract Shionogi sublines 
Cyclic AMP: Cyclic adenosine monophosphate 
DAB: 3,3’-Diaminobenzidine 
DAG:  diacylglycerides 
DPP:  diabetes prevention program  
EDTA:  ethylenediaminotetraacetic acid 
ER: endoplasmic reticulum 
FA:  fatty acid 
FBS:  fetal bovine serum 
FFAR1:  free fatty acid receptor 1 
GABA:  γ-amino butyric acid 
GHS-R1a:  growth hormone secretagogue receptor type 1a 
GIP: gastrointestinal inhibitory polypeptide 
GIP-R: gastric inhibitory polypeptide receptor 
GL:  glycerolipid 
GLP-1: glucagon-like peptide 1 
GLP-2: glucagon-like peptide 2 
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GLUT-4:          insulin-sensitive glucose transporter-4 
GSIS:               glucose-stimulated insulin secretion 
H2O2:                        hydrogen peroxide 
HEL:                Hen Egg lysosomal  
HFD:                high fat diet 
HLA:                Human Leukocyte Antigen 
HNF:                 hepatocyte nuclear factor  
HRP:                 horse-radish peroxidase 
IAPP:                islet amyloid polypeptide 
Idd:                   insulin dependent diabetes  
IGT:                  impaired glucose tolerance  
IPF-1:     insulin promoter factor 1 
 
ipGTT:              Intraperitoneal glucose tolerance test 
ipITT:                Intraperitoneal insulin tolerance tests 
IRS-1:                insulin receptor substrate-1  
LC-CoA:            long-chain acyl-CoA 
MAG:                 monoacylglycerides 
Mal-CoA:           malonyl-CoA 
MCFs:                metabolic coupling factors 
MHC:                 major histocompatibility complex  
MODY:              maturity onset diabetes of the young 
MODY2:            Glucokinase-related MODY 
NADPH:            nicotinamide adenine dinucleotide phosphate 
NBF:                   neutral buffered formalin 
NEFA:                 Non-esterified fatty acids 
NeuroD1:            neurogenic differentiation factor 1  
NGT:                 normal glucose tolerance  
NK:                    natural killer 
NOD:                 Non-Obese Diabetic mouse 
NODk :               NOD.BR-H2k/WickerANU 
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NODk.insHEL:  NODk transgenic 
NODk-REF:       NODk-Refreshed 
NPY:  neuropeptide Y 
OAA: oxaloacetate 
ob/ob: obese mouse 
PBS: phosphate buffered saline 
PC: prohormone convertases 
PC:  pyruvate carboxylase 
PDH: pyruvate dehydrogenase 
PEG: polyethylene glycol-sodium phosphate buffer 
PP: pancreatic polypeptide 
PYY: peptide YY 
REF: Refreshed  
rER:  rough endoplasmic reticulum 
RIA:  insulin radioimmunoassay 
SNPs:  single-nucleotide polymorphisms  
SRP:  signal recognition particles 
SSN-R:  somatostatin receptor 
SST:  somatostatin 
SUR1:  sulphonylurea receptor 
TG:  triacylglycerides 
TMB:  3’,5,5’-tetramethylbenzidine 
α-ADR-R:  α2-adrenergic receptor 
α-cells:   alpha cells 
δ-cells:   delta cells 
Δψm:   change in plasma membrane potential 
-cell:   beta-cell 
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1.1 Introduction 
 
Type 1 diabetes results from the destruction of insulin-producing pancreatic islet -cell 
by a -cell-specific autoimmune process. Cytotoxic T cells are believed to be 
particularly important in this process, but -cell autoantigens, and other immune 
effector cells such as macrophages/dendritic cells and B lymphocytes are also involved 
(Mannering et al., 2016). Genetic susceptibility is believed to be an essential component 
type 1 diabetes to develop (She and Marron, 1998). The genetic susceptibility is most 
strongly carried within a restricted set of class II major histocompatibility complex 
(MHC) alleles (Yoon and Jun, 2005). The autoimmune assault against the -cell causes 
progressive β-cell death with 70-80% reduction in the -cell mass by the time of 
diagnosis (Thomas et al., 2009). Thus, type 1 diabetes is considered to be primarily a 
result of dysfunction of the immune system directed at islet -cells. 
The pathogenesis of type 2 diabetes is more variable, with different degrees of β-cell 
failure along with varying degrees of insulin resistance (Cnop et al., 2005, Nolan et al., 
2011). Overweight and obesity results in insulin resistance which needs to be 
compensated by increased insulin secretion for normoglycaemia to be maintained. If 
this compensatory islet -cell response fails, glucose intolerance develops which is later 
followed by type 2 diabetes (Turner et al., 1995, Nolan et al., 2011).  
The mechanisms underlying the development of islet -cell failure in type 2 diabetes are 
believed to be very different to those causing type 1 diabetes. It results from a 
combination of reduced islet -cell function and loss of β-cell mass (Butler et al., 2003, 
Nolan et al., 2011). However, there is clearly marked heterogeneity in the pathogenesis 
of the -cell failure. This is likely to depend on the effects of both genetic background 
and life-style factors such as diet and exercise (Nolan et al., 2011). There has also been 
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recent interest into the potential role of the immune system and islet inflammation in        
-cell failure in type 2 diabetes (Donath et al., 2013). 
With improved technologies in determining genetic origins of diabetes, there is 
increasing evidence of marked genetic heterogeneity underlying both type 1 and type 2 
diabetes and increased interest in overlap of the two conditions, with the likelihood of 
some common mechanisms in -cell failure in both types of diabetes being high (Nolan 
and Delghingaro-Augusto, 2014, Tuomi et al., 2014, Cnop et al., 2013, Eizirik et al., 
2012). It is well recognised that islet -cells in type 2 diabetes almost certainly have 
intrinsic non-immune susceptibilities to failure. Unknown is if these same non-immune 
susceptibility factors contribute to the pathogenesis of type 1 diabetes (Nolan and 
Delghingaro-Augusto, 2014). 
The non-obese diabetic (NOD) mouse has been a key animal model for studying type 1 
diabetes. NOD mice develop autoimmune diabetes at a high rate (70-90% in females, 
10-40% in males) by 4-6 months of age. Genetic studies in these mice have identified 
more than 20 insulin dependent diabetes (Idd) loci, many of which have been shown to 
have effects on the immune system. The strongest individual locus in NOD mice is Idd1 
containing the major histocompatibility gene (MHC) complex, H2 (Wicker et al., 1995, 
Thayer et al., 2010). Of relevance to this thesis, congenic replacement of the high risk 
H2g7 MHC haplotype with the low risk allele H2k in NOD mice prevents them from 
developing insulitis and type 1 diabetes (Podolin et al., 1993, Dooley et al., 2016). 
From previous work from my laboratory on NODk mice that are congenic for this low 
risk H2k MHC (thus the nick-named NODk mice), we believe that NOD mice do have a 
non-immune -cell susceptibility (Dooley et al., 2016). In that work, the effects of 
stressing the islet -cells of NODk and B10.Br mice (nick-named B10k, as they have the 
same low-risk MHC) by islet -cell specific transgenic expression of modified Hen Egg 
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lysosomal (HEL) was assessed (insHEL transgenic mice). Expression of the HEL 
transgene in -cells driven by the insulin promoter resulted in -cell stress in all 
transgenic mice (male and female NODk.insHEL and B10k.insHEL), however, diabetes 
developed in male NODk.insHEL mice only. This diabetes was not a consequence of 
islet autoimmune damage, but islet -cell apoptosis and loss of -cell mass was seen in 
these mice (Dooley et al., 2016). As the B10k mice did not develop diabetes, despite this 
-cell stress, the conclusion was that NOD mice have a non-immune -cell defect, most 
likely of genetic origin (Dooley et al. 2016). The work of this thesis takes these findings 
further. 
1.2. Research hypothesis and objectives 
 
1.2.1. Hypothesis 
 
Non-immune -cell susceptibility factors contribute in the initiation of β-cell damage 
and pathogenesis of type 1 diabetes in NOD mice.  
1.2.2. Objectives of the study 
 
1.2.2.1. Overall objective 
 
The primary objective of the project was to utilise the effects of high fat feeding rather 
than a molecular islet stressor (HEL transgene) to determine if a susceptibility defect of 
a non-immune nature is present in islet -cells of the NODk mouse. 
1.2.2.2. Specific objectives 
 
In order to achieve the primary objective of the thesis, the following specific objectives 
or aims were formulated: 
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1. To study the metabolic characteristics of NODk mice, along with two comparison 
strains (B10k and Balb/c), after 10 weeks of chow and high fat diet feeding from the 
time of weaning (short-term study). 
2. To study the metabolic characteristics of NODk mice, along with two comparison 
strains (B10k and Balb/c), after 20 weeks of chow and high fat diet feeding from the 
time of weaning (long-term study). 
3. To study the histology of the pancreases of NODk, B10k and Balb/c mice after 10 
and 20 weeks of chow and high fat diet feeding, with particular interest on islet 
morphology, islet inflammation, -cell apoptosis and -cell mass measurement. 
This thesis is divided into 7 chapters: Chapter 1 provides an introduction to the research, 
and literature review on diabetes, role of insulin in the pathogenesis of diabetes, its 
function, processing and steps involved in the secretion of insulin. This chapter also 
briefly discusses about the mice models used in the study. Chapter 2 provides a 
complete description of the procedures and experimental set-ups used in this study. 
Chapter 3 describes the metabolic results and discussion obtained from the 
characterisation of mice strains during a short-term study (10 weeks on chow or high fat 
(HF) diet post-weaning). Chapter 4 describes the metabolic results and discussion 
obtained from the characterisation of mice strains during a long-term study (20 weeks 
on chow or high fat (HF) diet post-weaning). Chapter 5 describes the histological 
analyses of the pancreases at the time of harvest, along with the results of -cell mass, 
for mice of both the short and long-term studies. Chapter 6 shows the results from a 
preliminary study of a refreshed NODk mice colony (NODk-REF). The final chapter, 
Chapter 7, is a discussion of the overall findings of the thesis research, highlighting its 
significance, reflecting on its limitations and finally some concluding remarks and 
recommendations related to the future research direction. 
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1.3. Literature Review 
 
Briefly, this literature review is sub-divided into five sections, addressing: 
I. Diabetes an overview 
II. Pancreas and its hormones 
III. Insulin structure and function 
IV. The mechanisms of insulin secretion 
V. Introduction to the animal models used in this thesis 
1.3.1. Diabetes: an overview 
 
Diabetes mellitus (Diabetes) is a chronic condition marked by high levels of glucose in 
the blood. This condition is caused by the inability of the -cell of pancreas to produce 
insulin or of the insulin that is produced to be effective, or both (Assal and Groop, 
1999). 
Diabetes is undoubtedly one of the most challenging health problems in the 21st century. 
Diabetes is on the rise in Australia and across the world, and at times it is referred as an 
epidemic (Barr et al., 2006, Colagiuri et al., 2006). Lifestyle related factors such as 
eating disorder, obesity and inactive lifestyle play a contributory role in the onset of 
type 2 diabetes. In recent years, there has been progress in the development of 
behavioural strategies to modify these lifestyle behaviours for the prevention and 
treatment of the disease (Wing et al., 2001). 
Diabetes mellitus comprises a series of clinically and genetically heterogeneous 
disorders of carbohydrate, fat and protein metabolism, with the common characteristic 
of hyperglycaemia. The prevalence of diabetes increases with age, from less than 1% of 
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western populations affected before age 20 to more than 13% above age 75. 
Approximately 90% of adult patients with diabetes have type 2 diabetes, previously 
referred to as non-insulin dependent, in which the hyperglycaemia is caused by a failure 
of insulin secretion to sustain compensation for insulin resistance. Sustained 
hyperglycaemia can lead to a number of medical complications broadly classified into 
macrovascular (coronary artery disease, peripheral arterial disease and stroke) and 
microvascular categories.  
1.3.1.1. Type 1 Diabetes  
 
Type 1 diabetes, previously termed juvenile-onset or insulin-dependent diabetes, is an 
autoimmune disease and a metabolic disorder characterized by T-cell-mediated 
destruction of pancreatic β cells, resulting in insulin deficiency and hyperglycaemia. 
The aetiology of type 1 diabetes is thought to include a genetic predisposition which 
interacts with environmental factors with distinctive phases of initiation, development 
and progression of the disease (Burn, 2010). 
Type 1 diabetes research is focussed partly by the search for environmental “triggers” of 
the disease (Todd, 2010). The environmental risk determinants can be classified into 
three groups: viral infections (e.g. coxsackievirus and cytomegalovirus), early infant 
diet (e.g. breast feeding versus early introduction of cow's milk components), and toxins 
(e.g. N-nitroso derivatives) (Atkinson and Eisenbarth, 2001). Treatment for type 1 
diabetes is exogenous insulin therapy guided by monitoring of blood glucose levels 
(Tamborlane et al., 2008). Optimally insulin therapy should be “intensive” consisting of 
three or more daily injections of insulin or delivery of insulin by an external insulin 
pump. Dose adjustments are based on at least four self-monitored glucose 
measurements per day.  Intensive diabetes therapy has found to have long-term 
beneficial effects on type 1 diabetes, particularly microvascular, but with longer-term 
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follow-up, also macrovascular complications rates (Nathan DM et al., 1993, Nathan DM 
et al., 2005). 
1.3.1.1.1. Major histocompatibility complex (MHC) and type 1 Diabetes 
 
In humans, the MHC is known as the HLA, (Human Leukocyte Antigen) complex and 
contains over 200 genes. It is located on chromosome 6 and encodes HLA class I and 
class II molecules. The main function of these molecules, which are heterodimers made 
up of  and  chains, is to present antigens that have been processed into peptides to 
antigen-specific receptors on CD4+ and CD8+T lymphocytes. Class I molecules are 
expressed on most nucleated cells, and are encoded by genes within the HLA-A, B, and 
C loci, whereas class II molecules, are primarily expressed on antigen presenting cells 
and are encoded by genes within the HLA-DP, -DQ, and -DR loci (Notkins, 2002). 
While the MHC class II genotype is one of the strongest factors determining 
susceptibility to type 1 diabetes, it has long been apparent that susceptibility at MHC 
class II is a necessary but not sufficient predisposing genetic factor (Bertrams and Baur, 
1985).  
The NOD mouse spontaneously develops autoimmune type 1 diabetes; it is a key 
animal model for the study of autoimmune destruction of islet -cells. Multiple genes 
are involved in the development of diabetes and the MHC region of the NOD mouse 
encompasses an Idd gene, termed Iddl. The NOD allele at Idd1 is H2g7, a dominant 
gene, which is strongly associated with insulitis and spontaneous diabetes (Wicker et 
al., 1992, Podolin et al., 1993, Wicker et al., 1995). 
  Destruction of -cells in the NOD mouse occurs by penetration of mononuclear 
infiltrates, primarily of CD4+ T cells, along with CD8+ T cells, however, NK (natural 
killer) cells, B cells, dendritic cells, and macrophages can also be identified in the 
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lesions (Makino et al., 1980a). However, NOD disease is primarily dependent on CD4+ 
and CD8+ T cells (Bach, 1994). 
 1.3.1.2. Type 2 Diabetes 
 
Type 2 diabetes mellitus is a chronic metabolic disorder that results from defects in both 
insulin secretion and insulin action (DeFronzo, 1999, Nolan et al., 2011). A steady rise 
in plasma glucose occurs irrespective of the degree of control or type of treatment 
(Turner et al., 1998). Type 2 diabetes results from the interaction between 
environmental risk factors, such as modern life style, abundant nutrient supply and 
reduced physical activity and also genetic predisposition (Prentki and Nolan, 2006a). 
Although the genetic basis of type 2 diabetes is yet to be fully elucidated (Tuomilehto et 
al., 2001), certain environmental and lifestyle factors, such as reduced physical 
activity poor diet quality, are likely non genetic determining factors (Zimmet, 1988). 
Diet is known to influence body weight and thus is recognized as a modifiable risk 
factor for type 2 diabetes (Meyer et al., 2000). There are number of prospective 
randomised controlled studies such as the Diabetes Prevention Program (DPP) in the 
USA (Knowler et al., 2002), the 6 years Malmo feasibility study (Eriksson and 
Lindgärde, 1991), and the Finnish Diabetes Prevention Study (Tuomilehto et al., 2001), 
that showed that lifestyle modification involving diet and enhanced physical activity 
helps to delay or prevent the progression of impaired glucose tolerance (IGT) to 
diabetes. The Nurses' Health Study performed on a large cohort of middle-aged women, 
suggest that the majority of cases of type 2 diabetes could be prevented by weight loss, 
regular exercise, modification of diet, abstinence from smoking, and the consumption of 
limited amounts of alcohol (Hu et al., 2001). Similarly a 6 year follow up study of older 
Iowa women support inverse associations between total and whole-grain intake and risk 
of incident diabetes (Meyer et al., 2000). Dietary fibre is reported to improve the 
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postprandial glycaemic response and insulin concentrations, most likely by slowing the 
digestion and absorption of food and by regulating several metabolic hormones (Vinik 
and Jenkins, 1988). 
 1.3.1.2.1. Pathophysiology of Type 2 Diabetes 
 
Type 2 diabetes is characterised by hyperglycaemia as a consequence of failed islet             
-cell compensation for insulin resistance, most often in subjects who are overweight or 
obese (Nolan et al., 2011). For years the hyperglycaemia was put down relatively 
simply to a failure of insulin-induced uptake into peripheral tissues such as skeletal 
muscle and elevated endogenous glucose production by the liver, partly due to insulin 
resistance and partly due to inadequate insulin secretion (DeFronzo, 2009, Poretsky, 
2010). However, now additional mechanisms are thought contributory including 
pathogenic roles for the brain (appetite regulation and control of hepatic glucose 
metabolism), kidneys (increased tubular absorption of glucose), gut (incretin secretion 
and the gut microbiome), alpha-cells in the pancreatic islets (glucagon secretion) and 
adipose tissue (lipolysis, cytokine release), as well as the traditional roles for islet -
cells, the liver and skeletal muscle (DeFronzo, 2009). 
There is much debate about the extent to which insulin resistance or insulin secretion 
defects are the initiating factors in the development of type 2 diabetes. There is evidence 
supportive of type 2 diabetes being a consequence of -cell exhaustion from the need 
for these cells to compensate for insulin resistance (DeFronzo and Ferrannini, 1991, 
Kruszynska and Olefsky, 1996, Billings and Florez, 2010). However, reduced -cell 
function may also be an early pathogenic feature being demonstrable even when glucose 
tolerance is still normal, and showing progressive failure with the progression from 
normal glucose tolerance (NGT) to hyperglycaemia (Porte, 1991, Mitrakou et al., 1992). 
In reality, type 2 diabetes is more likely a heterogeneous disease, such that both of these 
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courses may be more correct depending on the individual affected. 
As well as defects being present in islet -cell function, type 2 diabetes gives rise to 
multiple intracellular deficiencies in insulin activity, being the basis of the insulin 
resistance. Mostly this occurs due to the impaired signal transduction from the insulin 
receptor through the intermediary signalling molecules such as insulin receptor 
substrate (IRS-1) and Akt (Epstein et al., 1994, Hoehn et al., 2008). Increased lipolysis 
may also contribute in the insulin resistance and failed insulin secretion. Elevated levels 
of free fatty acids can inhibit insulin secretion and decrease insulin sensitivity in the 
muscle and liver (Poretsky, 2010). 
1.3.1.2.2. Genetic factors in type 2 diabetes 
 
Genome-wide association studies of single-nucleotide polymorphisms (SNPs) have 
identified over 40 genetic variants that are associated with type 2 diabetes. More have 
been linked to -cell function than insulin sensitivity, with each having only a small 
effect (Nielsen et al., 2003, Billings and Florez, 2010, Wheeler and Barroso, 2011). 
Thus, it is likely that a combination of these genetic variants may be required. 
Furthermore, increasing support is arising for a role for epigenetics, meaning factors 
that alter the expression of genome that do not involve alterations in genomic DNA, in 
the pathogenesis of type 2 diabetes (Nolan et al., 2011). 
Type 2 diabetes is a phenotypically and genetically heterogeneous disorder and can be 
divided into early and late form (Hanis et al., 1996). The complexity of type 2 diabetes 
is related to factors such as genetic heterogeneity, interactions between genes, and the 
modifying role played by the environment (Busch and Hegele, 2001). The risk of  
developing type 2 diabetes in a person increases to 2·4 fold with a positive family and 
15–25% of first-degree relatives of patients with type 2 diabetes develop impaired 
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glucose tolerance or diabetes (Stumvoll et al., 2005). Genome-wide screens have led to 
the localization of susceptibility genes for type 2 diabetes differences between racial 
groups; including Mexican Americans (Hanis et al., 1996), Pima Indians of the south 
western United States (Hanson et al., 1998), and in Utah families of Northern European 
ancestry (Elbein et al., 1999). Each study localized susceptibility to different regions of 
the genome, suggestive for a combination of different susceptibility genes, which 
participate in the development of type 2 diabetes in these populations (Horikawa et al., 
2000). 
Some rare forms of diabetes result from mutations in a single gene, resulting in 
monogenic diabetes. Monogenic forms of diabetes account for about 1 to 5 percent of 
all cases of diabetes in young people.  
Maturity onset diabetes of the young (MODY) is a group of disorders with an 
autosomal dominant inheritance, with an early onset before 25 years of age and, almost 
always, a primary -cell defect (Jenkins and Campbell, 2004, Hattersley and Patel, 
2017). The MODY mutations occur in single genes, which change the structure and 
function of islet -cell proteins, some producing non-progressive -cell dysfunction, 
others leading to progressive -cell failure and a more severe phenotype. The classic 
MODY conditions result from mutations in any one of at least six different genes. One 
of these genes encodes the glycolytic enzyme glucokinase (Froguel et al., 1993) 
resulting in a mild abnormality of fasting hyperglycaemia. On the other hand, the other 
5 genes encode transcription factors: hepatocyte nuclear factor (HNF) 4α, HNF-1α, 
insulin promoter factor 1 (IPF-1), HNF-1β and neurogenic differentiation factor 1 
(NeuroD1), also known as beta-cell E-box transactivator 2 (BETA2) (Fajans et al., 
2001, Hattersley and Patel, 2017). All these genes are expressed in -cells, and mutation 
of any of them leads to -cell dysfunction and diabetes mellitus. 
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Glucokinase-related MODY (MODY 2) is a common form of this disorder, especially 
in children with mild hyperglycemia and in women with gestational diabetes and a 
family history of diabetes. It has been described in persons of all racial and ethnic 
groups (Desnick, 1973). Polymorphism linkages from the families of glucokinase 
mutations identified 40 different mutations which generally tend to cluster in exons 5, 6, 
7, and 8, which code for the glucose binding site of the enzyme (Vionnet et al., 1992, 
Gidh-Jain et al., 1993). 
1.3.2. Pancreas and its hormones 
 
1.3.2.1. Pancreas 
 
The pancreas is a long, soft organ that lies transversely along the posterior abdominal 
wall, posterior to the stomach, and extends from the region of the duodenum to the 
spleen. The human pancreas weighs about 100 grams and is 14-20 cm long (Hruban et 
al., 2007). The pancreas serves two functions, endocrine and exocrine.  
The exocrine function of the pancreas is involved in digestion. The pancreatic acini are 
clusters of cells that produce digestive enzymes and secretions, and they make up the 
bulk of the pancreas. The digestive enzymes and secretions are carried through the 
pancreatic duct system to the duodenum. 
The endocrine portion consists of the pancreatic islets, which secrete mainly insulin and 
glucagon, but also other hormones, that are involved in gluco-regulation. Insulin is the 
body’s only blood glucose-lowering hormone produced by the -cells of the islets of 
Langerhans.  
A human pancreas contains ~1 million pancreatic islets that are distributed throughout 
the exocrine parenchyma of the gland. Every pancreatic islet contains ~1,000 endocrine 
cells of which 75% are insulin-producing -cells (Rorsman, 2005). These islets are 
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highly vascularized by an extensive endothelial network and innervated by sympathetic, 
parasympathetic, and sensory nerves. 
1.3.2.2. Hormones of the pancreas 
 
The islets of Langerhans comprised of different endocrine cell types including β-cells 
(insulin), α-cells (glucagon), and δ-cells (somatostatin) and the PP-cells which secrete 
pancreatic polypeptide (PP). β-cells make up the majority of islets (around 75-80%), 
followed by α-cells (about 15%), δ-cells (about 5%) and very few PP-cells (Stefan et al., 
1982). These endocrine cells are described briefly in the following sections. 
1.3.2.2.1. Alpha cell hormone: glucagon 
 
Glucagon secreting alpha-cells are one of the main endocrine cell populations that 
coexist in the islet along with insulin-secreting-cells. The most important physiological 
role of the pancreatic alpha cell is the release of glucose-elevating glucagon in response 
to hypoglycaemia. 
There are three different proposed mechanisms that allow glucose regulation of 
glucagon secretion; one involves direct effects of glucose on the alpha cell. Another is 
based on an indirect action mediated by release of insulin, γ-amino butyric acid 
(GABA), Zn2+or somatostatin. And the third mechanism predicts that glucose sensing 
occurs in the hypothalamus with altered neural signalling to alpha cells (Vieira et al., 
2007).                                          
Insulin and glucagon have opposite effects on glycaemia as well as on the metabolism 
of nutrients. Insulin acts mainly on muscle, liver and adipose tissue with an anabolic 
effect, inducing the incorporation of glucose into these tissues and its accumulation as 
glycogen and fat. In contrast, glucagon induces a catabolic effect, mainly by activating 
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liver glycogenolysis and gluconeogenesis, which results in the release of glucose into 
the bloodstream. 
The pre-proglucagon-derived peptides glucagon, glucagon-like peptide 1 (GLP-1) and 
glucagon-like peptide 2 (GLP-2) are all encoded by the pre-proglucagon gene, which is 
expressed in the central nervous system, intestinal L-cells and pancreatic alpha-cells. A 
post-translational cleavage by prohormone convertases (PC) is responsible for the 
maturation of the pre-proglucagon hormone that generates all these peptides. The 
different expression of PC subtypes in each tissue mediates the production of each 
different peptide (Mojsov et al., 1987).  
An increase in glucagon synthesis along with secretion of epinephrine protects the 
organism against hypoglycaemia and its potential damaging effects, especially in the 
brain, which depends on a continuous supply of glucose, its principal metabolic fuel. 
Additionally, glucose-sensing neurons of the ventromedial hypothalamus further control 
responses to glycaemia changes. The main action of glucagon occurs in the liver where 
the insulin/glucagon ratio controls multiple steps of hepatic metabolism. Glucagon 
stimulates gluconeogenesis and glycogenolysis, which increases hepatic glucose output, 
ensuring an appropriate supply of glucose to body and brain, and at the same time, it 
decreases glycogenesis and glycolysis. The glucagon receptor in the liver is highly 
selective for glucagon, but it exhibits a modest affinity for glucagon-like-peptide 1 
(Quesada et al., 2008). 
1.3.2.2.2. Delta cells hormone: somatostatin 
 
Somatostatin (SST) is produced by delta cells, which are the third most abundant cell 
type in pancreatic islets of Langerhans. These cells are typically located on the 
periphery of the islets, usually between -cells and the surrounding mantle of alpha cells 
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(Rhoades and Bell, 2012). Human islets contain about 10% delta cells, which is twice 
the proportion of mouse islets (Brissova et al., 2005). 
SST has a strong and direct inhibitory effect on insulin and glucagon secretion. SST 
secretion from islet delta-cells is stimulated by increased extracellular glucose, although 
the threshold concentration for delta-cells to respond to glucose is lower than that for       
-cells and ionic events in stimulus-response coupling differ between   and delta-cells. 
The pancreatic delta-cell and hypothalamus SST consists of two different polypeptides, 
14-amino acid and 28-amino acid forms. In delta-cells, the 28-amino acid peptide 
predominates and, in hypothalamus, the 14-amino acid form predominates (Hauge-
Evans et al., 2009). 
The peptide hormone SST is also synthesized and secreted by neuroendocrine cells in 
the central nervous system and the gastrointestinal system, which is the major 
contributor to circulating SST (Reichlin, 1983). SST has an inhibitory role as well. It 
acts as an inhibitory regulator of endocrine systems, as a hypothalamic factor to 
suppress growth hormone secretion from the anterior pituitary, or as a local inhibitor of 
the release of gastrointestinal peptide hormones (Hauge-Evans et al., 2009).  
1.3.2.2.3. PP cells hormone: pancreatic polypeptide  
 
Pancreatic polypeptide (PP) is a 36 amino acid peptide, with a molecular weight of 
about 4200 Dalton. It produced and secreted by PP cells (originally termed F cells) of 
the pancreas, primarily located in the islets of Langerhans. These cells also occur 
scattered through the exocrine parenchyma and occasionally in pancreatic duct 
epithelium (Lonovics et al., 1981). It is part of a family of peptides that also include 
peptide YY (PYY) and neuropeptide Y (NPY). 
The effects of PP, including inhibition of pancreatic secretion, gall bladder activity, and 
intestinal motility, are mainly located in the gastrointestinal tract. In addition, PP affects 
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metabolic functions, including glycogenolysis, and decreases fatty acid levels. It may 
influence food intake, energy metabolism, and the expression of hypothalamic peptides 
and gastric ghrelin (Leiter et al., 1985, Berglund et al., 2003).          
1.3.2.2.4. Epsilon cells hormone: ghrelin  
 
Ghrelin is a novel 28 amino acid hormone secreted by epsilon (ε-cells), that has many 
functions in the body. It was first isolated from the stomach and identified as an 
endogenous ligand for growth hormone secretion from pituitary gland (Pick et al., 
1998).  
Ghrelin stimulates hunger and feeding behaviour (White, 2003). Circulating ghrelin is 
produced predominantly in the stomach, while substantially lower amounts are detected 
in other organs and sites including pancreas. Ghrelin and growth hormone secretagogue 
receptor type 1a (GHS-R1a) expression have been demonstrated in both human and 
rodent pancreatic islets  (Elleman et al., 2000). Ghrelin inhibits insulin release in mice, 
rats and humans (Fantl et al., 1993, Lavan et al., 1997, Björnholm et al., 2002). Its role 
in the pancreatic islets is not well understood. 
cell hormones: insulin and amylin 
 
Insulin is discussed in detail in the next section 1.3.3.  
Amylin or islet amyloid polypeptide (IAPP) is a small 37-amino acid peptide. It is a 
second islet -cell hormone that is normally co-secreted with insulin in response to 
meals and complements the effects of insulin in postprandial glucose control (Cooper et 
al., 1987). Amylin is co-secreted with insulin in the ratio of approximately 100:1. The 
best known functions of amylin are to reduce food intake, to reduce gastric emptying 
and to inhibit pancreatic glucagon secretion and pancreatic and gastric enzyme 
secretion. Plasma amylin levels, like insulin are low during fasting and increase during 
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meals and with glucose administration, and the levels are all directly proportional to 
body fat (Woods et al., 2006). Amylin is synthesized as a prohormone amyloid 
polypeptide of 67 amino acids produced by the pancreatic -cell, and this prohormone 
undergoes post-translational modifications including protease cleavage to produce 
amylin (Higham et al., 2000). 
1.3.3. Insulin structure and function 
 
Insulin was discovered in 1921-22, by Fredrick Banting, Charles Best, J.J.R. Macleod 
and James Collip, as one of the great medical breakthroughs of all time (Strakosch, 
2004).  
1.3.3.1. Insulin structure 
 
Insulin is a small protein, with a molecular weight of about 5808 Daltons (Egea et al., 
2005). It was the first protein to have its amino acid sequence sequenced, in 1955 by 
Fred Sanger (Pillai and Panchagnula, 2001), earning him a Nobel Prize in 1958.  
Insulin is built from 51 amino acids and is monomeric when biologically active and in 
circulation. It is structured with two polypeptide chains, in humans, chain A has 21 
amino acids, and chain B has 30 linked by two disulphide bonds, that bridges between 
the cysteine residues at positions A7 and B7, and A20 and C19. An additional 
disulphide-bridge connects the cysteine residues at A6 and A11, which is important for 
determining the tertiary structure and receptor binding of the molecule.  There is also a 
third disulphide bond that connects these same amino acids within Chain A. (Stretton, 
2002, Pillai and Panchagnula, 2001).  
The insulin gene is only expressed in -cells of the pancreas (Roy et al., 2003). When 
this gene is expressed, the messenger RNA transcript is translated into an inactive 
protein called pre-proinsulin which is composed of 110 amino acids (Wood, 2007). It is 
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relatively inactive and has to be processed into proinsulin in order to eventually make 
the insulin hormone. Pre-proinsulin contains a hydrophobic N-terminal signal peptide, 
which interacts with cytosolic ribonucleoprotein signal recognition particles (SRP). SRP 
facilitates preproinsulin translocation across the rough endoplasmic reticulum (rER) 
membrane into the lumen. This process occurs via the peptide-conducting channel 
where the signal peptide from preproinsulin is cleaved by a signal peptidase to yield 
proinsulin      (Fu et al., 2013). In the endoplasmic reticulum, the single chain proinsulin 
folds back onto itself, aligning the future A-and B-chain and creating the disulphide 
bonds in this process. The A-chain and B-chain are still connected by the connecting 
peptide (C-peptide) (Steiner et al., 1969). In the Golgi-complex, the proinsulin is stored 
in so-called beta-granules. These contain the proteolytic enzymes that will cleave and 
remove the  C-peptide from proinsulin, resulting in equimolar amounts of insulin and C-
peptide in the mature beta-granule (Duckworth et al., 1998).  
1.3.3.2. Insulin secretion 
 
Insulin concentrations are normally maintained by a feedback control system that is 
responsive to the prevailing level of plasma glucose (Bell and Polonsky, 2001). Insulin 
output must cope with size, composition and appearance rate of meals on one hand and 
with target tissue sensitivity on the other. Insulin secretion rate must adapt to stimuli 
both on a minute-by-minute basis, like catecholamines, and in the longer term, like 
thyroid hormones (Ferrannini and Mari, 2004). First-phase insulin secretion begins 
within 2 minutes of nutrient ingestion and continues for 10 to 15 minutes. The second 
phase of prandial insulin secretion follows, and is sustained until normoglycemia is 
restored (Ferrannini and Mari, 2004). Overt hyperglycemia causes a defect in insulin 
action, which is called insulin-resistant state. The body compensates against this 
condition by increasing insulin secretion per cell, consistent with functional 
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compensation. Islet -cells can also maintain the compensation by an increase in -cell 
mass, particularly seen in rodents, which is achieved by neogenesis of the islet precursor 
cells in the pancreatic ductal epithelium. (Burks and White, 2001).  
13.3.3. Islet -cell mass 
 
Regulation of blood glucose concentrations requires an adequate number of pancreatic   
-cells that respond appropriately to blood glucose concentrations. The collective -cell 
numbers are often referred to as the -cell mass (Matveyenko and Butler, 2008). 
Autoimmune destruction of -cells in type 1 diabetes causes the complete 
disappearance of -cells and causes an absolute insulin deficiency (Rahier et al., 2008).  
Whereas, type 2 diabetes is characterized by a progressive decline in -cell function and 
chronic insulin resistance, where obesity is a major risk factor in the development of the 
disease. However, most people who are obese and relatively insulin resistant do not 
develop diabetes as -cells compensate for the insulin resistance for long periods of 
time with an increase in secretory capacity and an increase in β-cell mass, or both 
(Kahn, 1994, DeFronzo, 1997, Polonsky, 2000). 
An increase in -cell mass also happens during pregnancy when maternal metabolism 
undergoes profound changes and maximum nutrient supply is required for the 
developing foetus. Detailed rodent studies of β-cell mass and insulin secretion during 
pregnancy has shown that, there is marked insulin resistance accompanied by a dramatic 
increase in the insulin response to glucose and an almost doubling of the -cells mass in 
rodents, although the latter may not happen to the same extent in human pregnancy. Rat 
-cell mass and insulin secretion decreases rapidly after birth reaching pre-pregnancy 
values at around 10 days postpartum (Edström et al., 1974, Parsons et al., 1992). 
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Regulation of the -cell mass involves a balance between -cell replication and 
apoptosis, and can include islet neogenesis from exocrine pancreatic ducts. Disruption 
of any of these pathways of -cell formation or increased rates of -cell death could 
cause a decrease in -cell mass (Butler et al., 2003). 
Rodent models of diabetes, such as the ob/ob and db/db mice (Gapp et al., 1983) and the 
Zucker fatty rat (Tokuyama et al., 1995), and hyperinsulienaic humans with obesity 
and/or type 2 diabetes exhibit mild to marked islet hyperplasia at varying times of their 
disorders (Pinar et al., 2000). However, the factors contributing to -cell hyperplasia in 
insulin-resistant states are not well understood. 
Deficits of -cell mass have been found in various autopsy studies from different 
European, Asian, and North American populations, where the patients of type 2 diabetes 
have been reported to have significant reductions in -cell pancreatic area compared 
with nondiabetic individuals (Klöppel et al., 1985, Butler et al., 2003). The decrease in 
-cell mass in type 2 diabetes individuals has been estimated to be about 40% (Maclean 
and Ogilvie, 1955). 
The number of islet -cells present at birth is mainly generated by the proliferation and 
differentiation of pancreatic progenitor cells, a process called neogenesis. Shortly after 
birth, -cell neogenesis stops and a small proportion of cycling -cells can still expand 
the cell number to compensate for increased insulin demands, although at a slow rate. It 
appears that in the absence of major external stimuli, the -cell population has only a 
very limited potential for regeneration, unlike liver. This is probably due to the limited 
replication capacity of -cells and to the fact that neogenesis from precursor cells is not 
readily reactivated. Yet, under certain conditions where major external stimuli are 
applied, there can be a quite vigorous regenerative expansion of the -cell mass  
(Bouwens and Rooman, 2005). 
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In NOD mice, -cells are destroyed by a spontaneous autoimmune reaction leading to a 
type 1-like diabetes condition. Immune suppression in combination with GLP-1 analog-
treatment could restore normoglycaemia and improve islet histology (Ogawa et al., 
2004). This involves regeneration as well as increased survival of -cells. In animal 
models of type 2 diabetes induced by 90–95% pancreatectomy, daily administration of 
the GLP-1 analog exendin-4 during 10 days post pancreatectomy decreases the 
development of diabetes. Where, exendin-4 stimulates the regeneration of the pancreas 
and expansion of the -cell mass by the processes of neogenesis and replication of -
cells (Xu et al., 1999). 
1.3.3.4. The insulin receptor and insulin function 
 
The insulin receptor belongs to the receptor/tyrosine kinase family, which plays critical 
roles in development, cell division and metabolism (Fantl et al., 1993). The activation of 
the receptor/tyrosine kinase family by their cognate ligands causes autophosphorylation 
and selective protein substrates exclusively on tyrosine residues.  
The insulin receptor is composed of two alpha subunits and two subunits linked by 
disulphide bonds. The alpha chains are entirely extracellular and house insulin binding 
domains, while the linked -chains penetrate through the plasma membrane. Both 
receptor-subunits are glycosylated during the process of translation and contain 
complex N-linked carbohydrate side chains with terminal sialic acid residues, which are 
necessary for normal folding and function of the receptor (Elleman et al., 2000). 
The insulin receptor substrate (IRS) proteins are a family of cytoplasmic adaptor 
proteins that were first identified for their role in insulin signalling. There are at least 
four members of the IRS protein family, including IRS-1, -2, -3, and -4. IRS-1 and IRS-
2 are expressed in nearly all cells and tissues. Humans express one additional family 
member, IRS-4, which is more restricted in its expression pattern and is found primarily 
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in brain, kidney, thymus and liver and IRS-3, is expressed in rodents, but not in humans 
(Lavan et al., 1997, Björnholm et al., 2002). Most insulin responses are produced or 
modulated through tyrosine phoshorylation of IRS-1 or IRS-2. 
The function of insulin is to control glucose homeostasis by stimulating the clearance of 
glucose into skeletal muscle and, to a lesser degree, liver and adipose tissue. In muscle 
and adipocytes, insulin-stimulated glucose uptake is achieved by the translocation of the 
insulin-sensitive glucose transporter (GLUT-4) from intracellular storage vesicles to the 
cell surface (James et al., 1988). Insulin also suppresses endogenous glucose production 
from glycogenolysis and gluconeogenesis in the liver and it inhibits lipolysis in adipose 
tissue. 
1.3.4. The mechanisms of insulin secretion 
 
The blood glucose concentration affects the release of insulin from -cells. It is a 
complex and interesting mechanism that shows the complicated nature of glucose 
regulation. The regulation of insulin secretion by glucose is modulated by various 
physiological effectors including neural and hormonal factors (Bell and Polonsky, 2001, 
Muoio and Newgard, 2008). For example, the incretin (intestinal) hormones such as 
GLP1 and gastrointestinal inhibitory polypeptide (GIP) and the parasympathetic system 
neurotransmitter acetylcholine (ACh) all potentiate insulin secretion (Muoio and 
Newgard, 2008).  
The clustered -cells in islets are strategically connected to the vasculature. Capillaries 
surrounding islets show a remarkable number of small pores called fenestrae that allow 
for a greater nutrient exchange between the circulation and surrounding tissues. This 
allows unrestricted nutrient access so that -cells can sense the nutritional state quickly 
(Suckale and Solimena, 2008). The islet -cell is most responsive to glucose as a 
nutrient secretagogue, and causes glucose-stimulated insulin secretion (GSIS). GSIS is 
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also potentiated by other metabolic fuels, most notably fatty acids and amino acids. 
Interaction of amino acids and fatty acid metabolism with glucose metabolism produces 
metabolic coupling factors (MCFs), which are involved in signalling for insulin 
exocytosis (Nolan and Prentki, 2008). 
1.3.4.1. Mechanisms of nutrient-stimulated insulin secretion 
 
The islet -cell senses multiple nutrients, hormonal and neural inputs and accordingly 
secretes insulin appropriately for the requirements of the body at that moment, whether 
fasted or fed. Essential for insulin secretion is metabolic activation of the -cell in 
response to an increased mixed nutrient supply, of which glucose is the most important 
(Nolan and Prentki, 2008, Prentki et al., 2013).  
In order to couple glucose sensing to insulin release, islet -cell glucose metabolism is 
essential and this is via three pathways with the production of metabolic coupling 
factors.  
1.3.4.1.1. K+-ATP channel dependent pathway 
 
Glucose enters the -cell via GLUT2 and after being phosphorylated by glucokinase is 
metabolized via glycolysis to pyruvate and then acetyl-CoA via pyruvate dehydrogenase 
with subsequent oxidation in the tricarboxylic acid cycle (Newgard and McGarry, 1995, 
Suckale and Solimena, 2008). This gives rise to an increased cytosolic ATP/ADP ratio, 
which closes ATP-sensitive K+ channels, depolarises the plasma membrane potential, 
opens voltage-gated Ca2+ channels, and Ca2+ influx activates insulin granule exocytosis 
(Fig 1.1) (Rorsman, 2005, Nolan and Prentki, 2008, Prentki et al., 2013). The K+-ATP 
channels are composed of two tetramers of two proteins: a pore-forming K+ channel, 
Kir 6·2, and a regulatory subunit; the sulphonylurea receptor SUR1. The intercellular 
ATP binding to Kir 6·2 caused the channel to close whereas binding of ADP to SUR1 
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opens the channel, therefore the channels are regulated by the intracellular changes of 
ATP:ADP ratio. Closure of K+-ATP channels cause membrane depolarization until the 
threshold potential for opening of voltage-dependent Ca2+-channels is reached. When 
these channels open, influx of Ca2+ into -cell occurs, down the electrochemical 
gradient, which results in an increase in [Ca2+] (Henquin et al., 2003). 
The K+-ATP channel-dependent mechanism triggers a release of relatively small 
proportion (∼10%) of already docked granules at the plasma membrane of -cell from 
the immediately-releasable pool. This acute phase of insulin release occurs in the first 
10 minutes  in response of glucose stimulation (Ashcroft et al., 1984, Jensen et al., 
2008). The second phase of glucose-stimulated insulin secretion is due mainly to the 
K+-ATP channel-independent pathways acting in interaction with the K+-ATP channel-
dependent pathway, such as the anaplerosis  and glycerolipid/fatty acid cycling 
pathways (Straub and Sharp, 2002).  
1.3.4.1.2. The anaplerosis amplification pathway  
 
Pyruvate is the main end product of glycolysis in -cells, because the cell contains 
extremely low levels of lactate dehydrogenase, hence there is a limitation of the 
pyruvate conversion to lactate. The metabolic fate of pyruvate depends on the relative 
activities of pyruvate carboxylase (PC) and the pyruvate dehydrogenase complex. 
Pyruvate from glucose that is metabolized via PC enters the anaplerosis/cataplerosis 
pathway, which can impact on insulin secretion by increasing levels of cataplerosis-
derived metabolic coupling molecules such as Nicotinamide adenine dinucleotide 
phosphate (NADPH) from the malate-, citrate- and isocitrate/α-ketoglutarate-pyruvate 
shuttles, as well as malonyl-CoA and glutamate (Fig 1.1) (Newgard and McGarry, 
1995, Nolan and Prentki, 2008, Prentki et al., 2013). Of note, the anaplerotic enzyme 
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PC is expressed at very high levels, contributing to 0.4% of the total protein content of 
islet tissue (MacDonald, 1995).  
1.3.4.1.3. The glycerolipid/fatty acid cycling amplification pathway  
 
Non-esterified fatty acids (NEFA) are important to the pancreatic -cell for its normal 
function. NEFA deprivation of islet tissue causes loss of GSIS, which can be readily 
reversed by an exogenous NEFA replacement. However, while elevated NEFA supply 
can acutely augment GSIS, if chronically in excess particularly in association with 
elevated glucose, this can reduce insulin biosynthesis, secretion and can induce -cell 
cell apoptosis (Lee et al., 1994, Prentki et al., 2002, El-Assaad et al., 2003). 
Glycerolipid/fatty acid cycling is one pathway by which NEFA can affect insulin 
secretion (Prentki and Madiraju, 2012). 
To enable glycerolipid/fatty acid cycling, glucose interacts with NEFA by elevating 
malonyl-CoA, via the anaplerosis pathway, which inhibits partitioning of long chain 
acyl-CoA to the mitochondrion for fatty acid oxidation (via carnitine 
palmitoyltransferase-1 inhibition), such that the long chain acyl-CoA are then more 
available for esterification processes (Nolan et al., 2006, Nolan and Prentki, 2008, 
Prentki and Madiraju, 2012, Prentki et al., 2013). 
 Glycerolipids such as diacylglycerol and triacylglycerides formed are rapidly 
hydrolysed by lipases back to fatty acids and glycerol creating a cycle of newly formed 
lipids. This cycle produces lipid signaling molecules such as monoacylglycerols and 
diacylglycerols that are able to enhance GSIS (Fig 1.1) (Nolan and Prentki, 2008, 
Prentki and Madiraju, 2012, Prentki et al., 2013).  
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1.3.4.1.4. Other mediators of insulin secretion  
 
Amino acids, such as glutamine and leucine, also interact with the glucose metabolism 
pathways to enhance the coupling signals produced by glucose alone. The β-cell also 
responds to other neurohormonal/metabolic extracellular signals by various plasma 
membrane receptors and their signal transduction pathways (e.g. G-protein coupled 
signalling for example by cyclic AMP). Relevant to nutrient-induced insulin secretion, 
islet -cells have cell surface receptors for fatty acids (e.g. FFAR1) that can modulate 
GSIS. Effector metabolic coupling factors interact with the insulin granule exocytosis 
machinery to cause insulin secretion (Fig 1.1) (Nolan and Prentki, 2008, Prentki et al., 
2013). 
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Figure 1.1: Role of islet -cell metabolic activation by fuels and neuro-hormonal 
agonists in insulin secretion  
Islet -cell glucose metabolism is essential for glucose to stimulate insulin secretion via 
three key pathways that produce metabolic coupling factors: (1) The K+-ATP channel 
dependent pathway of GSIS. (2) The anaplerosis amplification pathway of GSIS. (3) 
The glycerolipid/fatty acid cycling amplification pathway (refer to text for details). 
Amino acids, such as glutamine and leucine, also interact with the glucose metabolism 
pathways to increase the coupling signals produced by glucose alone. The -cell also 
responds to other neurohormonal and metabolic extracellular signals via various plasma 
membrane receptors.  
PC=pyruvate carboxylase. PDH=pyruvate dehydrogenase. Ach-R=acetylcholine 
receptor. FA=fatty acid. GIP-R=gastric inhibitory polypeptide receptor. GLP-1-
R=glucagon-like peptide-1 receptor. FFAR1=free-fatty-acid receptor-1. α-ADR-R= α2-
adrenergic receptor. SSN-R=somatostatin receptor. OAA= oxaloacetate. 
CoA=coenzyme A. MAG=monoacylglycerides. DAG=diacylglycerides. 
TG=triacylglycerides. Δψm=change in plasma membrane potential. Mal-CoA=malonyl-
CoA. LC-CoA=long-chain acyl-CoA. GL=glycerolipid. FA=fatty acid. NEFA=non-
esterified fatty acids. Adapted from (Nolan et al., 2011).  
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1.3.5. Animal models 
 
Many mouse models are used for diabetes research, with most being more relevant to 
type 2 diabetes. As this thesis is concerned with investigation of possible non-immune 
susceptibility factors for type 1 diabetes, the key mouse model to be studied was the 
NODk mouse, derived from the type 1 diabetes NOD mouse model, with two 
comparator strains. In this section the background to these three mouse models relevant 
to, and/or used, in this thesis is provided. 
1.3.5.1. NODk congenic mice 
 
The NOD mouse is the most extensively studied animal model for the development of 
type 1 diabetes. Experiments conducted in NOD mice have informed immune system 
modulatory therapies that are being pursued for the prevention of type1 diabetes in 
humans (Delovitch and Singh, 1997). 
The inbred NOD strain was developed in Japan in 1980 by selective breeding of outbred 
ICR:Jcl mice at Shionogi Research Laboratories. These mice were established by 
selective mating of the offspring of a female mouse which spontaneously developed 
diabetes in one of the two sublines of cataract Shionogi (CTS) mice (Makino et al., 
1980b).  
The development of type 1 diabetes in the NOD mouse is under the control of multiple 
genes, of which one or more are linked to the MHC. The analysis of NOD mice with the 
outcross C57BL/10SnJ strain showed at least three non-MHC-linked genes as well, 
located on chromosomes 1, 3 and 11 (Todd et al., 1991) and one or more genes in the 
MHC (Hattori et al., 1986). The MHC class II region of the NOD mouse H2g7 is 
strongly linked to the development of diabetes (Podolin et al., 1993, Socha et al., 2003, 
Dooley et al., 2016). 
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Within the MHC class II I-A and I-E regions, the NOD mouse was found to express a 
unique I-A -chain that could clearly be implicated in the susceptibility of these mice in 
diabetes. In addition, another feature of the NOD Class II MHC was the absence of I-E 
 chain production (Todd et al., 1991, Wicker et al., 1987). In order to determine the 
importance of the absence of the I-E  chain in the propensity of NOD mice to develop 
diabetes, congenic mice for various I-E+ and I-E- MHC haplotypes were created. It was 
found that I-E+ NOD mice do develop insulitis and diabetes (Podolin et al., 1993), In 
this work, a NOD.H2k congenic strain was created by outcrossing NOD mice from 
Taconic Farms (NOD/MrkTac) with B10.BR (congenic for the H2k MHC haplotype 
from C57BR) which were back-crossed with NOD to retain the H2k MHC haplotype. 
The resultant congenic NOD.BR-H2k/Wicker mice, in which the H2g7 locus of the 
MHC Class II of the NOD had been replaced by the H2k, have been previously been 
called NODk mice (Dooley et al., 2016), and this abbreviated name is continued to be 
used for the purpose of this thesis. NODk mice do not show the development of 
spontaneous diabetes for 5-13 months of age (Podolin et al., 1993, Dooley et al., 2016). 
NODk congenic mice have been shown to contain all auto immune susceptibility loci for 
NOD except the H2g7 allele, which is been replaced by the H2k allele (Elkon, 2006a). 
 
1.3.5.2. NODk.insHEL transgenic mice 
 
A transgenic mouse carries a foreign gene that has been deliberately inserted into its 
genome. These genes are found in the nucleus of every cell of the body. As mentioned 
before in Section 1.1, the work of this thesis progresses on from earlier work performed 
with NODk.insHEL transgenic mice (Dooley et al., 2016). The HEL transgene is 
modified to a cell surface form by addition of coding segments for the transmembrane 
and cytoplasmic tail of the H2-Kb molecule. It is driven by the rat proinsulin gene 
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promoter (insHEL) such that it is highly expressed in islet β-cells (Dooley et al., 2016). 
Male NODk.insHEL, but not female NODk.insHEL or B10k.insHEL mice of either 
gender, develop diabetes.  Furthermore, the diabetes that develops in the NODk.insHEL 
mice appears to have a non-immune pathogenesis, but these mice clearly show evidence 
of islet -cell failure indicated by the presence of increased -cell apoptosis and a 
decrease in islet -cell mass (Dooley et al., 2016). Interestingly, all insHEL transgenic 
mice (male and female NODk.insHEL and B10k.insHEL) develop hyperinsulinaemia 
with normal sensitivity to exogenous insulin (Dooley et al., 2016). There was evidence 
for altered proinsulin processing in the insHEL transgenics, but this was also true for the 
female NODk.insHEL and B10k.insHEL of both genders, suggestive of an islet -cell 
susceptibility factor NODk.insHEL mice that is altered by gender (Dooley et al., 2016).  
Overexpression of HEL in -cells of the NODk provide stress by forcing the cells to 
produce a foreign highly disulphide bonded protein that can cause endoplasmic 
reticulum (ER) stress (Dooley et al., 2016). In the work of this thesis we wished to 
determine if a more usual stressor, such as the HF-diet, could also induce diabetes in the 
NODk mouse model 
 
1.3.5.3. B10k congenic mice 
 
A number of glycoproteins are coded at the I region of the mouse MHC complex. The 
Ia antigens are responsible for initiating an immune response to foreign antigens 
(McDevitt, 1981). Two different Ia antigen complexes exist, the A complex and the E 
complex (McDevitt, 1981, Klein et al., 1981). The A complex is generally expressed on 
B lymphocytes of all mouse haplotypes, yet certain strains fail to assemble the E 
complex to the cell surface (Mathis et al., 1983).  The C57BL/10 strain is one strain that 
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fails to express an I-E product. C57BL/10 mice do not develop overt diabetes and 
insulitis (Wicker et al., 1987).  
B10k is the abbreviated name given to B10.BR-H2k/SgSnJ mice; a C57BL/10 sub strain 
congenic for the C57BR H2k locus (Dooley et al., 2016). This strain was developed in 
1965 in Jackson lab, in which the H2k haplotype was backcrossed from C57BR/cdJ 
mice onto C57BL/10ScSn mice (Jackson, 1988; April). The H2k haplotype does express 
an I-E product. B10.BR also contain diabetic resistant alleles at most non-MHC loci            
(Elkon, 2006b). 
As B10k mice have the same low risk H2k MHC haplotype as NODk mice, this was 
selected as a control strain in the insHEL studies (Dooley et al., 2016). We have 
continued to use it as a control strain in the studies of this thesis, however, while it does 
not develop insulitis or diabetes, it does develop glucose intolerance (Chapters 3&4). 
1.3.5.4. Balb/c 
 
The Balb/c strain is genetically most related to the A/J strain of mice, which is a classic 
“diabetes-resistant” mouse strain, with low glucose levels (Naggert JK, May 2006). 
Balb/c, are more glucose tolerant than C57BL/6 and more resistant to the glucotoxic 
effects of streptozotocin (Cardinal et al., 1998). Balb/c mice have a relatively high -
cell mass due to a large number of islets (Clee and Attie, 2007).  
Our laboratory has previously studied Balb/c females on HF-diet for 10 weeks 
(Delghingaro-Augusto- unpublished). HF-fed Balb/c mice were found to maintain 
normal glycaemia in both the fed-state and during intra-peritoneal glucose tolerance 
testing (ipGTT). Considering that early experiments with B10k mice did not show it to 
be a suitable control strain due to its poor glucose tolerance even on chow diet (see 
results chapters), a decision was made to include diabetes resistant Balb/c mice as a 
third comparator strain for the studies of this thesis. 
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Materials & Methods 
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2.1. Introduction 
This Chapter describes the research design used in the study including: animal sources, 
experimental set up and procedures, sampling techniques, sample size, instrumentation, 
data collection, analysis procedures and data presentation.  
2.2. Animal sources, diet and housing  
Age matched 6 week old male and female B10.BR-H2K2H2-T18a/SgSnJArc mice, 
called B10k mice for the purposes of this thesis, were purchased from the Animal 
Resource Centre (ARC; Perth, WA, Australia). On arrival, the mice were initially caged 
in groups of 4-5 mice in the Canberra Hospital Animal Facility and fed standard 
laboratory diet. Sister and brother breeding couples were set up and a colony was 
maintained at the Canberra Hospital Animal Facility. 
NOD.BR-H2k/WickerANU, called NODk for the purposes of this thesis, were obtained 
from Prof. Goodnow’s laboratory at the John Curtin School of Medical Research at the 
Australian National University (ANU). Balb/c mice were obtained from ANU Animal 
Services. Sister and brother breeding couples were also set up for these two strains of 
mice at the Canberra Hospital Animal Facility. 
NODk mice were refreshed at ANU, under the management of the Animal Facility staff. 
Female NODk mice (NOD.BR-H2k/WickerANU) were crossed with male 
NOD.ShiLtJArc from ARC and the N1 progeny were further backcrossed twice to the 
NOD.ShiLtJArc strain. Breeders were selected on the basis of heterozygosity using 
PCR for H2k at the MHC. After two backcrosses, N3 brother and sister H2k 
heterozygotes were intercrossed in order to fix a H2k haplotype homozygous progeny 
(confirmed with PCR). These mice were given the strain name of ASD527:NODk.ANU 
N3F3 (after 3 intercrosses), abbreviated to NODk-Refreshed (NODk-REF) for the 
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purposes of this thesis. 
For mating of the various mouse colonies, males were put together with the female 
breeders for 3 consecutive nights. The gestation period was about 21 days for the 3 
strains. At 4 weeks of age, mice were weaned on to normal chow diet (unless otherwise 
stated), containing 59.8% (w/w) carbohydrate, 20% (w/w) protein and 5.4% (w/w) fat; 
energy content 12MJ/g (Gordon’s Speciality Stockfeeds, NSW, Australia) and 
autoclaved tap water. Mice were accommodated in a temperature-controlled room (21-
240C) with 40-60% humidity on an artificial 12-hour day and 12-hour night cycle.  
Only male mice were used for experiments due to their greater propensity to develop 
diabetes. They remained on normal chow diet from weaning or were placed on to a high 
fat (HF) diet containing 45% (w/w) sucrose, 19.40% (w/w) protein and 23% (w/w) fat; 
energy content 20MJ/g (SF03-020 Gordon’s Speciality Stockfeeds, NSW, Australia). 
The project was approved by the Australian National University Experimental Ethics 
Committee (Project A2011/027) and all animals received care in compliance with the 
guidelines prescribed by the committee and the National Health and Medical Research, 
Australian Code for the Care and Use of Animals for Scientific Purposes (NHMRC, 
2013). 
2.3. Fortnightly measurement of body weight and 
blood glucose  
Male experimental mice, randomized to either normal chow or HF-diet, were submitted 
to fortnightly assessment of body weight and fed-tail blood glucose levels. The blood 
glucose checks were performed between 9 and 10 AM using a glucometer (StatStrip 
Xpress, Nova Biomedical, Flintshire, UK) calibrated with low (ranging 2.6-4.2mmol/l, 
46-76 mg/dl), intermediate (ranging 5.0-7.2 mmol/l, 90-130mg/l) and high (ranging 
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14.4-18.3 mmol/l, 260-330mg/dl) glucose control solutions. The mice were identified, 
taken out of cages and quickly placed in a mouse restrainer. With a sterile surgical blade 
(blade size #15, Swan Morton, Limited, UK), a very small incision (2-3mm) was 
introduced onto one of the tail veins to produce one drop of blood. The first drop of 
blood was collected at the glucose test strip and the glucose measurement was then 
measured automatically by the glucometer. After obtaining the glucose measurement, 
gentle pressure was applied at the site of the cuts by gauze (Cat# 45849, Cutisoft, BSN 
Medical Pty. Ltd, Australia), to stop any further bleeding and the tails of the mice were 
cleaned by fresh gauze. The body weights of the mice were documented by weighing 
them on a standard laboratory scale (Fx-200i, A&D Company limited, Korea). After the 
measurements the mice were returned to their respective cages. 
2.4. Intraperitoneal glucose tolerance test (ipGTT) 
For ipGTTs, mice were fasted for 4 hours so as to be able to obtain baseline glucose and 
insulin levels, without putting the mice into a significant catabolic state (e.g. by 
overnight fasting). Food was removed from the original mice cages at 8:00 AM and 
mice were placed in a new cages with new bedding, without food, but with water during 
the 4 hours fast. Body weights were measured to calculate the glucose injection dose (2 
g glucose/kg body weight).  
A 25% working glucose solution was prepared from 50% glucose intravenous infusion 
(Baxter, Toongabbie, NSW, Australia) by using autoclaved milliQ water.  
Mice were restrained in a mouse restrainer and the tail was heated under a heat lamp to 
induce heat vasodilation, and the blood was collected via a small lateral cut ~5mm at the 
mouse’s tail and gentle massage of the tail. A time 0 min baseline glucose measurement 
was made as described in Section 2.3. An additional baseline blood sample of 60 µl was 
collected from each mouse into Eppendorf tubes (Eppendorf South Pacific Pty. Ltd, 
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NSW, Australia) containing 10µL of 0.5M ethylenediaminotetraacetic acid (EDTA, 
Cat# E9884, Sigma Aldrich, CA, USA) and the these samples were placed on ice. The 
intraperitoneal injection of 25% glucose solution (2g/kg body weight) was administered 
at time 0 h, which started the test. Consecutive measurements of blood glucose levels 
were taken at 15, 30, 60, 90 and 120 min after the glucose injection from droplets of tail 
blood by using the glucometer, as described above (Section 2.3). Also, 30-60 µL tail 
blood samples were collected at 15 and 90 min after the glucose injection for later 
measurements of insulin, TG and NEFA. On completion of the experiment, mice were 
returned to their respective cages with food and water. The collected blood samples 
were centrifuged at 6000 rpm (Rotor # SX4750, Allegra X-15R Centrifuge, Beckman 
Coulter, CA, USA) for 10 min at 40C to separate the plasma. EDTA plasma collected 
was stored at -800C. 
2.5. Intraperitoneal insulin tolerance test (ipITT) 
Intraperitoneal insulin tolerance tests (ipITT) were performed to assess insulin 
sensitivity. Insulin causes a fall in glycaemia, such that the mice with the highest insulin 
sensitivity should have the greatest fall. As for the ipGTTs (Section 2.3), the mice were 
fasted for 4 hours, housed in individual cages without food, but with bedding and water.  
Insulin solution for intraperitoneal injection was prepared freshly by diluting human 
insulin (0.1 units/ml), from a 100 units/ml insulin stock (Humulin R Cartridges, Lilly-
stored at 4˚C) in sterile saline (0.9%). The insulin dose for each mouse was calculated to 
be 0.75 units/kg body weight. 
Baseline blood glucose measurements and 60 l blood samples into EDTA-treated 
Eppendorf tubes were taken at time 0 min, as described in Section 2.3 after which the 
intraperitoneal injection of insulin was given. Consecutive measurements of blood 
glucose were performed at 15, 30, 45, 60 and 90 minutes after the insulin injection in 
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droplets of tail blood by the glucometer, as described in Section 2.3. On completion of 
the experiment, mice were returned to their respective cages with food and water. The 
time 0 min blood samples were centrifuged at 6000 rpm, (Rotor # SX4750, Allegra X-
15R Centrifuge, Beckman Coulter, CA, USA) for 10 min at 4˚C to separate the EDTA 
plasma which was stored at -80˚C for future analyses. 
2.6. Euthanasia and tissue harvesting 
2.6.1. Blood collection 
On the day of harvest, a 60 µL fed-tail blood sample from each conscious mouse was 
collected into an EDTA-Eppendorf tube from a lateral cut on the tail, while gently 
heating and massaging the tail under a heat lamp. Plasma from the blood samples were 
centrifuged at 6000 rpm (Rotor # SX4750, Allegra X-15R Centrifuge, Beckman 
Coulter, CA, USA) for 10 min at 40C and were stored at -800C for further measurement 
of insulin, pro-insulin, C-peptide and TG and NEFA. 
2.6.2. Anaesthesia, cardiac blood collection and euthanasia  
After collection of the tail blood samples, the mice were anaesthetized by using 
ketamine (100 mg/ml, Troy Laboratories, NSW, Australia) at 100mg/kg body weight 
and xylazine (20 mg/ml, Xylazil, Troy Laboratories, NSW, Australia) at 20 mg/kg of 
body weight. The anaesthesia was prepared by mixing 1 ml of ketamine and xylazine 
from stock in 8 ml of saline solution. The dose of anesthesia given to each mouse was 
10 µL per gram body weight of the mixed stock and was injected into the peritoneal 
cavity through the left lower abdominal region using a 25G needle (0.5mm X 25mm, 
Cat#301807, BD precision glide needle, NJ, USA) with a 1 ml tuberculin syringe 
(Cat#302100, BD, Biosciences, NJ, USA). 
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Once each mouse was unconscious, a cardiac puncture was made to collect blood by 
using a 0.5M EDTA rinsed 1 ml tuberculin syringe (Cat#302100, BD, Biosciences, NJ, 
USA) and a 25G needle (.05mm X 25mm, Cat#301807, BD precision glide needle, NJ, 
USA). These cardiac blood samples were collected into 4 ml BD vacutainers (Cat# 
366164, BD UK, Polymouth, UK) and immediately placed on ice. Later, these blood 
samples were centrifuged at 3000 rpm (Rotor # SX4750, Allegra X-15R Centrifuge, 
Beckman Coulter, CA, USA) for 15 min at 40C and were stored at -800C for 
measurement of proinsulin, C-peptide, TG and NEFA. 
2.6.3. Tissue dissection 
All groups of mice were euthanised still under anaesthesia by cervical dislocation. The 
abdominal cavity was opened widely and pancreas, liver, adipose tissue; including 
epididymal and subcutaneous fat were dissected and weighed on laboratory bench 
scales (FX-200i, Max=220g, d=0.001 g, A&D Company Ltd). 
2.6.3.1. Pancreas  
After opening the abdominal cavity of each mouse, the pancreas and other abdominal 
structures were identified prior to removal of the pancreas. The pancreas was carefully 
held by the spleen and removed by dissection from its bed and attachments, such as to 
the duodenum, with cleaning of the attached fat. After removal, the pancreas was further 
cleared of fat and lymph nodes with vision aided by a Stemi 1000 dissecting microscope 
(Carl Zeiss, Germany).  The pancreas was then weighed and recorded on laboratory 
bench scales (FX-200i, Max=220g, d=0.001 g, A&D Company Ltd) and placed inside a 
plastic cassette (Embedding cassette, Cat#LID-05, Techno Plas, SA, Australia). The 
tissue was then fixed in 10% neutral buffered formalin solution (Cat# ANBFB, 
Biostain, VIC, Australia) and embedded for later histological analyses. 
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2.6.3.2. Liver  
After removal of the pancreas, the whole liver was then quickly dissected. It was 
weighed and cut in to small pieces and snap-frozen in 7 mL screw cap tubes 
(Cat#58.536, Sarstedt, Germany) for storage at -80°C for future experiments.  
2.6.3.3. Adipose tissue  
Epididymal and abdominal subcutaneous adipose tissue  depots were dissected from the 
right side of the mice, because of the site of the anaesthetic injection on the opposite 
side. The adipose tissue depots were then weighed, cut into small segments and snap-
frozen in 7 mL screw cap tubes (Cat#58.536, Sarstedt, Germany) for storage at -80°C 
for future experiments.  
2.7. Blood Analytical analysis 
2.7.1. Insulin radioimmunoassay (RIA) 
 
The quantity of insulin in plasma collected from fed-tail blood and during the ipGTTs at 
times (0, 15 and 90 min) were quantitated using a rat insulin RIA. In this method, a 
known quantity of radiolabelled tracer antigen (125I-labelled insulin)  is mixed with a 
known dilution of antibody for that antigen, and as a result, the two specifically bind to 
one another (Abacus, Millipore, MA, USA). When, a sample of unlabelled antigen 
(sample containing an unknown amount of insulin) is added. This causes a competition 
between the unlabelled antigens from the plasma to compete with the radiolabelled 
antigen for antibody binding sites. Thus, an increasing concentration of unlabelled 
antigen decreases the ratio of antibody-bound tracer to free tracer and vice versa. The 
bound antigens are then separated from the unbound ones, and the radioactivity of the 
free antigen remaining in the supernatant is measured using a gamma counter.  
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Test samples and standards were diluted in bovine serum albumin (BSA) phosphate 
buffer (BSA phosphate buffer; for the constituents see Appendix 1) and were distributed 
in 12 x 75mm in Polypropylene tubes (Cat # T400A, Simport, represented by Lomb 
Scientific in Australia) to a volume of 50 l. A standard curve was generated using 
purified human insulin at concentrations of 0, 0.0625, 0.125, 0.5, 1, 2, 4, 8, and 16 
ng/mL. 125I-insulin (Cat# Abacus, Millipore, MA, USA) and approximately 5µCi/ml 
was added in aliquots of 50 l to all tubes, followed by addition of 50 μL of undiluted 
1st antibody: Guinea pig anti-rat insulin serum (Cat # ML1013-K, Millipore-Linco cat, 
Billerica, USA). This was followed by an overnight incubation 40C. The 1st antibody 
was not distributed into tubes 1 to 4, as these tubes contain 50μL of the 125I-insulin 
tracer alone for the determination of the total and non-specific binding, required for data 
analysis.  On the next day, 500 μl of secondary antibody mixture of 335μl of 
polyethylene glycol-sodium phosphate buffer (PEG; refer to Appendix 1), 85 μl BSA 
phosphate buffer, 40 μL of 1:5 diluted goat anti-guinea pig immunoglobulin G 
(Cat#GAGP80-459, Equitech-Bio Inc., TX, USA) and 40 μl of 0.057 mg/ml guinea pig 
serum (Cat#006-000-120, Jackson ImmunoResearch Laboratories. Inc., PA, USA) were 
added to all tubes (except total count tubes), followed by a further 2 hours incubation at 
40C. 
After the incubation, all tubes (except for the total count tubes) were centrifuged        
(Rotor # SX4750, Allegra X-15R Centrifuge, Beckman Coulter, CA, USA) at 2,500 
rpm for 15 min at 40C. Supernatant from all (except total count tubes) were discarded 
by inverting the tubes to remove unbound tracer. The tubes were left inverted on the 
paper towels to dry for 1 hour. Radioactivity of retained pallets was counted (1 
min/tube) using the gamma-counter (Perkin Elmer 2480 Wizard Automatic Gamma 
Counter, Massachusetts, USA). 
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2.7.2. Plasma non-esterified fatty acids (NEFA) 
The NEFA levels in plasma, collected from mice by cardiac puncture at the time of 
euthanasia, were measured using the Wako NEFA C kit (Cat#279-75401, Wako 
Chemicals, Osaka, Japan). Measurement of NEFA is based on the conversion of NEFA 
to acetyl-CoA, AMP and pyrophosphoric acid by acyl-CoA synthetase in the presence 
of coenzyme A and ATP. The acyl-CoA thus produced is oxidized by added acyl-CoA 
oxidase with generation of hydrogen peroxide. The presence of peroxidase permits the 
oxidative condensation of 3-methy-N-ethyl-N (β-hydroxyethyl)-aniline with                           
4-aminoantipyrine to form a purple coloured product, which can be measured 
calorimetrically at 570 nm. 
For the measurement of plasma NEFA, instructions from the Wako kit were followed. 
Briefly, standards at concentrations of 0, 0.125, 0.25, 0.5, 1, 2 and 3 mmol/l were 
prepared by using 1 mmol/l of the provided solution. 2.5 µl of the prepared standards 
and plasma samples were pipetted into duplicate wells of 96-well plates (Cat#167008 
Nunce, Thermo Fischer Scientific, Roskilde, Denmark). Fifty µL of Reagent A, 
previously prepared by combining reagent A with color A, was added by using an 
Eppendorf repeating manual pipette (Eppendorf 022260201, Hamburg, Germany). 
Plates were incubated at 370C for 10 min. Subsequently, 100 µl of Reagent B, also 
prepared by mixing reagent B with color reagent B, was added in every used well and 
incubated at 370C for 10 min. After the incubation, the plate was allowed to cool for 5 
minutes. The absorbance was read at 570 nm using the FluoStar Optima 
Spectophotometer (Serial # 413-2046, BMG Labtech, NC, USA). 
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2.7.3. Plasma Triglyceride (TG) 
The TG levels in plasma collected from the cardiac puncture samples was measured 
using the Wako TG C kit (Cat # 432-40201, Wako Chemicals, Osaka, Japan). This kit is 
based on the enzymatic hydrolysis of the triglycerides by lipase to glycerol and free 
fatty acids. The glycerol formed from the initial reaction is then phosphorylated to 
glycerol-3-phosphate when catalysed by glycerol kinase. The glycerol-3-phosphate is 
oxidized to hydrogen peroxide in a reaction catalysed by glycerol-3-phosphate oxidase. 
Peroxidase catalyses the redox-coupled reaction of H2O2 with 4-aminoantipyrine and N-
Ethyl-N-(3-sulfopropyl)-anisidine, to produce a brilliant blue colour which exhibits 
absorbance at 600 nm. 
TG concentrations were measured on a 96 well plate and then read on the FluoStar 
machine. For TG assay, instructions from Wako kit were followed; briefly working 
reagent was prepared by mixing one bottle of colour Reagent A with Solvent A.  
Plasma samples were thawed on ice for the assay, and 2.5 µl for standards; 0, 1.5, 3, 6, 
9, 12, 15, 18 µg/µl and plasma were loaded in a flat bottomed 96 well plate 
(Cat#167008 Nunce, Thermo Fischer Scientific, Roskilde, Denmark). 150 µl of working 
reagent was added by the Eppendorf micropipette repeater (Cat# 022260201 Eppendorf, 
Hamburg, Germany). Then, the plate was incubated at 37°C for 10 min, and cooled for 
5 minutes. The absorbance was measured at 600 nm using the FluoStar Optima 
Spectophotometer (Serial # 413-2046, BMG Labtech, NC, USA). 
2.7.4. Plasma Proinsulin  
Plasma proinsulin levels were measured from the cardiac plasma collected from the 
mice at the time of harvest by using the proinsulin ELISA kit, (Cat# 8-PINMS-E01, 
Alpco; New Hampshire, America). This kit is based on a sandwich type immunoassay 
where two monoclonal antibodies are directed against separate antigenic determinants 
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on the proinsulin molecule. A 96-well microplate is coated with a monoclonal antibody 
specific for proinsulin. After an initial incubation with standards and samples, followed 
by washing, a horseradish peroxidase enzyme-labeled monoclonal antibody is then 
added. After a further incubation and washing, 3’,5,5’-tetramethylbenzidine (TMB) 
substrate is added, and the microplate is incubated a third time. Once the third 
incubation is complete, addition of an acid stop solution stops the reaction giving a 
colourimetric endpoint, which exhibits absorbance at 450 nm.  
The manufacturer protocol was followed to perform the assay. High and low controls 
and standards at the concentrations of 0, 4, 15, 100 and 300 pM were reconstituted by 
adding 1.5 ml of deionized water. Ten μl volumes of standards, control and plasma 
samples were added in duplicates in the 96-well plates. 100 μl of working strength 
conjugate buffer; prepared earlier from conjugated stock by a 1/10th dilution was added 
into each well and incubated for 2 hours at room temperature with constant shaking  
(700-900 rpm) on a micro-plate shaker (Multitaskin Ascent, 354 Thermo Labsystems, 
Finland). Followed by the incubation, the contents of the wells were decanted and the 
micro-plate was washed 6 times with 350 μL of working strength wash buffer per well 
(prepared previously by diluting wash buffer concentrate with 20 parts distilled water). 
During the wash, wells of the micro-plate were filled with working strength wash 
buffer, and the liquid was discarded; the micro-plate was inverted, and firmly tapped on 
absorbent paper towels to remove the residual of wash buffer and bubbles. The washing 
was followed by 100 μl pipetting of TMB substrate with incubation of 30 min at room 
temperature, with shaking at 700-900 rpm on a micro-plate shaker (Multitaskin Ascent, 
354 Thermo Labsystems, Finland). After addition of 100 μl of stop solution, the 
absorbance of the plate was measured at 450 nm using the Spectophotometer 
(Multitaskin Ascent, 354 Thermo Labsystems, Finland). 
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2.7.5. Plasma C-peptide 
 
Plasma C-peptide levels were also measured from the cardiac puncture blood samples 
using a C-peptide ELISA kit (Cat #80-CPTMS-E01, Alpco; New Hampshire, America). 
This kit is based on a sandwich type immunoassay in which two monoclonal antibodies 
are directed against separate antigenic determinants on the C-peptide molecule. C-
peptide from the sample reacts with anti-C-peptide antibodies bound to the micro-plate 
wells. After an initial incubation period and washing, a peroxidase conjugated anti-C-
peptide antibody is added. Later, the bound conjugate is detected by reaction with TMB, 
which then develop a colourimetric pigment, which exhibits absorbance at 450 nm. 
The manufacturer protocol was followed to perform the assay. Briefly, high controls, 
low controls and standards at the concentration of 60, 250, 750, 1,500 and 3,000 pM 
were prepared by adding 1.5 ml of deionized water for reconstitution. The procedure for 
this assay is otherwise the same as described in section 2.7.4 of measurement of plasma 
proinsulin. 
2.7.6. Adiponectin 
 
Adiponectin concentrations in cardiac plasma were determined using the Quantikine® 
ELISA Mouse Adiponectin/Acrp30 Immunoassay (Cat# MRP300, R&D Systems, 
Minneapolis, MN, USA) according to manufacturer’s instructions. This assay uses the 
quantitative sandwich enzyme immunoassay technique, where plasma samples 
containing adiponectin were incubated in a 96-well microplate pre-coated with a 
monoclonal antibody specific for NS0-expressed recombinant mouse adiponectin 
protein. Addition of enzyme-linked polyclonal antibody specific for mouse adiponectin 
to the microplate wells causes binding to any mouse adiponectin that had attached to the 
antibody pre-coated microplate during the incubation period. Hydrogen peroxide and 
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tetramethylbenzidine addition produced a blue colour. This blue colour is suggested to 
be proportional to the amount of mouse adiponectin in the well. 
Prior to assay performance, plasma samples were diluted 2000-fold in Calibrator 
Diluent RD5-26 (1X) provided in the kit. Mouse adiponectin standard (lyophilized 
recombinant mouse adiponectin) was reconstituted in Calibrator Diluent RD5-26 (1X) 
to produce a stock solution of 10 ng/mL and a 2-fold dilution series in Calibrator 
Diluent RD5-26 (1X) of 5, 2.5, 1.25, 0.62, 0.31 and 0.16 ng/mL concentrations was 
prepared. A zero standard of 0 ng/mL adiponectin was created by adding only 
Calibrator Diluent RD5-26 (1X) without the standard stock solution. A positive control 
of lyophilized recombinant mouse adiponectin with known concentration range was 
also assayed. 
50 µL of plasma samples, standard dilution series and control was distributed to 
corresponding wells in the microplate provided by the kit. 50 µL of Assay Diluent 
RD1W (buffered protein base) was added to all the wells and the plate incubated at 
room temperature for 2 hours. Wells were then washed five times with 200 µL of wash 
buffer (provided by the kit) and 100 µL of mouse adiponectin conjugate (enzyme-linked 
polyclonal antibody specific for mouse adiponectin) was added to all the wells. The 
plate was then incubated at room temperature for 1 hour. After this incubation period, 
the plate was flipped over and any unbound enzyme-antibody reagent was removed by 
washing five times with 200 µL of wash buffer.  
100 µL of substrate solution (containing equal parts of hydrogen peroxide and 
chromogen (tetramethylbenzidine)) was added to all the wells. The microplate was 
covered with aluminium foil to protect from light and then incubated at room 
temperature for 30 min producing a blue colour. 100 µL of stop solution containing 
diluted hydrochloric acid was added to each well to stop the reaction from producing 
65 
 
yellow colour. The optical density of each well was determined within 30 min using a 
microplate reader (Multiskan Ascent, Thermo Lab systems, USA), reading at 450 nm 
and then at 540 nm. Optical imperfections in the plate were corrected by subtracting the 
readings at 540 nm from readings at 450 nm.  
2.8. Histological analysis 
2.8.1. Haematoxylin and eosin (H&E) staining and scoring 
Pancreases removed during the harvest were fixed in formaldehyde for 18 h at room 
temperature. Formaldehyde serves to stabilize the fine structural details of cells and 
tissues prior to examination by light or electron microscopy. The standard solution is 
10% neutral buffered formalin (NBF), which is approximately 3.7% formaldehyde in 
phosphate buffered saline. After 18 h the pancreases were transferred to the ACT 
Pathology Department at The Canberra Hospital for washing in 70% ethanol and then 
further serial dehydration with xylene followed by embedding into low melting point 
paraffin (56°C). The paraffin blocks were subjected to sectioning into a series of 4 µm 
thick sections by microtome (Microm HM200 Ergostar, USA).  Sections were stained 
with H&E according to the standard laboratory protocol (ACT Pathology). 
Histological analysis of blinded pancreas sections was performed by Prof Jane 
Dahlstrom, an experienced pathologist. Islet morphology, presence of exocrine pancreas 
and islet inflammation, accumulation of pancreas fat deposits, and islet endocrine cell 
apoptosis were all scored using a scoring sheet as shown in Appendix 2.  
2.8.2. Insulin Immunohistochemistry 
The pancreas paraffin blocks were subjected to sectioning by microtome (Microm 
HM200 Ergostar, USA). Three consecutive sections of 5μm at distance of 100 μm were 
cut and collected on HDS microscopic slides (HD scientific supplies, Australia). 
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Sections were baked in the oven at 700C for 30 min. Before proceeding with the 
staining protocol; the slides were deparaffinised and rehydrated. Incomplete removal of 
paraffin could cause poor staining of the section. Slides were placed in a rack and the 
following washes were performed in a fume hood (Dynasafe control system MK3, 
Australia): two Xylene (Xylene lab serve-Victoria) washes: 3 minutes each, followed by 
2 minutes wash each with 100% ethanol (Cat# BSPEL 9.95.2.5,LabServ, Biolab, (Aust) 
Ltd, VIC, Australia), 95% ethanol and 70% ethanol. This was followed by washing the 
slides in running under cold tap water after which they were immersed in 1x phosphate 
buffer solution (PBS; Cat# 09-8912-100, Medicago AB, Uppsala, Sweden) (Refer 
Appendix 1). From this step onwards the slides were not be allowed to dry, as drying 
would cause non-specific antibody binding and could cause high background staining. 
The pancreatic sections were targeted by a primary antibody, and subsequently by a 
secondary antibody, which was conjugated with a horse-radish peroxidase (HRP) 
enzyme; horseradish peroxidase. The peroxidase binds with 3,3’-Diaminobenzidine 
(DAB) as a substrate and oxidizes it, producing an easily observable brown colour. 
A blocking and dilution buffer was prepared by mixing 5% fetal bovine serum (FBS; 
Cat# 10082-147, Gibco, Life Technologies Corp., NY, USA) with 1x PBS solution for 
15 min. The blocking solution was used to reduce background or unspecific staining. 
The slides were stained with the primary antibody: guinea pig anti-insulin (Cat# A0564, 
Dako, CA, USA) with the dilution of 1:100 with 5% FBS/PBS solution. The 
combination of primary antibody and FBS/PBS solution was vortexed well and placed 
on ice until dispensation on sections. The slides were then incubated in a humidity 
incubation chamber (Lab Scientific, USA) with some water for 1 h. 
After the incubation, slides were washed twice with 1x PBS for 2 min each, followed by 
20 min incubation with 3% hydrogen peroxide (Cat# H1009, Sigma Aldrich, CA, USA) 
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made with 1x PBS solution. This acted as endogenous peroxidase blocker. After 
blocking, the slides were rinsed with 1x PBS twice for 2 minutes. After removing the 
blocking solution, the surface was dried around the tissue section and the slides were 
stained with secondary antibody: rabbit anti-Guinea pig IgG-HRP (Cat# P0141, Dako, 
Glostrup, Denamark) prepared with 5% FBS/PBS solution in 1:40 ratio. The tissue 
sections on the slides were completely covered with the added volume of HRP 
conjugated antibody and the slides were incubated for 45 minutes in the humidity 
incubation chamber at room temperature. 
 After the staining, the slides were rinsed and washed twice with 1 M PBS for 2 min 
each. The slides were then stained for 2 min using chromogen 3,3’-Diaminobenzidine 
tablets (DAB; Cat# D4293, SIGMAFAST™ Sigma-Aldrich, Castle hill, NSW, 
Australia). The DAB tablets were dissolved by vortex (Cat# BV100 Vortex Mixer, 
Benchmark Scientific Inc., NJ, USA) in 10mL dH2O in a 15mL falcon tube. DAB 
staining was followed by a PBS wash and a quick rinse in running water and immersed 
in 1x PBS solution. 
The slides were counterstained with Harris Hemotoxylin (Cat #HHX2.5L, POCD, 
Artarmon, NSW, Australia), for 30 seconds and rinsed under running water. The slides 
were immersed with 1% sodium bicarbonate solution (Cat# S3817, Sigma-Aldrich CA, 
USA) for 15 seconds and again washed under tap water. 
The slides were dehydrated through a series of dips in 75%-90% ethanol, followed by 2 
minutes incubation in 100% ethanol and then xylene solution. The slides were mounted 
by Medite (Cat# 41-4012-00 Pertex-Germany) and cover slipped (Cat# 25X 50#1, 
Surgipath®Leica, Biosynthesis).  Slides for insulin immunohistochemistry were scanned 
on Aperio ScanScope XT (Aperio Technologies, Inc, CA, USA). Analysis of the 
scanned images was performed on  Aperio ImageScope 12.3 (Aperio Technologies, Inc, 
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CA, USA) slide scanner and analysed by Image J 1.48v software (Wayne Rasband, 
National Institute of Health, USA). 
2.8.3. Measurement of -cell mass 
Pancreatic images for immunohistochemistry were obtained by using the slide scanner; 
Aperio ScanScope XT (Aperio Technologies, Inc, CA, USA) at 20x magnification. The 
image was then opened on Image J 1.48v software (Wayne Rasband, National Institute 
of Health, USA). The images were cleared from presence of any dirty background, fat 
tissue or lymph node on the software, prior to any measurement. The software was 
calibrated for images according to number of pixels and length. Threshold adjustments 
would allow selection of whole pancreas area, as well as areas immuno-stained for 
insulin (-cell areas). The process of -cell area measurement was repeated for each of 
3 levels (L1, L2 and L3) from which the average percentage β-cell area per pancreas 
was calculated. The β-cell mass was calculated, when the % β-cell area per pancreas was 
divided by 100 and multiplied by the pancreatic weight (mg) registered during 
harvesting (Refer to Appendix 3). 
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3.1. Introduction 
 
A previous study performed in our laboratory on B10k.insHEL transgenic and 
NODk.insHEL transgenic mice (see section 1.3.5) showed that islet -cell expression of 
the HEL transgene resulted in all transgenic mice (male and female NODk.insHEL and 
B10k.insHEL) developing hyperinsulinaemia, but without evidence of impaired 
sensitivity to exogenous insulin (Dooley et al, 2016). Only male NODk.insHEL mice 
developed non-immune diabetes with a decrease in -cell mass due to apoptosis. Hence, 
these gender specific NODk mice have the background and propensity to develop islet 
-cell failure (Dooley et al, 2016). 
To further investigate this propensity to -cell failure, a more usual diet stressor of islet 
-cells was studied in the experiments of this chapter. Male NODk and B10k mice, 
without the HEL transgene, were stressed by HF-feeding for 10 weeks post-weaning 
and their metabolic responses were characterized. Unexpectedly, the initial experiment 
between the NODk and B10k mice showed that the B10k mice on chow-diet did not have 
normal glucose tolerance, and for this reason, the B10k mice couldn’t be used as a 
control strain. Hence, Balb/c mice, known to have normal glucose tolerance on chow-
diet, were added to the study as a control third experimental strain.  
3.2. Experimental design 
 
This set of experiments was designed to characterise the metabolic phenotype of the 
three mice strains fed either chow or high fat diet from weaning to the age of 14 weeks. 
To differentiate from a longer-term study performed later in the thesis, these 
experiments are described as the “short-term study”. This chapter comprises the results 
of a time course study of body weight and non-fasting blood glucose levels. ipGTTs 
were also performed at 13 weeks, at which time, fasting plasma TG and NEFA were 
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also measured. In addition, at 14 weeks, a 9:00 AM non-fasted blood sample was used 
to measure blood glucose, plasma insulin, TG and NEFA and cardiac plasma was used 
to measure pro-insulin, C-peptide and adiponectin.  
The experimental design for the short-term study is illustrated in Figure 3.1.  
 
 
Figure 3.1. Outline of experimental design for the characterization of Balb/c, B10k 
and NODk mice fed chow or HFD for 10 weeks (post weaning to 14 weeks of age). 
Intraperitoneal glucose tolerance test (ipGTT), non-esterified fatty acid (NEFA) and 
triglycerides (TG). 
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3.3. Results  
 
3.3.1. Body weight measurement 
 
Body weight of Balb/c, B10k and NODk mice were measured in the non-fasting state 
between 9:00 and 10:00 AM, every fortnight from 4 weeks of age (i.e. after weaning) 
until 14 weeks of age. Body weight results are shown in Figure 3.2. The growth curves 
for body weight over time are shown in Fig 3.2A-D. Fig 3.2E shows the weight at 
weaning of the 3 different mice strains prior to starting on diet. 
NODk mice were heavier than the other two strains and this was evident from as early as 
post weaning at week 4, where the NODk mice were 26.9% heavier than Balb/c and 
36.5% heavier than B10k mice (Fig 3.2E). Furthermore, B10k mice were lighter than 
Balb/c mice at this time point (Fig 3.2E).  
All mice of the respective strains were heavier on the high fat diet compared to chow 
diet at 14 weeks of age. However, this was only significant for the B10k and NODk mice 
strains (Fig 3.2A-D).  By 14 weeks of age, the chow and HF-fed NODk mice were still 
heavier than the respective chow and HF-fed Balb/c and B10k mice (Fig 3.2F). 
Whereas, the increase in body weight of the HF-fed NODk mice from weaning to 14 
weeks of age was greater than for the HF-fed Balb/c and HF-fed B10k mice (Fig 3.2G).   
On considering the growth curves (Fig 3.2A-D), it is apparent that the HF-fed NODk 
mice develop an earlier and more progressive diet induced obesity in comparison to the 
other mice strains  (Fig 3.2A-C).  
Analysis of the data using a general linear model with repeated measures analysis on 
SPSS statistical program showed a three-way “time*strain*diet”, interaction (p=0.001). 
This is consistent with a different pattern of body weight gain in response to diet 
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between strains, with a greater propensity of the NODk mice to develop obesity when 
stressed by a HF-diet. 
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Figure 3.2. Body weight measurement during time-course study (age 4-14 weeks) in Balb/c, B10k and NODk mice fed chow or high 
fat diet (HFD). 
(A) Balb/c chow (n=10) and HFD (n=7) mice. (B) B10k chow (n=10) and HFD (n=11) mice. (C) NODk chow (n=11) and HFD (n=10) 
mice. (D) All groups shown. (E) Body weight at 4 weeks (baseline measurement) for all mice. (F) Body weight measured at 14 weeks for 
all groups. (G) Difference in body weight from 4 to 14 weeks of age in all groups. Means ± SEM. One-way ANOVA of body weight data 
at 4 weeks shown in table. Two-way ANOVA of body weight data at 14 weeks and difference in body weight shown in table and 
Bonferroni post-hoc tests:  **p<0.01, ***p<0.001 vs chow diet of the same strain; # # # p<0.001 vs different strain on the same diet.  
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3.3.2. Tissue weight measurement 
 
Liver, epididymal fat and subcutaneous fat were harvested and weighed from chow and 
HF-fed Balb/c, B10k and NODk mice at 8 and 12 weeks of age. The graphs with the 
absolute tissue weights and the relative weight as percentage body weight shown in 
Figure 3.3 (8 week results in Part 1 and 12 week results in Part 2). 
At 8 weeks of age, HF-feeding increased the absolute liver weight in NODk mice only 
(Fig 3.3A), however, this difference was not evident when liver weights were corrected 
for mouse body weight (Fig 3.3D). By 12 weeks, the effects of HF-feeding on total liver 
weights was similar to the 8 week time point (Fig 3.3G). Interestingly, with HF-feeding, 
liver weight of the B10k mice expressed as a percentage of body weight was 
significantly reduced (Fig 3.3J).  
At 8 weeks of age, the absolute tissue weights of the epididymal fat pads increased in all 
strains of mice with HF-feeding, but this was greatest in the HF-fed NODk mice              
(Fig 3.3B). Expressed as a percentage of body weight, the effect of HF-feeding to 
increase this fat depot size was similar in all strains (Fig 3.3E).  
The pattern of fat depot weight change in subcutaneous tissues with HF-feeding, 
however, was different from the epididymal fat depots, as the subcutaneous fat of 
Balb/c mice did not increase with HF-feeding, expressed as absolute weight or as a 
percentage of body weight (Fig 3.3C,F).   
Interestingly, at 12 weeks of age, the resistance to fat mass expansion of subcutaneous 
fat of Balb/c mice with HF-feeding was also evident in the epididymal fat depots of this 
mouse strain (Fig 3.3H,K). By 12 weeks of age, at variance from the Balb/c strain, HF-
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feeding of B10k and NODk mice caused expansion of both fat depot sites to a similar 
degree (Fig 3.3H-L).  
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      Figure 3.3. (Part 1&2) Liver, epididymal fat and subcutaneous fat weights of chow and high fat diet (HFD) fed Balb/c, B10k and NODk 
mice at 8 and 12 weeks of age. 
(A-F) Tissue weights of mice in all groups at 8 weeks of age. Data are Means ± SEM (n=7-11) mice per group. (A) Total liver weight.                          
(B) Epididymal fat weight. (C) Subcutaneous fat weight. (D) Liver weight as percentage of body weight (BW). (E) Epididymal fat weight as 
percentage of BW. (F) Subcutaneous fat weight as percentage of BW. (G-L) Tissue weights of mice in all groups at 12 weeks of age. Data are 
Means ± SEM (n=4-6) mice per group. (G) Total liver weight. (H) Epididymal fat weight. (I) Subcutaneous fat weight. (J) Liver weight as 
percentage of BW. (K) Epididymal fat weight as percentage of BW. (L) Subcutaneous fat weight as percentage of BW. Two-way ANOVA of 
shown in table and Bonferroni post-hoc tests: *p<0.05, **p<0.01, ***p<0.001 vs chow diet of the same strain; # p<0.05, # # p<0.01, # # # 
p<0.001vs different strain same diet. 
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3.3.3. Non-fasting blood glucose measurement  
 
For determination of the diabetic phenotype, a measurement of non-fasting blood 
glucose was performed between 9:00 and 10:00 AM fortnightly for 10 weeks during the 
short-term experiment. A drop of tail-blood was used to obtain the glucose 
measurement by a glucometer.  
The non-fasting blood glucose measurement of B10k mice at 4 weeks of age (baseline), 
was mildly but significantly elevated compared to the Balb/c and NODk mice (One-way 
ANOVA) (Fig 3.4E). None of the chow-fed mice had a change in glucose from baseline 
to 14 weeks of age (Fig 3.4A-D). 
The effects of HF-feeding on non-fasting glucose levels was clearly evident in NODk 
mice with the emergence of hyperglycaemia at 10 weeks of age (Fig 3.4 C), such that 
the HF-fed NODk mice were markedly hyperglycaemic by 14 weeks of age (Fig 
3.4C,F). In contrast, HF-feeding had no effect on non-fasting glycaemia in Balb/c and 
B10k mice (Fig 3.4A, B, D, F, and G).  
Using a general linear model with repeated measures to analyse the data, a three-way 
interaction of strain*diet*time was shown (p=0.05). This suggests that the abnormal 
glucose in NODk mice with HF-feeding was time dependent. 
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 Figure 3.4. Non-fasting blood glucose concentration during time-course study (age 4-14 weeks) in Balb/c, B10k and NODk mice fed 
chow or high fat diet (HFD). 
 (A) Balb/c chow (n=10) and HFD (n=7) mice. (B) B10k chow (n=10) and HFD (n=11) mice. (C) NODk chow (n=11) and HFD (n=10) 
mice. (D) All groups shown. (E) Blood glucose at 4 weeks (baseline measurement) for all groups. (F) Blood glucose measurement at 14 
weeks for chow and HFD mice for all groups. (G) Difference in blood glucose levels from 4 to 14 weeks of age in all groups. Means ± 
SEM. One-way ANOVA of blood glucose data at 4 weeks shown in table. Two-way ANOVA of blood glucose data at 14 weeks and 
difference in blood glucose levels shown in table and Bonferroni post-hoc tests: ***p<0.001 vs chow diet of the same strain; # # p<0.01, # # # 
p<0.001 vs different strain on the same diet.  
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3.3.4. ipGTT 
 
To determine the effects of HF-feeding on blood glucose regulation and insulin 
secretion on the three mice strains, ipGTTs were performed in Balb/c, B10k and NODk 
mice on chow and HF-diet at 13 weeks of age. 
 The test was performed after 4 hours of fasting and by injecting the mice with 2g/kg 
body weight of 25 % glucose intraperitoneally. 
The 13 weeks of age ipGTT blood glucose results are shown in Figure 3.5, with the 
glucose curves shown in Fig 3.5A-D.  
The fasting glucose concentrations alone are shown in Fig 3.5E, the two hour glucose 
concentrations alone are shown in Fig 3.5F and the total glucose area under the curve 
(AUC) results for all groups are shown in Fig 3.5G. 
On chow diet, there was a non-significant trend for B10k mice toward higher fasting 
glucose levels than the other two groups (Fig 3.5E).  
Chow-fed B10k mice however had impaired glucose tolerance compared to chow-fed 
NODk and Balb/c mice (Fig 3.5D, G).  
High-fat feeding resulted in no significant change in glucose tolerance in Balb/c mice, 
but severe glucose intolerance in both the B10k and NODk mice strains, as evidenced by 
elevated fasting glucose levels (Fig 3.5E), 2 hour blood glucose levels (Fig 3.5F) and 
the total area under the ipGTT glucose tolerance curves (Fig 3.5A, B, C, D, G). The 
worst glucose tolerance was evident in the HF-fed B10k mice (Fig 3.5D,G). 
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Two-way ANOVA showed a significant effect of strain (p<0.0001) and diet (p<0.0001) 
on glucose tolerance during the ipGTT, with a significant interaction of diet and strain 
(p=0.0029) (Fig 3.5G). 
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Figure 3.5. Blood glucose concentrations during ipGTT at 13 weeks of age in Balb/c, B10k and NODk mice fed chow or high fat diet 
(HFD). Mice fasted for 4 hours were injected with 2g/kg glucose intraperitoneally at time 0.  
(A) Balb/c chow (n=10) and HFD (n=7) mice.  (B) B10k chow (n=10) and HFD (n=11) mice. (C) NODk chow (n=11) and HFD (n=10) 
mice. (D) All groups shown. (E) Blood glucose measured at time 0 (fasting) during ipGTT for all groups. (F) Blood glucose measured at 2 
hours during ipGTT for all groups. (G) Total area under the curve (AUC) measured during ipGTT for all groups. Means ±SEM. Two-way 
ANOVA as shown. Bonferroni post-hoc tests: ***p<0.001 vs chow diet same strain; # p<0.05, # # p<0.01, # # # p<0.001vs different strain 
same diet. 
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3.3.5 Measurement of plasma insulin levels during ipGTT 
 
Obesity causes insulin resistance. To maintain normoglycaemia, the pancreatic islet -
cells need to compensate for the insulin resistance with insulin hyper-secretion. The 
generally accepted view is that when the -cells are not able to sustain this 
compensatory response to insulin resistance, hyperglycaemia emerges and progresses 
onto the development of type 2 diabetes. Thus, tail blood plasma was collected during 
the ipGTT at time 0, 15 and 90 minutes at 13 weeks of age to measure plasma insulin by 
RIA.  
The results are shown in Fig 3.6, with the insulin response over time shown in                     
Fig 3.6A-D, the fasting plasma insulin concentrations shown in Fig 3.6E, the total 
plasma insulin AUC shown in Fig 3.6F and the change in insulin AUC from the plasma 
insulin concentration at time 0 min in Fig 3.6G. 
On chow-diet, there was a non-significant trend for fasting plasma insulin to be higher 
in NODk mice compared to Balb/c and B10k mice (Fig 3.6E). Chow-fed B10k mice did 
not show a usual increase in plasma insulin at 15 min (Fig 3.6B). The total AUC of the 
insulin responses however was similar for chow-fed mice, irrespective of strain (Fig 
3.6F). 
In response to HF-feeding, there was an increase in insulin levels overall, with a marked 
significant increase in fasting and total insulin AUC in HF-fed NODk mice compared to 
the other strains (Fig 3.6A-F). Of note, the change in plasma insulin AUC from baseline 
was positive for HF-fed Balb/c and B10k mice, compared to a marked negative change 
in plasma insulin AUC in HF-fed NODk mice (Fig 3.6G), indicative of dysfunctional 
insulin secretion in this strain, even though there is an obvious compensatory response 
to insulin resistance. 
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Also of note, despite the very severe hyperglycaemia in response to HF-feeding in the 
B10k mice (Fig 3.6B), a significant increase in total plasma insulin AUC was not seen in 
this mouse group, indicative of poor -cell compensation for insulin resistance in this 
strain.  
90 
 
Figure 3.6. Plasma insulin concentrations during ipGTT at 13 weeks of age in Balb/c, B10k and NODk mice fed chow or high fat 
diet (HFD). Mice fasted for 4 hours were injected with 2g/kg glucose intraperitoneally at time 0. 
 (A) Balb/c chow (n=10) and HFD mice (n=7).  (B) B10k chow (n=10) and HFD (n=11) mice. (C) NODk chow (n=11) and HFD (n=10) 
mice. (D) All groups shown. (E) Plasma insulin measurement at time 0 (fasting) during ipGTT. (F) Total area under the curve (AUC) for 
plasma insulin measurement during ipGTT for all groups. (G) Change from basal AUC during ipGTT for all groups. Means ± SEM. Two-
way ANOVA as shown. Bonferroni post-hoc tests. **p<0.01 ***p<0.001 vs chow diet same strain; # # p<0.01, # # # p<0.001vs different 
strain same diet. 
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3.3.6. Measurement of non-fasting plasma insulin and 
derivatives 
 
Non-fasting tail blood was collected immediately before anaesthesia for measurement of 
plasma insulin from Balb/c, B10k and NODk mice at 14 weeks of age. Further non-
fasting blood was collected from cardiac puncture under light anaesthesia. The plasma 
from the cardiac blood was used to measure C-peptide and proinsulin. 
Insulin is synthesized as a precursor molecule, called proinsulin, which is later 
converted during post-translational modification in the -cell to insulin. A connecting 
peptide or  C-peptide is an amino acid segment, which connects the insulin A-chain and 
B-chain together in the proinsulin molecule. Later, the C-peptide is cleaved, leaving the 
A-chain and B-chain, bound together by disulphide bonds, constituting the mature 
insulin molecule. An increased level of proinsulin in plasma has been reported in type 2 
diabetes in humans and is believed to relate to dysfunction of islet -cells. C-peptide is 
secreted in proportion to mature or fully processed insulin. Measurement of insulin, 
proinsulin and C-peptide in plasma was performed to provide information on the quality 
of insulin of the three strains of mice on the two different diets.  
The non-fasting plasma insulin, proinsulin and C-peptide results in all mice strains are 
shown in Fig 3.7A-C, with ratios of plasma proinsulin to insulin, proinsulin to C-
peptide and insulin to C-peptide are shown in Fig 3.7D-F. 
The overall pattern of non-fasting plasma insulin levels as shown in Figure 3.7A is 
identical to that of fasting insulin levels already shown in Figure 3.6E. Again, a non-
significant trend for higher insulin levels was shown in chow-fed NODk mice compared 
to the other two strains. The NODk mice again became markedly hyperinsulineamic in 
response to HF-feeding, which was not evident in the other two strains (Fig 3.7A). 
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Interestingly, the NODk mice on chow-diet had significantly higher proinsulin levels 
than the chow-fed Balb/c and B10k mice, which increased in response to HF-feeding 
(Fig 3.7 B). HF-feeding, however, had no effect to alter the non-fasting plasma 
proinsulin concentrations in the Balb/c and B10k mice (Fig 3.7B). 
Plasma C-peptide levels were lowest in B10k mice compared to the other two strains, 
but this was significantly different from NODk mice only (Fig 3.7C). Unexpectedly, 
NODk mice fed HF diet had no further increase in C-peptide levels compared to the 
effect of HF-feeding, on insulin levels (Fig 3.7A-C). 
Of note, the proinsulin/insulin ratio was not increased in NODk mice on HF-diet 
suggesting that abnormal insulin processing, resulting in a greater percentage of 
proinsulin, was not evident in these hyperinsulinaemic mice (Fig 3.7D). 
Of particular interest there was a markedly increased insulin/C-peptide ratio in the HF-
fed NODk mice suggestive of impaired clearance of insulin from the blood of these mice 
(Fig 3.7F). The proinsulin/C-peptide ratio was higher in HF-fed NODk compared to HF-
fed Balb/c mice, but this was not the case in comparison to HF-fed B10k mice. 
 
94 
 
 
Figure 3.7. Non-fasting plasma insulin, proinsulin and C-peptide concentrations at 14 weeks of age in Balb/c, B10k and NODk 
mice fed chow or high fat diet (HFD).  
(A) Non-fasting plasma insulin from all groups from tail-blood. (B) Plasma proinsulin from all groups from cardiac blood.  (C) Plasma C-
peptide from all groups from cardiac blood. (D) Ratio of proinsulin to insulin.  (E) Ratio of proinsulin to C-peptide. (F) Ratio of insulin to 
C-peptide. Data are Means ±SEM 7-10 mice per group. Two-way ANOVA as shown. Bonferroni post-hoc tests: **p<0.01, ***p<0.001 
vs chow diet same strain; # p<0.05, # # p<0.01, # # # p<0.001 vs different strain same diet. 
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3.3.7. Measurement of adiponectin  
 
Adiponectin levels were measured from non-fasting cardiac plasma of NODk, B10k and 
Balb/c mice at 14 weeks. Adiponectin is an adipokine secreted from adipose tissue. 
Adiponectin levels are inversely proportional to body weight such that they are usually 
lower in association with obesity and metabolic syndrome. 
Unexpectedly, there was a strain effect, but not a diet effect on non-fasting plasma 
adiponectin levels (Fig 3.8). The increased body weights associated with HF-feeding 
within each of the strains were not associated with lower adiponectin levels. Plasma 
adiponectin levels in chow and HF-fed NODk mice, however, were significantly lower 
than the respective diet groups of chow and HF-fed Balb/c and B10k mice (Fig 3.8).  
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Figure 3.8. Non-fasting plasma adiponectin concentration from cardiac blood, 
measured at 14 weeks of age in Balb/c, B10k and NODk mice fed chow or high fat 
diet (HFD).  
All groups together shown. Data are Means ± SEM 4-10 mice per group. Two-way 
ANOVA as shown. Bonferroni post-hoc tests: # # # p<0.001vs different strain same diet. 
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3.3.8. Measurement of Non Esterified Free Fatty Acid (NEFA) 
 
NEFAs, or FFAs, are released from the hydrolysis of triglyceride in adipose tissues. 
NEFA reflect body fat mobilization in response to negative energy balance or stress 
conditions. Obesity and diabetes tend to chronically increase circulating NEFA, which 
diminishes tissue glucose uptake, while promoting hepatic glucose output. Hence, 
plasma NEFA was measured in both fasted and non-fasted experimental mice. 
Fasting plasma NEFA was measured at time 0 during the ipGTT at 13 weeks. The 
results show a main strain effect, with lowest levels in B10k mice and highest levels in 
NODk mice, but no main diet effect on NEFA levels (Fig 3.9A).  
Fed 9:00 AM NEFA was measured from tail blood collected before anaesthesia and 
mice harvest at 14 weeks of age. There was again a main strain effect, but there was not 
a significant main diet effect. (Fig 3.9B). Of note, in contrast to the fasted state, the 
Balb/c mice had the lowest levels and the NODk mice, the highest fed-state NEFA 
levels. Following Bonferroni post-hoc testing, fed-state NEFA levels in HF-fed NODk 
were higher compared to HF-fed Balb/c mice (Fig 3.9B).    
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 Figure 3.9. Plasma NEFA concentrations of Balb/c, B10k and NODk mice fed     
chow or high fat diet (HFD).  
(A) Fasting plasma NEFA from tail-blood at 13 weeks of age, all groups shown. (B) 
Non-fasting NEFA from tail-blood at 14 weeks of age, all groups shown. Data are 
Means ±SEM 5-10 mice per group. Two-way ANOVA as shown. Bonferroni post-hoc 
tests: # p<0.05 vs different strain same diet. 
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3.3.9. Measurement of TG 
 
Elevated TG levels are characteristic of the metabolic syndrome and type 2 diabetes. TG 
levels are affected by insulin sensitivity, the fed-fasted state transition, dietary content 
and physical activity. 
TG was measured from fasting plasma collected from Balb/c, B10k and NODk mice at 
time 0, at 13 weeks of age. 
Fasting plasma TG was lowest in chow fed Balb/c mice, similar in chow-fed B10k and 
NODk, and increased after HF-feeding in NODk mice only (Fig 3.10A). Bonferroni 
post-hoc test showed that fasting TG levels were significantly 2 fold higher in HF-fed 
NODk mice compared to HF-fed B10k mice and >10 fold higher compared to HF-fed 
Balb/c mice.  
Fed (9:00 AM) non-fasting TG was measured from blood collected before anaesthesia 
and mice harvest at 14 weeks age. The pattern of non-fasting TG concentrations                
was essentially the same as the fasting TG levels (Fig 3.10A, B), with a very strong 
main strain effect and a strain-diet interaction, with the NODk mice having the only 
significant TG concentration increase with the HF-diet. Clearly, the NODk mice are 
most prone to developing hypertriglyceridemia that is aggravated by HF-feeding. 
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Figure 3.10. Plasma TG concentrations in Balb/c, B10k and NODk mice fed chow 
or high fat diet (HFD).  
(A) Fasting plasma TG from tail-blood at 13 weeks of age, all groups shown. (B) Non-
fasting TG from tail-blood at 14 weeks of age, all groups shown. Data are Means ± 
SEM 5-10 mice per group. Two-way ANOVA as shown. Bonferroni post-hoc tests: 
**p<0.01, ***p<0.001 vs chow diet same strain; # p<0.05, # # p<0.01, # # # p<0.0001 vs 
different strain same diet. 
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3.4. Discussion 
 
The major finding of the experiments of this Chapter is that NODk mice, despite having 
excellent glucose tolerance on a standard chow diet, develop a severe type 2 diabetes 
phenotype with high fat diet feeding. The HF-fed NODk mice have rapid weight gain, 
become profoundly hyperinsulienaic, dyslipidaemic and by 14 weeks of age are 
markedly hyperglycaemic. Thus, the NODk mouse derived from the type 1 diabetes 
model NOD; is prone to develop diabetes if stressed by overexpression of a foreign 
protein in its -cells (Dooley et al., 2016) or by a high fat diet. These findings are in 
keeping with the hypothesis of this thesis, that non-immune islet -cell susceptibilities 
to dysfunction may contribute to the pathogenesis of both type 1 and type 2 diabetes. 
The second major and unexpected finding was that B10k mice have very poor glucose 
tolerance, even when fed on standard chow. But most interesting is that, despite this 
poor glucose tolerance on chow diet, with HF-feeding B10k mice do not develop 
diabetes by 14 weeks of age, as determined by elevation of 9 AM fed-state blood 
glucose levels. 
The Balb/c mice had excellent glucose tolerance on chow diet and was relatively 
resistant to the development of HF-diet induced obesity and completely resistant to the 
development of HF-diet induced glucose intolerance and diabetes. 
3.4.1 Mouse body and tissue weights 
 
Male NODk mice weighed more at weaning and were more prone to develop HF-diet 
induced obesity by 14 weeks of age than the other two strains. However, increases in 
adipose tissue depots of NODk and B10k mice, expressed as percent of body weight,   
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were not different in response to HF-feeding at 8 and 12 weeks of age. The Balb/c mice, 
however, were quite resistant to HF-diet induced expansion of adipose depot mass, 
particularly evident at 12 weeks of age. It has been reported that multiple genes and/or 
alleles contribute in the variation in body weight, feeding and drinking pattern, when 28 
strains were studied for the preference of food and water intake and spout side 
preference (Bachmanov et al., 2002), also to the pre-disposition to type 2 diabetes 
(Doria et al., 2008; Montgomery et al. 2013). Interestingly, Jackson Laboratories 
reported similar findings of diet-induced obesity and the development of 
hyperglycaemia in male “non-obese non-diabetic mice (NON mice)”, a mouse strain 
with the NOD background, but like the NODk mice studied in this thesis, a low risk 
MHC (H2nb1) for autoimmune diabetes (Jackson, 2006). There are few studies of HF-
feeding of C57BL/10 mice, however, consistent with the findings here in B10k mice, 
they are prone to diet-induced obesity (Radley-Crabb et al., 2011). The resistance of 
Balb/c mice to diet-induced  
obesity and adipose tissue expansion is consistent with previous reports (Fearnside et 
al., 2008, Marcelin et al., 2013). 
Total liver weight increased with HF-feeding in NODk mice, but this was not seen in the 
other two strains. This is could be due to an increase in hepatic triglyceride content, or 
hepatosteatosis. However, expressed as a percentage of body weight, the increase in 
liver size was proportional to the increase in total body weight. Of interest, is the 
decrease in liver weight, expressed as a percentage of body weight in B10k mice. This 
could be indicative of this mouse strain being less prone to hepatosteatosis than NODk 
mice. For confirmation of the extent to which the strains develop hepatosteatosis in 
response to HF-feeding, assessment of liver triglyceride content, liver histological 
analysis and liver metabolic gene expression would be necessary.  
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Food intake measurements were not performed during this experiment due to 
difficulties with crumbling of the HF diet and activity was not measured, as we had no 
access to the equipment required. Balb/cByJ mice, a substrain of Balb/c, however, have 
previously been shown to eat less fat than C57BL/6, when provided free access to fat, 
protein or carbohydrate. This is likely to be at least part of the reason for Balb/c mice 
being more resistant to diet-induced obesity (Qiu et al., 2001).  
3.4.2. Non-fasting blood glucose and glucose tolerance 
 
In Balb/c mice, HF-feeding had no effect at all on the 9AM fed-state glucose levels, 
consistent with the resistance of this strain to develop diet-induced obesity and 
hyperglycaemia. The B10k mice, as early as weaning (4 weeks of age), had slightly 
higher 9 AM fed glucose levels than the other two strains. However, in this strain, HF-
feeding did not significantly increase the 9 AM fed-state glucose levels, even though 
there seemed to be a minor increases at 6 and 10 weeks of age, not progressing to 14 
weeks of age. In contrast, the HF-fed NODk mice developed marked fed-state 
hyperglycaemia by 14 weeks of age (14.82.5 mmol/l), consistent with the development 
of diabetes, with the increase beginning by about 10 weeks of age.  This was clearly an 
effect of HF-feeding, as chow fed NODk mice maintained excellent fed-state glucose 
levels for the duration of this time course (6.80.4 mmol/l). 
Intraperitoneal glucose tolerance was examined at 13 weeks of age. Again, the Balb/c 
mice showed resistance to the effects of HF-feeding on glucose metabolism, as glucose 
tolerance was not significantly worsened. The results in B10k mice were unexpected. 
On chow diet, these mice had very poor glucose tolerance compared to the other two 
strains. Furthermore, despite this strain not developing diabetes as determined by the 9 
AM fed-state glucose levels, HF-feeding led to severe worsening of glucose tolerance 
with frankly diabetic curves. Also, in contrast to the fed-state glucose levels, fasting 
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blood glucose was elevated to a diabetic level (15.51.0 mmol/l). Consistent with the 9 
AM fed-state glucose levels, chow-fed NODk mice displayed excellent glucose 
tolerance at 13 weeks of age and HF-fed NODk mice had diabetic glucose tolerance 
tests curves. It should be noted that glucose bolus injections were calculated according 
to the mouse body weight, which may have partially contributed to the differences in 
glucose tolerance between the chow-fed and HF-fed states. 
The development of hyperglycaemia after only 4 hours of fasting was also unexpected 
in the B10k mice. This may be indicative of an exaggerated stress response to fasting, or 
the development of an imbalance of the glucagon/insulin ratio. This phenomenon could 
also be indicative of an important role of the liver in gluco-regulation in this mouse, as 
it is likely that dysregulated hepatic glycogenolysis and gluconeogenesis will have 
contributed to this fasting effect (Basu et al., 2005). To explore this further, glucagon 
and the other counter-regulatory hormones such as the catecholamines and 
glucocorticoids would need to be measured, and endogenous glucose production could 
also be measured using metabolic-tracer methodologies, which are beyond the scope of 
this thesis. 
3.4.3. Insulin levels and insulin derivatives 
 
The hyperglycaemia of diabetes can be a consequence of predominant insulin 
deficiency (e.g. from islet -cell destruction in type 1 diabetes) or a failure of islet -
cells to compensate for the presence of insulin resistance (as occurs in type 2 diabetes). 
Hence, in order to determine the cause of hyperglycaemia in the NODk and B10k mice, 
it was essential to measure insulin levels, particularly in response to a glucose load. 
The ipGTT plasma insulin levels of Balb/c mice showed a normal pattern of increase at 
15 min and a returning to basal at 90 min. Furthermore, there appeared to be the 
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expected increase in levels as would be expected from feeding the mice a HF-diet. The 
ipGTT insulin levels of the chow and HF-fed B10k mice were very similar to those of 
the respective Balb/c mice, but this was unexpected considering the hyperglycaemic 
glucose tolerance curves of both the chow and HF-fed B10k mice. Furthermore, the 
chow-fed B10k mice did not show the normal increase in insulin that is expected at the 
15 min time point. Thus, a failure of insulin secretion to respond to hyperglycaemia is 
likely to be a factor contributing to the severely abnormal glucose tolerance of B10k 
mice. Again, in marked contrast, the insulin levels of the NODk mice were profoundly 
increased in the HF-fed compared to the chow-fed NODk mice. Insulin secretion in the 
chow-fed NODk mice appeared to be normal at which time glucose tolerance was 
normal. Fasting levels of insulin, however, increased by about 9 fold in response to 
them being on HF-diet. Furthermore, the pattern of secretion was very abnormal in the 
HF-fed NODk, which showed a fall rather than increase in levels at 15 min compared to 
the fasting levels. This is indicative of the islet -cells of the NODk mice at least trying 
to compensate for HF-diet induced insulin resistance compared to the apparent lack of 
effort of the B10k mice. But the results also show evidence of -cells dysfunction in the 
NODk mice, as they were not able to increase plasma insulin levels in response to a 
glucose load. 
As explained in the introduction, insulin is the result of post-translational modification, 
including the cleaving of C-peptide from proinsulin, to form mature insulin. Type 2 
diabetes is associated with an increase in the ratio of proinsulin to insulin which could 
be indicative of islet -cell stress, and it has been proposed that an elevated proinsulin to 
insulin ratio can be an indicator of -cells dysfunction (Saisho et al., 2007). After the 
release of insulin and C-peptide into the extracellular space from the secretory vesicles, 
the insulin has a relatively shorter serum half-life ∼2–3 min and C-peptide has a longer 
half-life of ∼30 min, as it escapes from the first-pass metabolism by the liver (Faber et 
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al., 1978, Wahren et al., 2012). As C-peptide is stable in plasma for longer, it is used 
clinically as a marker of -cells function (Yosten and Kolar, 2015).  
For the above reasons, we measured fed-state insulin, proinsulin and C-peptide from the 
mice at the time of mice euthanasia and tissue sampling. The marked increase in total 
insulin of HF-fed NODk mice was again demonstrated. However, the ratio of proinsulin 
to insulin was reduced, rather than increased, in these hyperinsulinaemic mice. This 
suggests that proinsulin processing is not an issue in NODk mice. Surprising, however, 
was the C-peptide results. Despite total insulin levels being 7 fold higher in HF-fed 
compared to chow-fed NODk mice, the C-peptide levels were not different. This raises 
the possibility that the profound hyperinsulinaemia of NODk is a consequence of 
reduced clearance rather than increased secretion. Insulin clearance in the liver has been 
reported in subjects with glucose intolerance (Bonora et al., 1983). Also worth noting is 
the finding that C-peptide levels of B10k mice are generally much lower than in the 
other strains, which would be consistent with B10k mice being an insulin hypo-secreting 
strain. 
The appropriateness of insulin secretion and levels needs to take into account the degree 
of insulin resistance, which was not measured in the short-term studies of this Chapter. 
The marked hyperinsulinaemia of the HF-fed NODk mice could be reflective of greater 
insulin resistance developing in this strain in response to the diet. Insulin tolerance tests 
were performed in the cohort of animals of the long-term study reported in Chapter 4. 
3.4.4. Plasma lipid and adiponectin levels  
 
Plasma lipid levels and adipokine levels reflect the complex metabolic relationships 
between organs including the adipose tissue (Reaven, 1995). Adiponectin is a protein 
that is synthesized and released from adipocytes. Plasma adiponectin levels are 
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generally decreased in obesity and other insulin-resistant states (Weyer et al., 2001), and 
its concentration falls with weight increase (Yang et al., 2001). Interestingly, the plasma 
adiponectin concentrations were reduced in NODk mice compared to the other two 
mouse strains, irrespective of the diet they were on. This would be consistent with a 
constitutive difference in the behaviour of adipose tissue in NODk mice from the other 
two strains. Unexpected, was an absence of effect of HF-diet on adiponectin levels in 
any of the three strains of mice. 
With respect to plasma lipid levels, fasting and non-fasting NEFA and TG were 
measured and metabolic differences between the three mouse stains were again found. 
NEFAs, are released from the hydrolysis of triglyceride in adipose tissue. NEFA 
concentrations in plasma fall after each meal, as insulin suppresses adipose tissue 
lipolysis (Paolisso and Howard, 1998, McGarry, 2002). Plasma NEFA appeared to 
follow the physiological rules of the fasting-feeding transition best, as NEFA levels 
showed suppression in the fed-state. NEFA levels were intermediate in B10k mice, with 
little evidence of effect of the nutritional state. NEFA levels tended to be highest in 
NODk mice, with an effect of HF-diet to reduce suppression of levels in the fed-state. 
With respect to TG levels, Balb/c mice had the lowest levels and NODk mice the highest 
levels, even on chow diet as shown in the fed-state. 
Although, the measurements of plasma lipid and adipokine levels are minimal, there is a 
suggestion from this data, particularly of chow-fed mice, that the adipose tissue of 
NODk mice may be more prone to the abnormalities that are typical of the metabolic 
syndrome and type 2 diabetes (McGarry, 2002). Certainly the adipose of Balb/c mice is 
not prone to develop characteristics of metabolic syndrome. It has been shown that the 
acute elevated plasma FFA by intravenous infusion of heparinized triglyceride 
emulsions causes a >80% inhibition of insulin-stimulated whole-body glucose uptake in 
skeletal muscles and disappears approximately 4 h after normalization of plasma FFA 
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(Boden, 2008). An elevated fasting TG has also been identified in predicting the future 
of type 2 diabetes (Tirosh et al., 2008).  
 
3.5. Summary 
 
The analysis of metabolic physiology of Balb/c, B10k and NODk mice strain in response 
to HF diets, clearly shows marked variability across multiple parameters of body 
weight, relative tissues weight, fed-state and fasting glucose levels, glucose tolerance, 
insulin secretion and plasma lipid and adipose tissues measures. Of relevance to our 
hypothesis, NODk mice develop a severe phenotype in response to HF-feeding 
suggestive of a propensity of this mouse to have non-immune susceptibility to failure. 
This mouse fed a HF-diet, however, develops a phenotype typical of type 2 diabetes, 
with profound hyperinsulinemia and a suggestion that the latter is due to reduced insulin 
clearance. Unexpected, were very interesting results for B10k mice which have very 
poor glucose tolerance, but are resistant to diabetes development. They seem to be poor 
secretors of insulin, which raises the possibility that insulin hypo-secretion could be a 
protection from progression to frank diabetes.  The reason for the resistance to obesity 
and diabetes of the Balb/c mice is also intriguing with the results being consistent with 
previous reports suggesting less over-eating and the adipose tissue are less prone to 
features typical of the metabolic syndrome. 
 Further studies are required to determine the mechanisms underlying the profound 
differences between these three mouse strains. 
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Chapter # 4: Results  
(Long Term Study) 
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4.1. Introduction 
 
From earlier work in our laboratory, it was shown that the expression of the HEL 
transgene in -cells of male NODk mice developed non-immune diabetes, but that 
expression of HEL in the -cells of B10k mice did not have this effect (Dooley et al., 
2016). The diabetes in the male NODk HEL mice was associated with a decrease in -
cell mass due to -cell apoptosis.  
In the work of Chapter 3, the aim was to determine if a more usual -cell stressor, high 
fat diet, could also cause non-immune -cell failure in the NODk mouse. Basically, we 
showed that high fat feeding of male NODk mice from weaning for a period of 10 
weeks did cause excess weight gain, severe hyperinsulinemia and diabetes. The male 
Balb/c mice fed HF-diet for 10 weeks had less weight gain and were able to maintain 
excellent glycaemic control with modest increases in insulinaemia. The findings of the 
B10k mice were unexpected and of particular interest. The B10k mice after 10 weeks of 
post-weaning chow diet displayed very poor glucose tolerance which did worsen if the 
diet was HF; however, neither chow-fed nor HF-fed B10k mice developed diabetes, as 
determined by 9 AM fed blood glucose levels. The B10k mice did gain weight on the 
HF diet, but less quickly than the NODk mice. Of particular note, they failed to respond 
with an increase in insulin levels to compensate for the insulin resistance induced by 
HF- feeding.  
This very interesting finding in B10k mice, of poor glucose tolerance, but resistance to 
the development of diabetes after 10 weeks of HF diet, prompted the longer-term 
experiments of this Chapter. The aim was to see if B10k mice maintain their resistance 
to diabetes development or later do develop diabetes. Hence, Balb/c, B10k and NODk 
mice were fed chow or HF diets for 20 weeks post-weaning (long-term experiment) for 
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further characterization of their glucose tolerance and diabetes status, with particular 
interest in the B10k mice. It was anticipated that the NODk mice on HF-diet would 
develop overt diabetes necessitating them to be euthanized early and the Balb/c mice 
would continue to compensate well to the longer period of HF-feeding. 
4.2. Experimental design 
 
This set of experiments called the “long-term study” was designed to characterise the 
metabolic phenotype of the three mice strains fed either chow or HF-diet from weaning 
to the age of 24 weeks. As performed in Chapter 3 but for a shorter time, a time course 
of measurement of body weight and non-fasting blood glucose levels was undertaken. 
An ipITT was performed to assess insulin sensitivity at 13 weeks of age, and an ipGTT 
was performed at 23 weeks of age to assess glucose tolerance and in vivo insulin 
secretion in response to glucose. Fasting plasma TG and NEFA were also measured at 
time 0 of the ipGTT. Prior to anaesthesia for terminal pancreas tissue harvesting, tail 
blood was obtained for non-fasting blood glucose, plasma insulin, TG and NEFA 
measurements. Under anaesthesia, prior to tissue harvest, cardiac blood was obtained 
for the measurement of plasma proinsulin and C-peptide. Blood sampling and pancreas 
harvest and their processing are described in Chapter 2. 
As overt diabetes was expected in the NODk mice, a protocol was set for early 
experimental termination of mice according to 9 AM non-fasting blood glucose 
measurements. If a mouse had blood glucose measurements of 20 mmol/l or above for 
two consecutive measurements, that mouse would be diagnosed as having overt 
diabetes and would be culled early, but with termination bloods and tissue harvest as for 
the other mice of this study. The experimental design for the long-term study is 
illustrated in Figure 4.1. 
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 Figure 4.1: Outline of experimental design for the characterization of Balb/c, B10k    
and NODk mice fed chow or HFD for 20 weeks (post weaning to 24 weeks of age). 
Intraperitoneal insulin tolerance test (ipITT), Intraperitoneal glucose tolerance test 
(ipGTT), non-esterified fatty acid (NEFA) and triglycerides (TG). 
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4.3. Results  
 
4.3.1 Body weight measurement 
 
Body weight of Balb/c, B10k and NODk mice were measured in the non-fasting state 
between 9:00 and 10:00 AM, every fortnight from 4 weeks of age (i.e. after weaning) 
until 24 weeks of age. Body weight results are shown in Figure 4.2. 
The growth curves for body weight over time are shown in Fig 4.2A-D. Fig 4.2E shows 
the weight at weaning of the 3 different mice strains prior to starting on diet. Body 
weight at 24 weeks is shown in Fig 4.2F and the difference in body weight from 4 
weeks to 24 weeks in the mice groups is shown in Fig 4.2G. 
At 4 weeks of age (i.e. at weaning) the NODk mice were significantly heavier than the 
B10k and Balb/c mice (Fig 4.2E). Furthermore the Balb/c mice were also significantly 
heavier than the B10k mice at this same age, prior to commencement of high fat feeding 
(Fig 4.2E). Diabetes did develop in 5 of the 6 HF-fed NODk mice, requiring ethical 
culling prior to 24 weeks of age, as indicated in Fig 4.2C. For this reason, results for 
body weight at 24 weeks of age (Fig 4.2F) and the change in body weight from 4 to 24 
weeks (Fig 4.2G) for NODk mice are not shown. However, it is clearly demonstrated in 
Fig 4.2C that HF-diet feeding of the NODk rapidly increased the body weight of this 
strain of mice compared to its chow-fed controls. 
 Analysis of the data up to 12 weeks of age using a general linear model with repeated 
measured analysis on SPSS statistical program showed a three-way “time*strain*diet”, 
interaction (p<0.0005), indicative of greater early effect of HF-diet on body weight in 
NODk compared to the other two strains (Fig 4.2A-D).  
B10k and Balb/c mice were heavier on the HF-diet compared to their respective chow 
fed groups at 24 weeks of age, however, there was not a diet-strain interaction for body 
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weight or the change in body weight from 4 to 24 weeks of age between these two mice 
strains (Fig 4.2F-G).  
116 
 
          
Figure 4.2. Body weight measurement during time-course study (age 4-24 weeks) in Balb/c, B10k and NODk mice fed chow or high 
fat diet (HFD). 
 (A) Balb/c chow (n=6) and HFD (n=6) mice. (B) B10k chow (n=6) and HFD (n=6) mice. (C) NODk chow (n=6) and HFD (n=6) mice. 
Several HF-fed NODk mice were euthanized before 24 weeks due to severe hyperglycemia. Numbers in brackets refer to the number of 
mice remaining (D) All groups shown. (E) Body weight at 4 weeks (baseline measurement) for all mice. (F) Body weight measured at 24 
weeks for B10k and Balb/c mice only. (G) Change in body weight from 4 to 24 weeks of age for B10k and Balb/c mice only. Means ± 
SEM. One-way ANOVA of body weight data at 4 weeks shown in table (E). Two-way ANOVA of body weight data at 24 weeks and 
change in body weight shown (F&G). Bonferroni post-hoc tests:  **p<0.01, ***p<0.001 vs chow diet of the same strain; # # p<0.01, # # # 
p<0.001 vs different strain on the same diet.  
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4.3.2. Non-fasting blood glucose measurement 
 
For determination of the diabetic phenotype, a measurement of non-fasting blood 
glucose was performed between 9:00 and 10:00 AM fortnightly up to 24 weeks of age 
during the long-term experiment. A drop of tail-blood was used to obtain the glucose 
measurement by a glucometer. Fed-blood glucose concentrations are shown in Figure 
4.3. 
At 4 weeks of age (weaning), there were no differences between the non-fasting glucose 
levels of the three mice strains (Fig 4.3E). On chow-diet until 24 weeks of age, Balb/c, 
B10k and NODk mice all maintained normal fed-state glycaemia (Fig 4.3A-D).  
With HF-feeding, non-fasting blood glucose did not change in Balb/c mice, but there 
was a minimal increase in HF-fed B10k glucose levels, which was significantly different 
from their chow fed counterparts at 24 weeks of age (Fig 4.3A, B, D, F& G). Similarly, 
the change in fed-state blood glucose concentrations from 4 to 24 weeks was positive in 
the HF-fed B10k mice compared to no change in the HF-fed Balb/c mice and chow-fed 
mice of both strains (Fig 4.3G). 
HF-fed NODk mice, however, did develop fed-state hyperglycaemia and diabetes, 
requiring 5 of the 6 animals to be culled before the completion of the experiment             
(Fig 4.3 C, D&H). The percentage of non-diabetic NODk mice is shown in the survival 
curve (Fig 4.3H), where 100% chow-fed NODk mice survived and were non-diabetic by 
24 weeks of age.  
Whereas, only 1 of 6 HF-fed NODk mice survived during the long-term experiment and 
could be regarded non-diabetic. Analysis of the data by log-rank test showed the 
diabetes free survival of HF-fed NODk to be significantly less than the chow-fed NODk 
mice (p=0.0039). 
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Analysis by general linear model of the blood glucose data using repeated measures to 
12 weeks of age showed a three-way interaction between strain, diet and time (p<0.05). 
This suggests that the effect of HF diet to induce hyperglycaemia in NODk mice is time 
dependent. 
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Figure 4.3. Non-fasting blood glucose concentration during time-course study (age 4-24 weeks) in Balb/c, B10k and NODk mice fed 
chow or high fat diet (HFD). 
 (A) Balb/c chow (n=6) and HFD (n=6) mice. (B) B10k chow (n=6) and HFD (n=6) mice. (C) NODk chow (n=6) and HFD (n=6) mice. 
Several HF-fed NODk mice were euthanized before 24 weeks due to severe hyperglycemia. Numbers in brackets refer to the number of 
mice remaining (D) All groups shown. (E) Blood glucose at 4 weeks (baseline measurement) for all groups. (F) Blood glucose 
measurement at 24 weeks for B10k and Balb/c mice only. (G) Change in blood glucose concentration from 4 weeks to 24 weeks in B10k 
and Balb/c mice only. (H) Percentage of NODk mice non-diabetic over time course. Means ± SEM.  One-way ANOVA of blood glucose 
data at 4 weeks shown in table (E). Two-way ANOVA of blood glucose concentration at 24 weeks and change in blood glucose 
concentrations in tables (F&G). Bonferroni post-hoc tests: *p<0.05 vs chow diet of the same strain; # p<0.05, vs different strain on the 
same diet. Survival curve log-rank (Mantel-Cox) test (H). 
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4.3.3. ipITT 
 
At 13 weeks of age ipITTs were performed to measure insulin sensitivity in Balb/c, 
B10k and NODk mice on chow or HF-diet. Mice were fasted for 4 hours and the test was 
conducted after intraperitoneal injection of human insulin with a dose of 0.75 U/kg 
body weight.  
Blood glucose concentrations were measured before insulin injection and 15, 30, 45, 60 
and 90 min post insulin injection. Results for the ipITTs are shown in Figure 4.4. 
The blood glucose concentrations during the ipITTs for Balb/c, B10k and NODk mice 
are shown in Fig 4.4A-D. The blood glucose results expressed as % of baseline glucose 
are shown in Fig 4.4E. The blood glucose percentage fall at the nadir is presented in Fig 
4.4F. 
The fasting blood glucose concentrations of chow-fed Balb/c, B10k and NODk mice 
were similar, but the fasting blood glucose levels of the HF-fed B10k and NODk mice 
were elevated (Fig 4.4A-D).  
The chow fed mice of the three strains had similar reductions of blood glucose in 
response to the exogenous insulin injection (Fig 4.4 D-F). It should be noted that ipITT 
studies were performed in only 3 of 6 HF-fed NODk mice, as 3 mice had developed 
diabetes by the time of this test.  
The glucose fall in HF-fed Balb/c mice did not suggest the presence of insulin 
resistance (Fig 4.4A, D-F). Following an initial trend for blood glucose to increase after 
the  ip insulin injection in HF-fed B10k mice, glucose levels did fall, with the percentage 
fall to nadir being not different between chow and HF-fed B10k mice (Fig 4.4B, D-F). 
Whereas, the ipITT results of the chow and HF-fed NODk mice were suggestive of HF 
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diet induction of insulin resistance in this strain, particularly when assessed by the 
percentage fall in blood glucose from baseline to nadir (Fig 4.4C-F). Due to the reduced 
number of HF-fed NODk mice tested, however, the insulin resistance caused by HF diet 
in NODk mice could not be statistically shown.  
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Figure 4.4. Blood glucose concentrations during ipITTs at 13 weeks in Balb/c, B10k and NODk mice fed chow or high fat diet 
(HFD). Mice were fasted for 4 hours and were injected with 0.75 units/kg insulin (diluted to 0.1 units/ml) intraperitoneally at time 0 
minutes.  
(A) Balb/c chow (n=6) and HFD (n=6) mice. (B) B10k chow (n=6) and HFD (n=6) mice. (C) NODk chow (n=6) and HFD (n=3) mice. 
Three HF-fed NODk mice were euthanized before the ipITTs were to be performed due to the development of diabetes. (D) All groups 
shown. (E) Percentage of baseline glucose concentration shown for all mice groups during ipITT. (F) Blood glucose fall at nadir, expressed 
as percentage fall from baseline; all groups shown. Means ±SEM. Two-way ANOVA as shown (F). 
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4.3.4. ipGTT 
 
ipGTTs were performed at 23 weeks of age in chow-fed and HF-fed Balb/c, B10k and 
NODk mice. These tests were performed to determine the effects of longer-term HF-
feeding on blood glucose regulation and insulin secretion of the three mice strains.  
The test was performed after 4 hours of fasting and by injecting mice 2g of 25% glucose 
per kg body weight intraperitoneally. Of note, an ipGTT was only performed in one 
mouse from the HF-fed NODk group, as 5 of the 6 mice from this group had been culled 
earlier because of the development diabetes with severe hyperglycaemia. 
The ipGTT results are shown in Figure 4.5, with the glucose curves shown in Fig 4.5        
A-D.  The total glucose area under the curve (AUC) results for chow-fed Balb/c, B10k 
and NODk are shown in Fig 4.5E.  
The fasting and the 2 h post-glucose load blood glucose levels, and the total blood 
glucose AUC results, are for chow and HF-fed Balb/c and B10k mice are shown in Fig 
4.5F-H. 
In keeping with the results of the short-term study, glucose tolerance of chow-fed          
B10k  mice was significantly impaired compared to chow-fed Balb/c and NODk mice   
(Fig 4.5 B,D-E). Furthermore, the total glucose AUC results showed that chow-fed 
NODk mice even have better glucose tolerance than chow-fed Balb/c mice (Fig 4.5E). 
Even after this much longer period of HF-feeding, Balb/c mice showed no deterioration 
in glucose tolerance (Fig 4.5E). 
 As already mentioned, HF-feeding of NODk mice caused diabetes in 5 of the 6 mice 
studied, such that it was not a surprise that severe glucose tolerance was evident in the 
one HF-fed NODk mouse that underwent the ipGTT (Fig 4.5C). HF-feeding of B10k 
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mice caused elevated fasting blood glucose and severely abnormally glucose tolerance, 
as was also seen in the short term study (Fig 4.5 C, F-H).  
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Figure 4.5. Blood glucose concentrations during ipGTTs at 23 weeks of age in Balb/c, B10k and NODk mice fed chow or high fat 
diet (HFD). Mice were fasted for 4 hours and injected with 2g/kg glucose intraperitoneally at time 0 minutes.  
 (A) Balb/c chow (n=6) and HFD (n=6) mice. (B) B10k chow (n=6) and HFD (n=6) mice. (C) NODk chow (n=6) and HFD (n=1) mice. 
Five HF-fed NODk mice were euthanized before the ipGTTs were to be performed due to the development of diabetes. (D) All groups 
shown.   (E) Total glucose area under the curve (AUC) measured during ipGTT for chow-fed mice of all groups. (F) Fasting blood glucose 
concentrations during ipGTT for Balb/c and B10k mice only. (G) 2 hours blood glucose concentrations during ipGTT for Balb/c and B10k 
mice only. (H) Total glucose area under the curve (AUC) during ipGTT for Balb/c and B10k mice only. Means ±SEM. One-way ANOVA 
of total glucose AUC for chow mice only shown (E). Two-way ANOVA shown (F-H). Bonferroni post-hoc tests: **p<0.01, ***p<0.001 vs 
chow diet of the same strain; # # p<0.01, # # # p<0.001vs different strain same diet. 
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4.3.5. Measurement of plasma insulin levels during ipGTT 
 
Despite severe glucose intolerance in chow and HF-fed in B10k mice, in the short-term 
study, these mice failed to respond with increased insulin secretion. NODk mice, 
however, responded to 9 weeks of HF-feeding with increased basal insulin, but 
abnormal insulin responses (no increase) following ip glucose. Insulin responses to 
ipGTTs were again assessed in the three mice groups on chow and HF-diets after the 
longer period of 19 weeks on diet. As discussed in Section 4.3.2, only one HF-diet 
treated NODk mouse underwent the ipGTT within this longer-term cohort. 
The results are shown in Figure 4.6, with the insulin response over time shown in             
Fig 4.6A-D, the fasting plasma insulin concentrations for chow groups shown in               
Fig 4.6E, the total insulin AUC shown in Fig 4.6F and the change in insulin AUC from 
the plasma insulin concentration at time 0 min in Fig 4.6G. 
Fasting plasma insulin values for the chow-fed NODk mice trended higher compared the 
other two strains (p=0.052; strain effect with one way ANOVA) (Fig 4.6E). The pattern 
of insulin response to ip glucose was normal (increase at 15 min followed by fall back 
towards baseline) in chow-fed Balb/c mice only (Fig 4.6A-D).  
Of note, despite excellent glucose tolerance in chow-fed NODk mice (see Fig 4.5C), the 
pattern of insulin secretion was not normal in these mice. Despite the glucose 
intolerance, chow-fed B10k mice again had low insulin levels and no increase in 
response to the glucose load (Fig 4.6B).  
In response to HF-feeding, Balb/c mice did show a compensatory increase in plasma 
insulin levels, while maintaining a normal pattern of insulin release following the ip 
glucose load (Fig 4.6A, F-G). Again B10k mice did not mount a compensatory increase 
in insulin levels in response to HF-diet, and this mouse strain did not show the normal 
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increase in insulin levels that should occur after an ip glucose load. Data from the one -
NODk mouse that underwent the ipITT needs to be interpreted carefully, but again 
showed an abnormal pattern in response to ip glucose (Fig 4.6C). 
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Figure 4.6. Plasma insulin concentrations during ipGTTs at 23 weeks of age in Balb/c, B10k and NODk mice fed chow or high fat 
diet (HFD). Mice were fasted for 4 hours and were injected with 2g/kg glucose intraperitoneally at time 0 minutes.  
(A) Balb/c chow (n=6) and HFD mice (n=6). (B) B10k chow (n=6) and HFD (n=6) mice. (C) NODk chow (n=6) and HFD (n=1) mice. Five 
HF-fed NODk mice were euthanized before the ipGTTs were to be performed due to the development of diabetes. (D) All groups shown.   
(E) Fasting insulin concentration during ipGTTs of chow-fed mice of all groups. (F) Total area under the curve (AUC) for plasma insulin 
concentrations during ipGTTs of Balb/c and B10k mice only. (F) Change from basal plasma insulin AUC during ipGTTs for Balb/c and 
B10k mice only. Means ±SEM. One-way ANOVA of total glucose AUC for chow-fed mice (E). Two-way ANOVA shown (F-G). 
Bonferroni   post-hoc tests. ***p<0.001 vs chow diet same strain. 
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4.3.6. Measurement of non-fasting plasma insulin and 
derivatives 
 
Tissues of Balb/c, B10k and NODk mice were harvested at 24 weeks of age. Prior to 
anaesthesia non-fasting tail blood was obtained for measurement of plasma insulin and 
fed NEFA and TG. Under light anaesthesia and prior to organ harvest, cardiac blood 
was collected from the mice for the measurement of plasma proinsulin and C-peptide 
levels. 
The non-fasting insulin, proinsulin and C-peptide results of all mice strains are shown in 
Fig 4.7A-C. As the age at which tissue harvest was performed was earlier in 5 of the 6 
HF-fed NODk mice, the fed insulin, proinsulin and C-peptide results of the NODk mice 
on chow-diet and HF-diet, according to age at the time of sampling, are also shown in 
(Fig 4.7D-F). 
In the chow-fed mice, the non-fasting plasma insulin of NODk mice was higher than for 
the other two strains, being significantly higher to the insulin of the B10k group with 
post hoc testing (Fig 4.7A). Plasma proinsulin was also significantly higher in chow-fed 
NODk compared to chow-fed Balb/c and B10k mice (Fig 4.7B). A similar trend was 
observed for non-fasting C-peptide levels to be highest in chow-fed NODk mice (Fig 4.7 
C).  
In contrast to the short-term studies, HF-fed NODk mice did not show a massive 
increase in non-fasting plasma insulin compared to their respective chow-fed mice (Fig 
4.7A&D), which would be consistent with islet -cell failure to compensate in these 
mice at the time of diabetes development. None of the strains at this age showed an 
effect of HF-feeding to increase non-fasting plasma insulin, pro-insulin or C-peptide 
levels (Fig 4.7A-C). The age of harvest had little effect on levels in the HF-fed NODk 
mice (Fig 4.7D-F). 
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The ratios of fed proinsulin/insulin, proinsulin/C-peptide and insulin/C-peptide of the 
data shown in Fig 4.8A-C. For the same reason as in Figure 4.7, the fed 
proinsulin/insulin, proinsulin/C-peptide and insulin/C-peptide ratios for the NODk mice 
on chow-diet and HF-diet, according to age at the time of sampling, are also shown in 
Fig 4.8D-F. The same pattern of a higher proinsulin/C-peptide in B10k mice compared 
to Balb/c mice, as seen at 14 weeks of age (Fig 3.7), was again seen at 24 weeks of age 
(Fig 4.8B). The markedly increased proinsulin/C-peptide and insulin/C-peptide ratios in 
plasma of fed HF-fed compared to chow-fed NODk mice seen at 14 weeks of age, was 
not seen in older NODk mice at the time of harvest (Fig 4.8B, C, E, F). 
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Figure 4.7. Non-fasting plasma insulin, proinsulin and C-peptide concentrations at 24 weeks of age (or end of study if before 24 
weeks) in Balb/c, B10k and NODk mice fed chow or high fat diet (HFD).  
Non-fasting (A) plasma insulin concentrations from all groups, measured from tail-blood. (B) Plasma proinsulin concentrations from all 
groups, measured from cardiac blood. (C) Plasma C-peptide concentrations from all groups, measured from cardiac blood. (D) Plasma 
insulin concentrations from chow-fed NODk and HF-fed NODk mice only, based on the age at sampling. (E) Plasma proinsulin 
concentrations from chow-fed NODk and HF-fed NODk mice only, based on the age at sampling. (F) Plasma C-peptide concentrations 
from chow-fed NODk and HF-fed NODk mice only, based on the age at sampling. Means ±SEM. Two-way ANOVA shown (A-C). 
Bonferroni post-hoc tests: # p<0.05, # # p<0.01 vs different strain same diet. 
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Figure 4.8. Ratios of non-fasting proinsulin to insulin, proinsulin to C-peptide and insulin to C-peptide at 24 weeks of age (or 
end of study if before 24 weeks) in Balb/c, B10k and NODk mice fed chow or high fat diet (HFD).  
 (A) Ratio of proinsulin to insulin in all groups. (B) Ratio of proinsulin to C-peptide in all groups. (C) Ratio of insulin to C-peptide in all 
groups. (D) Ratio of proinsulin to insulin in chow-fed NODk and HF-fed NODk mice only, based on the age of sampling. (E) Ratio of 
proinsulin to C-peptide in chow-fed NODk and HF-fed NODk mice only, based the age of sampling. (F) Ratio of insulin to C-peptide 
chow-fed NODk and HF-fed NODk mice only, based on the age of sampling. Means ±SEM. Two-way ANOVA shown (A-C). 
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 4.3.7. Measurement of Non Esterified Free Fatty Acid 
(NEFA) 
 
Fasting plasma NEFA levels were measured at time 0 min during the ipGTT test at 23 
weeks of age and the results are shown for Balb/c and B10k mice in Fig 4.9A. An 
ipGTT was performed in only one HF-fed NODk mouse, hence the NODk mice results 
are shown separately in Fig 4.9C. The fasting NEFA levels were higher in the Balb/c 
compared to B10k mice, however, the NEFA levels of these two strains of mice, at this 
age, was not affected by diet (Fig 4.9A). The NEFA levels of the chow-fed NODk mice 
were also similar to the chow-fed Balb/c mice (Fig 4.9C). 
Non-fasting NEFA levels were measured from tail vein blood collected prior to 
anaesthesia on the day of tissue harvesting at 24 weeks of age. There was a significant 
strain effect, with the highest levels in NODk mice, again without a significant effect of 
diet (Fig 4.9B). The non-fasting NEFA concentrations HF-fed NODk mice according to 
the age of blood sampling are shown separately in (Fig 4.9D). 
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Figure 4.9. Plasma NEFA concentrations in Balb/c, B10k and NODk mice fed chow 
or high fat diet (HFD). 
(A) Fasting plasma NEFA from tail-blood at 23 weeks of age, Balb/c and B10k mice 
groups shown only. (B) Non-fasting NEFA from tail-blood at 24 weeks of age (or end 
of study if before 24 weeks), all groups shown. (C) Fasting plasma NEFA 
concentrations from chow-fed NODk and HF-fed NODk mice only, based on age of 
blood sampling. (D) Non-fasting plasma NEFA concentrations from chow-fed NODk 
and HF-fed NODk mice only, based on age of blood sampling. Data are Means ±SEM 
1-6 mice per group. Two-way ANOVA shown (A-B). 
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4.3.8. Measurement of TG 
 
Fasting plasma TG concentrations were measured from blood collected from the tail 
vein of Balb/c, B10k and NODk mice at time 0 min of the ipGTT at 23 weeks of age. 
The results are shown for Balb/c and B10k mice in Fig 4.10A. An ipGTT was performed 
in only one HF-fed NODk mouse, hence the NODk mice results are shown separately in 
Fig 4.10C. The fasting plasma TG concentrations of Balb/c and B10k mice were not 
significantly different and were not affected according to chow or HF-feeding                  
(Fig 4.10A). The NEFA levels of the chow-fed NODk mice were also similar to the 
other two strains of mice (Fig 4.10C). 
Non-fasting TG levels were measured from tail vein blood collected prior to anaesthesia 
on the day of tissue harvesting, at 24 weeks of age. Non-fasting TG concentrations of 
NODk mice were the highest, with B10k mice having the lowest levels (Fig 4.10B). 
Again there was no evidence for diet effect in the TG levels (Fig 4.10B). The non-
fasting NEFA concentrations of HF-fed NODk mice, according to the age of blood 
sampling, are shown separately in Fig 4.10D.  
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Figure 4.10. Plasma TG concentrations in Balb/c, B10k and NODk mice fed chow 
or high fat diet (HFD). 
(A) Fasting plasma TG concentrations from tail-blood at 23 weeks of age, Balb/c and 
B10k mice groups shown only. (B) Non-fasting plasma TG concentrations from tail-
blood at 24 weeks of age (or end of study if before 24 weeks), all groups shown. (C) 
Fasting plasma TG concentrations from chow-fed NODk and HF-fed NODk mice only, 
based on age of blood sampling. (D) Non-fasting plasma TG concentrations from chow-
fed NODk and HF-fed NODk mice only, based on age of blood sampling. Data are 
Means ±SEM 1-6 mice per group. Two-way ANOVA shown (A-B). Bonferroni post-
hoc tests: # # p<0.01, # # # p<0.001 vs different strain same diet. 
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4.4. Discussion 
 
The long-term study in part is confirmatory of the findings of the short-term study 
reported in Chapter 3, again showing markedly different metabolic responses to                
HF-feeding of the three mice strains. In short, out to 24 weeks of age, Balb/c mice again 
showed resistance to the development of diabetes, the B10k mice did not progress to 
diabetes despite extremely poor glucose tolerance and insulin secretion, and the NODk 
mice again developed a severe type 2 diabetes phenotype in response to the HF-diet that 
required early ethical culling due to the severity of hyperglycaemia.  
Additionally in the long-term study (not assessed in the short term study), insulin 
resistance was assessed by ipITTs at 13 weeks of age. There was not an obvious 
difference in insulin sensitivity between the three strains on chow-diet. HF-feeding, 
however, did appear to worsen insulin sensitivity in the NODk mice, although the 
results were not significant due to limited numbers of mice studies (only 3 in the HF-fed 
NODk mice). The findings also need to be interpreted with caution due to the significant 
limitations of this method. 
At variance in the long-term from the short-term study was the lesser degree of 
hyperinsulinaemia in HF-fed NODk mice in blood taken from conscious mice prior to 
anaesthetic for tissue harvesting. This would be consistent with a severe degree of islet 
-cell failure having developed by the time of HF-diet induced diabetes development in 
the NODk mice. 
4.4.1. Mouse body weights 
 
Again the NODk mice were heavier than the other 2 strains at the weaning age of 4 
weeks. Furthermore, the NODk mice appeared to be most susceptible to HF-diet induced 
obesity, with HF-fed NODk mice being 33% heavier than their chow-fed NODk 
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counterparts at 10 weeks of age compared to the Balb/c and B10k mice that were only 
15% and 10% heavier than their chow-fed counterparts at the same age. 
4.4.2. Non-fasting blood glucose and glucose tolerance 
 
According to the non-fasting glucose levels, HF-feeding resulted in a severe diabetic 
phenotype in the NODk mice and this developed between the age of 12-24 weeks. Only 
one HF-fed NODk mouse made it to the end of the study and had an ipGTT. This ipGTT 
showed severe glucose intolerance, such that the mouse was also likely to develop 
diabetes.  Non-fasting glucose levels and glucose tolerance of the chow-fed NODk mice, 
however, remained normal. This is consistent with a propensity for NODk mice to 
develop diabetes only when stressed, this time by HF-feeding. This is again consistent 
with the previous report from the Jackson Laboratories of a propensity for “NON mice”, 
NOD mice congenic for low risk MHC haplotypes, to develop diet-induced obesity and 
hyperglycaemia (Jackson, 2006). 
The main reason for doing this extended study was to determine if B10k mice would 
develop diabetes with an extra 10 weeks on HF-diet. The results again were remarkable, 
as despite very poor glucose tolerance even on chow diet, the HF-fed B10k mice did not 
develop diabetes, as assessed by 9 AM fed-glucose levels, and although a minor 
increase in non-fasting glucose was observed. Again, in response to 4 h of fasting the 
HF-fed B10k mice had markedly elevated fasting glucose levels and severely impaired 
glucose tolerance. As discussed in Chapter 3, the mechanisms underlying this variance 
between fed-state and fasted state glucose homeostasis is not known, but is of interest. 
Again in Balb/c mice, non-fasting 9 AM glucose levels and ipGTT glucose levels 
remained unaffected by HF-feeding out to the older age of 24 weeks, indicative of the 
resistance of this strain of mice to diet-induced hyperglycaemia. 
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4.4.3. Insulin levels and insulin derivatives 
 
HF-fed Balb/c mice increased their insulin levels during ipGTT testing, consistent with 
this strain of mice being able to compensate appropriately for HF-diet induced obesity 
and insulin resistance. Furthermore, this was the only strain than maintained a normal 
pattern of insulin secretion in the ipGTT, having a glucose-induced rise in insulin at the 
15 min time point.  
Interestingly, the non-fasting insulin levels of the normoglycaemic chow-fed NODk 
mice at 24 weeks of age were higher than the other 2 strains, suggesting some degree of 
insulin resistance in these mice. This trend was also present in the short-term study. 
However, in contrast to the marked non-fasting hyperinsulinemia in response to HF-
feeding of NODk seen in the short-term study, marked hyperinsulinemia was not evident 
in the HF-fed NODk mice of the long-term study. This would be consistent with failure 
of islet -cell compensation in these mice with the development of a type 2 diabetes 
phenotype (Nolan et al., 2006, Weir and Bonner-Weir, 2004). Also worth noting are the 
C-peptide levels which were similar between the chow-fed and HF-fed NODk mice, 
which is against a marked reduction of insulin clearance in HF-fed compared to chow-
fed NODk mice, as was suggested by the equivalent measures in NODk mice at 14 
weeks of age.  
It is not possible to comment much about the insulin levels during the ipGTT of HF-fed 
NODk mice during the long-term study, as only one mouse had this procedure. The 
pattern of insulin response in NODk mice on chow diet at 24 weeks of age, however, 
was not normal, with failure of the mice to increase insulin levels at the 15 min time 
point. This would also be consistent with this mouse having an underlying defect in 
glucose-stimulated insulin secretion even though glucose tolerance remained normal on 
chow diet. 
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The B10k insulin results of the long-term study were very similar to those of the short-
term study. Again, despite very poor glucose tolerance, the B10k mice failed to mount a 
compensatory islet -cell response either in the non-fasting blood sample prior to 
animal harvesting or in response to the ipGTT. Again, the B10k mice showed the lowest                 
C-peptide levels across the 3 strains consistent with this strain being an insulin hypo-
secretor. 
4.4.4. Insulin sensitivity measurements 
 
The gold standard measure of insulin sensitivity is the euglycaemic hyperinsulinaemic 
clamp (Bowe et al., 2014). However, this procedure was beyond the scope of this thesis, 
in which the focus was more on islet -cell function. For this reason, ipITTs were 
performed in the long-term cohort of mice at 13 weeks of age (Bowe et al., 2014). 
Despite relative non-fasting hyperinsulinaemia in chow-fed NODk mice, insulin 
sensitivity (as determined by the % fall in blood glucose from time 0 min) was not 
different between the three mouse strains. However, in response to HF-feeding the 
insulin sensitivity of the HF-fed NODk  mice appeared to be reduced, but this difference 
was not significant, possibly due to the small number of HF-fed NODk mice (n=3 only) 
that had this test. The interpretation of ipITT’s is difficult here, however, due to the 
differences between groups on the baseline glucose levels (the HF-fed B10k and NODk 
mice were hyperglycaemic) and due to differences in mouse weights (higher in NODk 
mice), as the insulin dose is in proportion to the weight of the mice.  
4.4.4. Plasma lipid levels 
 
As the majority of NODk mice did not have an ipGTT, fasting lipid levels were not 
available for the HF-fed NODk mice. In the non-fasting results, however, the previous 
finding of higher non-fasting NEFA and TG levels in NODk mice was found in the 
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longer-term study. These results are again consistent with the NODk mice being prone 
to a type 2 diabetes phenotype, including dyslipidaemia, with HF-feeding. 
4.4.5. Propensity of different strains to diet-induced diabetes 
 
The Balb/c mice were again found to be resistant to the development of diabetes 
consistent with previous reports (Montgomery et al., 2013). The reason for this 
resistance is unclear, but this mouse strain is not as prone to develop diet-induced 
obesity. Of note, Balb/c mice have been reported to be relatively resistant to the 
development of hepatic accumulation of lipid with HF-feeding (Montgomery et al., 
2013), and hepatic lipid is known to be associated with dysfunctional hepatic glucose 
regulation (Williams et al., 2012). Of importance, the response of pancreatic islets of 
Balb/c mice to HF-feeding appears to be a normal compensatory response.  
The relative hyperinsulinaemia and the failure of a normal insulin response to ip glucose 
in the chow-fed NODk mice is supportive of the view that this strain of mice has an 
underlying islet -cell defect. The failure to sustain marked hyperinsulinaemia by the 
time of diabetes development is also consistent with the dogma that type 2 diabetes is a 
consequence of islet -cell failure to sustain a compensatory response to insulin 
resistance (Prentki and Nolan, 2006). 
The findings of the long-term HF-feeding of B10k mice are of most interest in this 
Chapter, as the results do suggest that poor islet responsiveness may protect them from 
failure, as has been previously argued (Andrikopoulos, 2010). A normally functioning    
-cell responds to an increased nutrient load with mitochondrial metabolism and the 
production of metabolic coupling factors that promote insulin exocytosis (Nolan and 
Prentki, 2008). However, this reliance on mitochondrial metabolism increases the 
production of reactive oxygen species and the potential for oxidative stress, 
endoplasmic reticulum stress and -cell damage. Hence, it has been argued that the 
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most fuel responsive -cell cells may be the most vulnerable (Nolan and Prentki, 2008, 
Andrikopoulos, 2010). 
The hypothesis of slowing down metabolism to protect -cells was tested by 
overexpressing the Foxo1 transcription factor in INS832/13 -cells. Foxo-1 
overexpression protected them against oxidative stress by strong suppression of genes 
responsible for glucose oxidation and insulin secretion (Buteau et al., 2007).  
The metabolic deceleration theory is also supported by studies of C57BL/6J and DBA/2 
mouse models. Obesity due to the leptin (ob) or leptin receptor (db) causes diabetes 
depending on the mouse background, with C57BL/6J mice being diabetes resistant and 
DBA/2 mice being diabetes prone. The DBA/2 mouse has been shown to have the 
propensity to hyper-secrete insulin in both in vivo and in vitro. Furthermore, a genome 
wide search reported that the glucose-induced insulin hyper-secretion phenotype of the 
DBA/2 mouse was likely due to a five-fold higher expression of the nicotinamide 
nucleotide transhydrogenase (Nnt) gene in DBA/2 compared to C57BL/6J mice (Aston-
Mourney et al., 2007, Andrikopoulos, 2010). Nicotinamide nucleotide transhydrogenase 
(Nnt) is involved in mitochondrial metabolism and cellular redox and energy 
homeostasis  (Murphy, 2015). 
Glucolipotoxicity has been proposed as a mechanism to induce islet -cell failure in 
subjects at risk of type 2 diabetes (Prentki and Nolan, 2006b, Poitout and Robertson, 
2008, Zraika et al., 2004). The NODk mice that did develop diabetes in response to HF-
feeding has higher circulating lipid levels, as shown in both the short and long-term 
studies. The contribution of the dyslipidaemia of this mouse strain to islet -cell 
compensatory responses and then failure under HF-diet conditions also warrants 
attention in further studies. 
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4.5. Summary 
 
The results of the long-term study essentially confirmed the findings of the short-term 
study, but provides strength to the view that a hyper-responsiveness of islet -cell to 
stress is associated with a greater risk for -cell failure (e.g. NODk mice) and that a                  
hypo-responsiveness of the islet -cell to stress is protective of complete -cell failure 
(e.g. B10k mice).  
The next chapter (Chapter 5) reports findings of the histological examination of the 
pancreases of both the short- and long-term studies. 
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Chapter # 5: 
Results (Histology) 
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5.1. Introduction 
In Chapters 3 and 4, we have presented results that characterize the metabolic 
phenotype of the chow and HF-fed Balb/c, B10k and NODk male mice after 10 and 20 
weeks on the diets post weaning (short and long-term studies). The three mice strains 
have remarkably different phenotypes. The Balb/c mice are relatively resistant to diet-
induced obesity and are diabetes resistant. The B10k mice have very poor glucose 
tolerance on chow diet, are prone to diet-induced obesity, but despite worsening of 
glucose tolerance on HF-diet, do not progress onto diabetes even out to 24 weeks of 
age. The NODk mice have excellent glucose tolerance on chow diet, are the most prone 
to diet-induced obesity and they develop a severe type 2 diabetes phenotype when fed a 
HF-diet. Some understanding of the pathophysiology can be deduced from the 
physiological testing with ipGTTs and ipITTs and measurements of insulin, proinsulin 
and C-peptide, but mechanisms have not been explored further than this. 
In this Chapter, in order to further understand the mechanisms involved, we present the 
results of histological assessment of pancreatic islets from H&E pancreas sections and 
of -cell mass calculated from insulin immuno-stained pancreas sections and computer 
assisted morphometric analysis. 
From the H&E sections, particular interest was placed on the presence of inflammatory 
cells in both the pancreas, peri-islet regions and in islets (insulitis). From the previous 
work on the NODk.insHEL transgenic mouse, there was no evidence for an immune 
mechanism contributing to the diabetes (Dooley et al., 2016). Considering that the 
NODk mouse is derived from the NOD mouse, an animal model of autoimmune type 1 
diabetes that is characterized by insulitis, it was again important to determine the 
presence or absence of insulitis in this study.  
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In several of the H&E sections, apoptotic endocrine cells were observed and these were 
formally assessed. With HF-feeding, it was also noted that some, but not all strains of 
mice were prone to develop intra-pancreatic fats depots. This was also formally 
assessed. 
From the immuno-stained sections, the main interest was measurement of islet -cell 
mass, as the classic changes in type 2 diabetes are firstly, an increase in islet -cell 
mass, in the islet -cell compensation phase, followed by loss of -cell mass 
corresponding to the time that blood glucose levels reach the diabetic range (Prentki and 
Nolan, 2006a). 
5.2. Experimental approach 
 
The histological and immunohistochemistry methodologies are presented in Chapter 2. 
Briefly, at the time of euthanasia and tissue harvest, the pancreases were rapidly 
removed, weighed and fixed in formalin and processed into paraffin blocks. Sections 
were cut for H&E staining and insulin immunohistochemistry.  
A very experienced and senior anatomical pathologist, Professor Jane Dahlstrom from 
ANU Medical School, scored blinded H&E pancreas sections for acute and chronic 
inflammation, presence of fat deposits in exocrine pancreas and endocrine cell 
apoptosis. 
Islet cell mass was also assessed by blinded assessment of insulin immuno-stained 
sections (3 sections per pancreas). These sections were analyzed on Image J and from 
the total stained area, as a percentage of pancreas area, and the pancreas weight, islet -
cell mass was calculated. Complete description of the procedure for the measurement of 
islet -cell mass is detailed in Chapter 2. 
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The results of both the short-term and long-term experiments are described below. 
 
5.3. Results 
 
5.3.1. Assessment of islet inflammation 
 
Representative microscopic images of H&E stained pancreatic sections showing typical 
inflammatory infiltrates in chow and HF-fed mice at 14 weeks and 24 weeks of age are 
shown in Fig 5.1, and Fig 5.2, respectively. Average blinded scores for inflammatory 
infiltrates are presented in Fig 5.6 and Table 5.1. 
Exocrine pancreatic tissue acute inflammation, if seen, was always within a single focus 
of mild severity. It was seen in a small number of pancreases only, without evidence of 
clear differences between mouse strains or diet use (Table 5.1).  
Chronic inflammation, however, was more frequently seen and this was more likely to 
be present in B10k mice and NODk mice than Balb/c mice (Fig 5.6 and Table 5.1). The 
chronic inflammation was at worst moderate. It was not seen to invade islets (i.e. 
insulitis was not seen), but was predominantly present as peri-ductal collections, with at 
times extension into peri-islet regions and occasionally into exocrine tissue lobules                    
(Fig 5.1 and 5.2). Pancreatic inflammatory infiltrates were not seen at all in Balb/c mice 
on chow or HF-diet in the short-term study or in chow-fed Balb/c mice in the long-term 
study (Fig 5.1, Fig 5.2, Fig 5.6 and Table 5.1) however, mild inflammatory infiltrates 
were evident in the long-term HF-fed Balb/c mice (Fig 5.2, Fig 5.6 and Table 5.1). The 
majority of B10k mice pancreases had some evidence of peri-ductal/peri-islet infiltrates 
with possible worsening of severity with ageing, but not high-fat feeding (Fig 5.1, Fig 
5.2, Fig 5.6 and Table 5.1), although greater mouse number would be required to 
confirm this finding. Inflammatory infiltrates were also commonly seen in NODk mice, 
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perhaps with greater severity with HF-feeding, particularly in the older age group (Fig 
5.1, Fig 5.2, Fig 5.6 and Table 5.1). Again greater numbers would be needed to confirm 
these trends in severity.  Importantly, invasive insulitis was not seen in the HF-fed 
NODk mice, even in the long-term study in which they invariably had diabetes at the 
time of pancreas harvest. 
5.3.2. Pancreatic fat deposits 
 
Many of the pancreases displayed fat deposits in the H&E sections. On fixation, the 
lipid dissolves leaving a classic rounded ‘empty’ appearance. The presence or absences 
of these fat deposits are shown in lower power representative images in Figures 5.3 and 
5.4 for the short and longer-term studies, respectively.  
Minor fat deposits were present in chow-fed Balb/c mice, particularly in those from the 
longer-term study, but the deposits were clearly greater with HF-feeding (Fig 5.3, Fig 
5.4, Fig 5.6 and Table 5.1). Interestingly, chow-fed B10k mice had minimal intra-
pancreatic fat and this minimally increased with HF-feeding (Fig 5.3, Fig 5.4, Fig 5.6 
and Table 5.1). Also unexpected was the finding of fat deposits in the pancreases of 
most chow-fed NODk mice, with some evidence of worsening with HF-feeding in the 
short-term study mice. In the HF-fed NODk mice of the long-term study, the 
accumulation of fat deposits did not seem worse than the corresponding mice on chow 
diet, however, these HF-fed NODk mice had diabetes at the time of harvest, which may 
have reduced these deposits due to induction of a catabolic state (Fig 5.3, Fig 5.4, Fig 
5.6 and Table 5.1).  
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Figure 5.1. Representative images of pancreas sections stained with H&E showing inflammation in chow and high fat diet (HFD) fed Balb/c, 
B10k and NODk at 14 weeks of age (Short-term study). 
 (A) Chow-fed Balb/c mouse pancreas with no inflammation in the pancreatic section. (B) Chow-fed B10k mouse showing minimal peri-ductal 
inflammation. (C) Chow-fed NODk mouse showing mild peri-ductal inflammation. (D) HF-fed Balb/c mouse with no evidence of inflammation.                 
(E) HF-fed B10k mouse with mild peri-ductal inflammation. (F) HF-fed NODk mouse with moderate peri-ductal and peri-islet inflammation. Scale bar, 
50 μm. Arrows point to area of inflammation. 
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Figure 5.2. Representative images of pancreas sections stained with H&E showing inflammation in chow and high fat diet (HFD) fed Balb/c, 
B10k and NODk at 24 weeks of age (Long-term study). 
 (A) Chow-fed Balb/c mouse pancreas with no inflammation. (B) Chow-fed B10k mouse showing minimal periductal and peri-islet inflammation.               
(C) Chow-fed NODk mouse showing minimal peri-islet inflammation. (D) HF-fed Balb/c mouse with mild peri-ductal inflammation. (E) HF-fed B10k 
mouse with mild peri-ductal and peri-islet inflammation. (F) HF-fed NODk mouse with moderate peri-ductal and peri-islet inflammation. This mouse 
harvested at 24 weeks. Scale bar, 50 μm. Areas point to arrows of inflammation.              
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Figure 5.3. Representative images of pancreas sections stained with H&E showing presence of fat deposits in chow and high fat diet (HFD) fed 
Balb/c, B10k and NODk at 14 weeks (Short-term study). 
 (A) Chow-fed Balb/c mouse pancreas showing negligible fat deposits. (B) Chow-fed B10k mouse showing no presence of fat. (C) Chow-fed NODk 
mouse showing negligible fat deposits. (D) HF-fed Balb/c mouse showing mild accumulation of fat deposits. (E) HF-fed B10k mouse showing 
infrequent fat deposits. (F) HF-fed NODk mouse with moderate accumulation of fat deposits in exocrine pancreas. Scale bar, 500 μm. Arrows point to 
fat deposits. 
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Figure 5.4. Representative images of pancreatic sections stained with H&E showing presence of fat deposits in chow and high fat diet (HFD) 
fed Balb/c, B10k and NODk at 24 weeks (Long-term study). 
 (A) Chow-fed Balb/c mouse pancreas showed negligible fat deposits. (B) Chow-fed B10k with negligible fat deposits. (C) Chow-fed NODk mouse 
showing infrequent fat deposits. (D) HF-fed Balb/c mouse showing moderate accumulation of fat deposit in the exocrine pancreas. (E) HF-fed B10k 
mouse showing negligible fat presence. (F) HF-fed NODk mouse showing infrequent fat presence in exocrine pancreas. Scale bar, 500 μm. Arrows 
point to fat deposits. 
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5.3.3. Islet endocrine cell apoptosis 
Islet endocrine cell apoptosis was observed by Professor Dahlstrom in some of the 
blinded sections and this was scored. Representative images of apoptotic endocrine cells 
are shown in Fig 5.5. Other than one apoptotic cell being seen in a chow-fed B10k mice, 
apoptotic endocrine cells were only seen in HF-fed NODk mice (3 of 11 mice in the     
short-term study and 5 of 6 mice in the long-term study) (Fig 5.5 and Table 5.1). 
Although, it is most likely that the apoptosis is in islet -cells, this cannot be concluded 
from these H&E sections.    
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Figure 5.5. Representative image of H&E sections of pancreas for apoptosis in high fat diet (HFD) fed Balb/c, B10k and NODk at the time of 
harvest on the long-term study. 
(A) HF-fed Balb/c mice at 24 weeks of age. (B) HF-fed B10k mice at 24 weeks of age. (C) HF-fed NODk mice at 24 weeks of age. In these images 
apoptotic endocrine cells are evident in the HF-fed NODk mouse section only, as shown by the circling of apoptotic cells.  
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Figure 5.6. Blinded scoring of pancreas H&E sections for grade of chronic inflammation (A&C) and grade of pancreatic exocrine fat presence 
(B&D) in chow and high fat fed Balb/c, B10k and NODk mice harvested from the short-term experiment at 14 weeks of age (A&B) and from the 
long-term experiment at 24 weeks of age or earlier in some HF-fed NODk mice (C&D). 
Results presented as percentages of all mice pancreases examined (n=9-11 mice short term study, n=5-6 long term study). 
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Table 5.1: Summary of blinded scoring of pancreatic H&E sections for presence of acute inflammation, chronic inflammation, apoptosis and 
exocrine tissue fat deposits in chow and high fat fed Balb/c, B10k and NODk mice harvested at 14 weeks of age  (short-term study) and at 24 
weeks of age (long-term study).  
Several HF-fed NODk mice were euthanized before 24 weeks due to severe hyperglycaemia. The results shown include the total number of pancreases 
assessed in each mouse group and the number of pancreases within each group in which the particular histological features were found to be present.    
Chi-Square statistical analysis was performed and p-values are shown. 
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               Table 5.1 
       
   
SHORT-TERM STUDY 
   
  
Balb/c Balb/c B10k B10k NODk NODk 
Chi-
square 
Chow diet HF-diet Chow diet HF-diet Chow diet HF-diet P-value 
Total (n) 7 10 11 10 9 11   
Acute inflammation 
0 0 2 2 0 1 0.22 
present (n) 
Chronic 
0 0 7 7 6 10 <0.0001 
Inflammation present (n) 
    Apoptosis present (n) 0 0 1 0 0 3 0.08 
Pancreatic fat 
2 8 1 5 8 11    <0.0001 
present (n) 
        
 
  
LONG-TERM STUDY 
   
  
Balb/c Balb/c B10k B10k NODk NODk 
Chi-
square 
Chow diet HF-diet Chow diet HF-diet Chow diet HF-diet P-value 
Total (n) 5 6 6 6 6 6   
Acute inflammation 
0 2 1 1 0 0 0.54 
present (n) 
Chronic 
0 4 5 6 2 4 0.01 
Inflammation present (n) 
Apoptosis present (n) 0 0 1 0 0 5 0.003 
Pancreatic fat 
5 6 1 4 6 6 0.0006 
present (n) 
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5.3.4. Assessment of pancreas sections immuno-stained for 
insulin and measurement of islet -cell mass 
 
Representative images of pancreas sections immuno-stained for insulin from chow and 
HF-fed Balb/c, B10k and NODk mice from the short-term and long-term study are 
shown in Figures 5.7 and 5.8, respectively. Mouse pancreas weight, number of islets per 
section, islet -cell area and islet -cell mass results, including corrections for body 
weight, are shown in Fig. 5.9 and 5.10, for the short-term and long-term studies, 
respectively.  
In the short-term study, pancreas weights were higher in B10k and NODk mice 
compared to Balb/c mice, but were not affected by diet (Fig 5.9A). Pancreas weight, 
corrected for body weight as a percentage, however, was reduced by HF-feeding, 
indicative of the effect of HF-diet to increase weight in tissues other than pancreas (Fig 
5.9B). At variance with this though, HF-diet appeared to increase pancreas weight in 
B10k mice proportional to whole body weight in the longer-term study (Fig 5.10A, B). 
In the long-term study, HF-fed NODk mice were harvested earlier than 24 weeks of age 
in most mice due to the development of diabetes, such that it was expected that their 
pancreas weights would be lower (Fig 5.10A); however, after adjustment for body 
weight, some of the HF-fed NODk mice pancreases were still clearly small  (Fig 
5.10B,E). 
From the insulin immuno-stained sections and pancreas weights, islet number per 
pancreas section and islet area per section were measured, and -cell mass was 
calculated. On viewing the representative images of the short-term studies, it appears 
that HF-feeding increased the size of the islets in all strains, but that the intensity of 
insulin staining was reduced in the HF-fed NODk islets (Fig 5.7). The representative 
insulin immuno-stained section of the long-term HF-fed NODk mouse pancreas again 
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showed less intense, but also irregular, insulin staining compared to the other mice, and 
the islets appeared smaller (Fig 5.8). The morphometric analysis of the insulin stained 
areas of all of the pancreases confirmed changes in -cell mass between strains caused 
by HF-feeding (Fig 5.9 and 5.10) as presented in the following paragraphs. 
In the short-term study, there was no effect of diet to change islet number per pancreas 
and there was no significant difference across strains (Fig 5.9C). There was, however, 
an across strain effect of HF-feeding to increase -cell area, which in the Balb/c mice 
was more than two-fold (Fig 5.9C, D). Islet -cell mass was greatest in the larger NODk 
mice, but this was not found after correction for body weight (Fig 5.9E, F). Also, HF-
feeding had an across strain effect to increase -cell mass, but again this effect was not 
significant after correcting for body weight of the mice (Fig 5.9E,F). 
In the long-term study, the fact that most of the HF-fed NODk pancreases were 
harvested before 24 weeks of age needs to be taken into consideration (Fig 5.10). Panels 
J-L of Fig 5.10 show the data according to age at harvest. However, the measurements 
of -cell area per pancreas section and -cell mass corrected for body weight should be 
less affected by the age of harvest. In these older mice, there was now a difference in 
the number of islets/section across the strains, with the NODk mice having the fewest          
(Fig 5.10D). With -cell area, there was a strain-diet interaction, with -cell area 
increasing in Balb/c mice and falling in NODk mice with HF-feeding (Fig 5.10G).              
A strain-diet interaction was also evident for -cell mass, with a fall in -cell mass in 
the NODk mice with HF-feeding compared to the other two strains, but this interaction 
was not significant after correction for body weight (Fig 5.10H,I). Consistent with the 
representative image, however, -cell area and mass was reduced rather than increased 
with HF-feeding in the longer-term HF-fed NODk mice. 
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Figure 5.7. Representative images of pancreas sections with insulin immunohistochemistry in chow and HF-fed Balb/c, B10k and NODk at 14 
weeks of age (Short-term study). 
The insulin immune-stain is brown in colour and is shown within the pancreatic islets. (A) Chow-fed Balb/c mouse pancreas section. (B) Chow-fed 
B10k mouse pancreas section (C) Chow-fed NODk mouse pancreas section. (D) HF-fed Balb/c mouse pancreas section. (E) HF-fed B10k mouse 
pancreas section. (F) HF-fed NODk mouse pancreas section. Scale bar, 500 μm. Arrows point to insulin-staining within pancreatic islets. 
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Figure 5.8. Representative images of pancreas sections with insulin immunohistochemistry in chow and HF-fed Balb/c, B10k and NODk at 24 
weeks of age (Long-term study). 
The insulin immune-stain is brown in colour and is shown within the pancreatic islets. (A) Chow-fed Balb/c mouse pancreas section. (B) Chow-fed 
B10k mouse pancreas section. (C) Chow-fed NODk mouse pancreas section. (D) HF-fed Balb/c mouse pancreas section. (E) HF-fed B10k mouse 
pancreas section. (F) HF-fed NODk mouse pancreas section. Scale bar, 500 μm. Arrows point to insulin-staining within pancreatic islets. 
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Figure 5.9. Summary of morphometric analysis of insulin immuno-stained pancreas sections, including measurement of islet -cell mass, of 
Balb/c, B10k and NODk, fed on chow or high fat diet (HFD), harvested at the end of the short-term study (14weeks of age). 
(A) Pancreatic weight for all groups. (B) Pancreatic weight as percentage of body weight (BW) for all groups. (C) Average number of islets per section 
for all groups. (D) -cell area as percentage of total pancreas area for all groups. (E) -cell mass per mouse for all groups. (F) -cell mass per BW of 
mice for all groups. Data are Means ± SEM of 4-5 mice per group. Two-way ANOVA shown in tables below graphs. Bonferroni post-hoc tests:                     
*p<0.05 vs chow diet of the same strain; # p<0.05 vs different strain on the same diet.  
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Figure 5.10. (Part 1&2) Summary of the morphometric analysis of insulin immuno-stained pancreas sections, including measurement of islet         
-cell mass, of Balb/c, B10k and NODk, fed on chow or high fat diet (HFD), harvested at the end of the long-term study (24 weeks of age). 
 Part 1 (A) Pancreatic weight for all groups. (B) Pancreatic weight as percentage of body weight (BW) for all groups. (C) Average number of islets per 
section for all groups. (D-F) As several HF-fed NODk mice were euthanized before 24 weeks due to severe hyperglycaemia, data for NODk mice are 
also shown according to age at pancreas harvest. (D) Pancreatic weight for chow and HF-fed NODk mice only, according to the age at pancreas harvest. 
(E) Pancreatic weight as percentage of body for chow and HF-fed NODk mice only, according to the age at pancreas harvest. (F) Average number of 
islets per section for chow and HF-fed NODk mice only, according to the age at pancreas harvest.  
Part 2 (G) -cell area as percentage of total pancreas area for all groups. (H) -cell mass per mouse for all groups. (I) -cell mass per BW of mice for 
all groups. (J-L) As several HF-fed NODk mice were euthanized before 24 weeks due to severe hyperglycaemia, data for NODk mice are also shown 
according to age at pancreas harvest. (J) -cell area as percentage of total pancreas area for chow and HF-fed NODk mice only, according to the age at 
pancreas harvest. (K) -cell mass per mouse for chow and HF-fed NODk mice only, according to the age at pancreas harvest.  (L) -cell mass per BW 
for chow and HF-fed NODk mice only, according to the age at pancreas harvest.  Data are Means ± SEM (n=4) mice per group. Two-way ANOVA 
shown in tables below graphs. Bonferroni post-hoc tests: # p<0.05, # # p<0.01, vs different strain same diet. 
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5.4. Discussion 
 
Type 1 diabetes is caused by an immunological destruction of islet -cells by invasion 
of islets by cytotoxic T-lymphocytes and to a lesser extent other immune cell types such 
as macrophages, B-lymphocytes and plasma cells, a process called insulitis (Tuomi et 
al., 2014, Mannering et al., 2016). The histological features of this process have been 
very well described in the NOD mouse model of type 1 diabetes (Delovitch and Singh, 
1997, Kay et al., 1997). The histological characteristics of the islets in type 2 diabetes 
are more variable, but the process of -cell mass expansion to compensate for insulin 
resistance followed by loss of -cell mass has been well described. Depending on 
genetic background, however, type 2 diabetes can also be a consequence of dysfunction 
of islet -cell cells, with and without, loss of -cell mass (Jeffery and Harries, 2016). 
More controversial is the role of inflammation in causing islet failure in type 2 diabetes, 
but there is increasing evidence to support this (Donath et al., 2013). Thus the 
histological examination of the pancreas, with attention to the presence or absence of 
inflammation and the measurement of islet -cell mass are important in determining the 
mechanisms by which diabetes may develop. 
-cell mass decreases in type 1 diabetes, where total loss of -cells occur due to insulitis 
(Maclean and Ogilvie, 1955). Whereas, in type 2 diabetes, certain stimuli could trigger 
apoptotic pathway in -cells, including elevated glucose, NEFA, cytokines, 
accumulation of islet amyloid polypeptide and ER stress (Cnop et al., 2005). 
From the previous work on the NODk.insHEL mouse model, particular efforts were 
made to exclude immune mechanisms in the development of diabetes (Dooley et al., 
2016). The experiments included study of the effects of -cell expression of the HEL 
protein on the immune incompetent NODk.Prkdcscid and NODk.Rag1−/− lines (Dooley et 
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al., 2016). These studies did suggest that NODk mice have an underlying non-immune                         
pre-disposition to -cell failure. In the work of this thesis, we hypothesized that such 
non-immune susceptibility to -cell failure would occur in NODk mice in response to 
HF-feeding. For this reason, it was important for us to examine the mice pancreases for 
islet inflammation.   
Also in the NODk.insHEL mouse model, islet -cell mass was reduced and apoptotic        
-cells were found to be increased (Dooley et al., 2016). Thus the NODk islet -cells 
stressed by this molecular mechanism are prone to apoptosis. We wished to determine if 
the -cells of NODk islets are also susceptible to apoptosis by the more physiological 
stressor of HF-feeding. For this reason islet endocrine cell apoptosis was looked for and 
-cell mass was measured.  
In addition, the histological responses of the other two strains of mice to HF-feeding 
was important to enable comparison, but also to provide some further insight in the 
failure of B10k mice to compensate with increased insulin secretion in response to HF-
feeding. 
5.4.1 Pancreas inflammation 
 
Within the three strains of mice, the Balb/c mice were least prone to inflammation in the 
pancreases, with the degrees of inflammation being similar between B10k and NODk 
mice. While HF-feeding did not seem to aggravate the degree of inflammation in B10k 
mice, some aggravation could have been occurring within the NODk mice, but this 
would require more mice to be certain. Nevertheless, the inflammation was usually of 
mild to moderate severity only and was not seen to cause insulitis in any of the strains. 
Most of the inflammation in the B10k and NODk mice was peri-ductal, with some 
occurrences of the peri-ductal inflammation spilling over to the peri-islet region. 
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Uncertain is whether any of this inflammatory infiltrates are pathogenic with respect to 
islet health. In previous experiments, peri-islet inflammatory infiltrates do not seem to 
be harmful to the islets unless the leukocyte penetrate the extracellular matrix of the 
peri-islet capsule, which is composed of the peri-islet basement membrane and 
subjacent interstitial matrix (Ziolkowski et al., 2012). Importantly, insulitis was not seen 
in any of three strains of mice, such that the glucose intolerance and diabetes within the 
B10k and NODk mice is not caused by aggressive immune destruction of -cells. An 
effect of inflammatory cytokines having an effect on islet function, however, cannot be 
excluded. 
5.4.2 Islet endocrine cell apoptosis and islet -cell mass 
 
There was an across strain increase in -cell area and mass in response to HF-feeding at 
the 14 week time-point, however, when corrected by mouse weights, this effect did not 
quite reach statistical significance. In the long-term study, however, this same response 
of -cell area and mass to increase with HF-feeding, while evident in Balb/c and B10k 
mice, was no longer evident in the NODk mice. Islet -cell mass of HF-fed NODk mice, 
after correction for body weight considering the different ages the mice were harvested, 
was reduced rather than increased. 
-cells mass is maintained by a well-organized regulation of -cell replication and 
apoptosis and also by the development of new islets from exocrine pancreatic ducts 
(Finegood et al., 1995, Bonner-Weir, 2000). Any disturbance causing a decrease in -
cell replication or an increase in the rate of -cells death will result in a decrease in -
cells mass. 
Of interest was the finding of scattered apoptotic endocrine cells almost exclusively in 
the islets of HF-fed NODk mice. They were more frequently seen in the mice of the      
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long-term study, but could also be seen in HF-fed NODk mice from the short-term 
study. As stated above, it is likely that this apoptosis is within islet -cells, but this 
needs to be confirmed with another imaging method, such as dual 
immunohistochemistry for insulin and activated caspase-3 as was performed in the 
NODk.insHEL islets (Dooley et al., 2016). The apoptotic cells correspond to a reduction 
in -cell area and mass in the NODk islets by the time of diabetes development. 
5.4.3. Pancreatic fat deposits 
 
Pancreatic steatosis or “non-alcoholic fatty pancreas disease (NAFLD)” refer to the 
occurrence of increased pancreatic fat  (Catanzaro et al., 2016). It occurs in association 
with obesity and the metabolic syndrome and has been implicated as a possible factor in 
the pathogenesis of type 2 diabetes, including islet -cell dysfunction, although the 
available evidence is far from clear (van der Zijl et al., 2010, Chen et al., 2015, Heni et 
al., 2010, Della Corte et al., 2015). It could also be that intrapancreatic fat reflects the 
increased fat accumulation of the whole body only and is not at all locally pathogenic or 
diabetogenic (Catanzaro et al., 2016).  
On this background, the results of intra-pancreatic fat deposit accumulation in this study 
are interesting. Even though Balb/c mice have been reported to be resistant to the 
development of fatty liver (Montgomery et al., 2013), in this study HF-feeding did 
promote intra-pancreatic fat accumulation. Clearly, the fat content of the liver in these 
mice need to be examined though. This intra-pancreatic fat accumulation was not 
associated with abnormal glucose tolerance, such that in this model it is benign. 
The NODk mice, even on chow diet with perfectly normal glucose tolerance, had 
evidence of increased fat content in the pancreases and this worsened with HF-feeding. 
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This would favor a role of intra-pancreatic fat in diabetes development, but this finding 
could also be a non-causative association. 
The B10k mice, that had poor glucose tolerance, had few pancreatic fat deposits, even 
with long-term HF-feeding. Of course these mice did not progress onto develop 
diabetes, and it could be argued that having little pancreatic fat protected them from 
complete  -cell failure, but again this is purely speculation.  
Elevated TG and FFA causes abnormal fat deposition in the liver, heart, muscles, and 
pancreas, which is called steatosis, known to be related to obesity and/or insulin 
resistance (Yin et al., 2004). The HF-fed NODk mice, in short-term study, displayed 
raised plasma TG and FFA concentrations in fasting and non-fasting state. They were 
significantly obese from the Balb/c and B10k on HF-diet in both studies and were 
insulin resistance during ipITT in long-term study.  
5.5. Summary 
 
In the HF-fed NODk mice, the diabetes was not caused by insulitis, however, a role for 
the mild to moderate peri-islet inflammatory infiltrates cannot be fully excluded. Such 
infiltrates were also present in the chow-fed mice that didn’t develop diabetes, although 
with HF-feeding there may have been some increase in their number and size. Diabetes 
in this mouse did seem to correspond to a reduction in -cell mass due to -cell 
apoptosis, however, the latter needs to be confirmed by further imaging with dual 
staining immunohistochemistry for insulin and activated caspase 3.  
The poor glucose tolerance of the chow-fed and HF-fed B10k mice was not a 
consequence of reduced -cell mass compared to the other strains. This suggests that the 
islet defect has to be a functional one. 
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The various findings of fat content in the different models suggest that it is associated 
with adiposity, but the greater propensity to develop is dependent on genetic 
background. While a pathogenic role for pancreatic fat cannot be excluded, its presence 
in HF-fed Balb/c mice suggest that under some circumstances it can be benign in nature. 
Overall, these histological findings are helpful in determining the differences in 
metabolic phenotype between the various mice strains on the two diets, further studies 
will be required to determine the molecular determinants of these differences. 
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Chapter # 6: 
NODk Refreshed (NODk-REF) Mice 
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6.1. Introduction 
NODk mice from John Curtin Medical Research Centre at ANU (from Prof Chris 
Goodnow) were used in this project to investigate the hypothesis that NODk mice have 
the propensity to develop islet -cell failure when stressed by HF-feeding. They 
originated from NOD.BR-H2k/Wicker mice dating back to 1993 (Podolin et al., 1993). 
We found that male chow-fed NODk mice maintain normoglycaemia, but with mild 
hyperinsulinemia and an abnormal pattern of insulin secretion to an ipGTT at age 24 
weeks. With HF feeding, male NODk mice develop a type 2 diabetes phenotype after 
only 10 weeks on HF-diet, characterised by diet-induced obesity, dyslipidaemia, 
hyperinsulinemia and hyperglycaemia. HF diet for more than 10 weeks results in severe 
diabetes in NODk mice associated with islet -cell dysfunction and apoptosis, almost 
certainly with loss of -cell mass, but without evidence of insulitis. All of this is highly 
suggestive that the islet -cells of the NOD mouse have a non-immune susceptibility to 
failure. This is demonstrable in NODk mice, as they are protected from islet -cell 
destruction from autoimmunity through carrying the autoimmune low-risk MHC H2k 
haplotype, such that other mechanisms of -cell failure are more easily delineated 
(Dooley et al., 2016). 
Through this project, some difficulty in breeding and maintaining the NODk colony was 
experienced. The frequency of litters was reduced and some male NODk mice were 
unexpectedly dying around 180-210 days, with autopsy suggesting this may have been 
related to obstruction of the urethra by gelatinous material and prostatitis. As there were 
no records of this mouse colony being refreshed since 1993, genetic drift with 
additional mutations was suspected as a possible contributor to these difficulties 
maintaining the colony. Genetic drift have previously been reported in NOD mice 
substrains (Simecek et al., 2015). For this reason a decision was made to refresh the 
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NODk colony.  
The NODk mice were refreshed at ANU as discussed in the experimental plan (Section 
6.2). In order to determine if the refreshed NODk mice would develop the same type 2 
diabetes phenotype as the original ANU NODk mice, two separate cohorts of refreshed 
male NODk mice were placed on chow or HF-diet from soon after weaning and were 
followed up to the age of 24-25 weeks. 
6.2. Experimental plan 
 
The NODk mice were refreshed at ANU, under the management of the animal facility 
staff. The female NODk mice (from the original ANU colony) were crossed with male 
NOD.ShiLtJArc from the Animal Resource Centre WA and the N1 progeny were 
backcrossed to the NOD.ShiLtJArc strain a further two times. Breeders were selected on 
the basis of heterozygosity using PCR for H2k at the MHC. After two backcrosses, N3 
male and female (brother and sister) H2k heterozygotes were intercrossed in order to fix 
a H2k haplotype homozygous progeny (confirmed with PCR) for continued inbreeding. 
These mice were given the strain name of ASD527:NODk.ANU N3F3 (after 3 
intercrosses) and we have given this refreshed strain the nick name of NODk-Refreshed 
(NODk-REF) for the purposes of this chapter. 
Male NODk-REF mice were placed on chow or HF-diet after weaning to characterise 
the phenotype of the mice. The experiment was conducted in two separate cohorts. For 
practical reasons, the first cohort of NODk-REF mice were placed on chow or HF-diet 
from 5 weeks of age and the second cohort from 4 weeks of age. All mice (both cohorts) 
remained on diet for 21 weeks. Body weight and non-fasting blood glucose levels were 
measured over time and ipGTT tests were performed after 9 and 20 weeks on diet. The 
experimental design for this study is illustrated in Figure 6.1. 
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Figure 6.1: Outline of experimental design for the characterization of NODk-REF 
mice fed chow or HF-diet for 21 weeks (post weaning to harvesting). 
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6.3. Results 
 
6.3.1. Body weight measurement 
 
The body weight measurements for male NODk-REF mice over time are shown in                         
(Fig 6.2). Although the NODk-REF mice tended to be slightly smaller to the NODk 
mice, they were susceptible to HF-diet induced obesity as shown by a 70% greater gain 
in body weight from weaning than their chow-fed counterparts (Fig 6.2A,D).
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Figure 6.2. Body weight measurement during time-course study according to weeks on diet (from weaning to harvest) in                
NODk-REF mice fed chow or high fat diet (HFD). NODk-REF chow (n=8) and HFD (n=9) mice. (A) Chow and HF-fed NODk-REF 
groups shown. (B) Body weight at weaning (baseline measurement) for NODk-REF mice. (C) Body weight measured at 21 weeks for   
NODk-REF mice (D) Change in body weight from weaning to harvest in NODk-REF mice group. Means ± SEM. Student’s unpaired t-
test: ***p<0.001 vs chow diet. 
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6.3.2. Non-fasting blood glucose measurement  
 
Non-fasting glucose was measured at 9AM from tail vein blood at 2 weekly intervals 
from the time of weaning. The results are shown in Fig 6.3. As expected, the chow fed 
NODk mice maintained normal blood glucose levels through the course of the feeding 
study (Fig 6.3). Unexpectedly, the HF-fed NODk mice also maintained normal blood 
glucose levels through the entirety of the study (Fig 6.3). Thus, unlike the NODk mice, 
the NODk-REF mice are resistant to the development of a type 2 diabetes phenotype. 
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Figure 6.3. Non-fasting blood glucose measurement during time-course study according to weeks on diet (from weaning to 
harvest) in NODk-REF mice fed chow or high fat diet (HFD). NODk-REF chow (n=8) and HFD (n=9) mice. (A) Chow and HF-fed 
NODk-REF groups shown. (B) Blood glucose concentrations at weaning (baseline measurement) for NODk-REF mice. (C) Blood glucose 
measurement at 21 weeks for NODk-REF mice (D) Difference in blood glucose levels from weaning to harvest in NODk-REF mice group. 
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6.3.4. ipGTT- glucose results 
 
ipGTTs were performed in the chow and HF-fed NODk-REF mice after 9 weeks and 20 
weeks on diet (at 13-14 weeks and 24-25 weeks of age, respectively). The results of the 
glycaemic responses are shown in Fig 6.4. The HF-diet induced a marginal increase in 
fasting glycaemia, which reached significance in the older mice only (Fig 6.4E,F).           
HF-feeding caused a moderate degree of glucose intolerance after 9 weeks (Fig 
6.4A,C,D) and moderately severe glucose intolerance after 20 weeks on diet, (Fig 
6.4E,G,H), but it did not cause the extremely severe glucose intolerance that was seen 
after only 10 weeks of HF feeding in the orginal NODk mice (data presented in Chapter 
3).  
 
 
197 
 
Figure 6.4: Blood glucose concentrations during ipGTT after 9 and 20 weeks on diet (from weaning to harvest) in NODk-REF 
mice fed chow or high fat diet (HFD). Mice fasted for 4 hours were injected with 2g/kg glucose intraperitoneally at time 0 min. (A-D)            
ipGTT performed after 9 weeks on diet, NODk-REF chow (n=5) and HFD (n=6) mice. (A) Blood glucose levels during course of ipGTT. 
(B) Blood glucose measured at time 0 h (fasting) during ipGTT. (C) Blood glucose measured at 2 hours during ipGTT. (D) Total Area 
under the curve (AUC) measured during ipGTT. (E-H) ipGTT performed after 20 weeks on diet, NODk -REF chow (n=8) and HFD (n=9) 
mice. (E) Blood glucose levels during course of ipGTT. (F) Blood glucose measured at time 0 h (fasting) during ipGTT. (G) Blood 
glucose measured at 2 hours during ipGTT. (H) Total Area under the curve (AUC) measured during ipGTT.  Means ± SEM. Student’s 
unpaired      t-test: *p<0.05, **p<0.01, ***p<0.001 vs chow diet. 
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6.3.5. ipGTT-plasma insulin results 
 
The results of plasma insulin levels of the ipGTT studies performed in the chow and       
HF-fed NODk-REF mice after 9 weeks and 20 weeks on diet, corresponding to the 
ipGTT glucose (Fig 6.4) are presented in Fig 6.5. The insulin results after 9 weeks on 
diet are shown in Fig 6.5 A-D. And Fig 6.5E-H, shows plasma insulin results after 20 
weeks of diet. 
In the chow fed NODk-REF mice, insulin levels showed a reasonably normal response 
to the ip glucose, with no obvious change from after 9 weeks on diet to after 20 weeks 
on diet (Fig 6.5). In response to HF-diet, hyperinsulinemia developed, and the abnormal 
pattern of insulin response, with a tendency for levels to fall rather than increase at 15 
min, was seen at both times (Fig 6.5). The degree of hyperinsulinemia was greater after 
20 compared to 9 weeks on the HF-diet. 
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Figure 6.5: Plasma insulin concentrations during ipGTT after 9 and 20 weeks on diet (from weaning to harvest) in NODk-REF 
mice fed chow or high fat diet (HFD). Mice fasted for 4 hours were injected with 2g/kg glucose intraperitoneally at time 0 min. (A-D) 
Plasma insulin measurement after 9 weeks on diet, NODk -REF chow (n=5) and HFD (n=6) mice. (A) Plasma insulin levels during course 
of ipGTT. (B) Plasma insulin measured at time 0 h (fasting) during ipGTT. (C) Total Area under the curve (AUC) for plasma insulin 
measurement during ipGTT. (D) Change from basal AUC during ipGTT. (E-H) Plasma insulin measurement after 20 weeks on diet, NODk 
-REF chow (n=8) and HFD (n=9). (E) Plasma insulin levels during course of ipGTT. (F) Plasma insulin measured at time 0 h (fasting) 
during ipGTT. (G) Total Area under the curve (AUC) for plasma insulin measurement during ipGTT. (H) Change from basal AUC during 
ipGTT. Means ± SEM. Student’s unpaired t-test: *p<0.05, **p<0.01, ***p<0.001 vs chow diet. 
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6.3.6. Non-fasting insulin measurement 
 
Non-fasting tail blood was collected immediately before anaesthesia for measurement 
of plasma insulin from chow and HF-fed NODk-REF after 21 weeks on diet. The non-
fasting insulin concentration was significantly elevated in HF-fed NODk-REF mice 
from the chow-fed NODk-REF group (Figure 6.6). 
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Figure 6.6: Non-fasting plasma insulin concentrations after 21 weeks of diet (from 
weaning) in NODk -REF mice fed chow or high fat diet (HFD). Data are Means ± 
SEM. Student’s unpaired t-test: **p<0.001 vs chow diet. 
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6.4. Discussion 
 
This experiment was set up to ascertain whether the refreshed NODk colony           
(NODk-REF) had the same metabolic phenotype as the NODk mice that have been 
used for the main body of this thesis. The initial plan was for a 10 week dietary study, 
but this was extended to 20 weeks due to the resistance of the NODk-REF mice to 
develop diabetes. The results were remarkable, in that 9 AM non-fasting glucose levels 
remained normal in the NODk-REF mice, even after 20 weeks on HF-diet. This is in 
stark contrast to the HF-NODk mice that developed a severe diabetes phenotype after 
10-20 weeks of HF feeding which resulted in a need for them to be ethically culled. 
This unexpected finding is of particular interest, as it raises very interesting hypotheses 
about what might be happening, and has important implications on the overall 
conclusions that can be made from the work of this thesis, as is discussed below. 
There are also limitations on the interpretation that can be made from the available 
data from these experiments. Due to the need to complete experiments for this thesis, 
analyses of plasma lipids, proinsulin and C-peptide have not been completed and 
pancreas histology has not yet been performed. These results, if available, would have 
been useful to be able to make a complete comparison between the NODk-REF and the 
original NODk mice. Also, an experimental design in which the NODk and NODk-REF 
mice were studied in parallel would have been much better in order to be able to 
directly compare the phenotypes. 
Nevertheless, the differences between the two NODk strains are remarkable, one 
developing a profound type 2 diabetes phenotype and the other obesity and glucose 
intolerance, but a resistance to diabetes development. 
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There was a trend for the NODk-REF mice to be a little smaller at 4-5 weeks of age 
and perhaps for the weight gain to be less rapid with HF-feeding, but this would need 
to be confirmed in comparing the two strains at the same time, under exactly the same 
environmental conditions. However, the NODk-REF mice did develop HF-diet induced 
obesity. They also developed HF-diet induced hyperinsulinemia and glucose 
intolerance, but with an apparent lesser severity after 9 weeks on diet compared to 20 
weeks on diet. The degree of hyperinsulinemia in the NODk-REF after 20 weeks on 
HF-diet was similar to that of the NODk mice after only 10 weeks on HF-diet, but the 
NODk mice had significant fasting hyperglycaemia after only 10 weeks on diet, as 
opposed to a very minimal increase in the NODk-REF mice after twice as long on HF-
diet. 
Thus, the major difference between the two strains is that the NODk mice of Chapter 3, 
4 and 5 are prone to develop diabetes and the NODk-REF mice of this chapter are 
diabetes resistant, at least up to 20 weeks after starting HF feeding from weaning age. 
Recently, environmental factors have been shown to be particularly important in 
determining the metabolic characteristics of mice, with interactions being present 
between mice genetic background, diet and the gut microbiome (Ussar et al., 2015, 
Perry et al., 2016). Differences in the gut microbiome between the strains is possible 
because of a different history of environments, but the environment including diets of 
the NODk and NODk-REF mice should have been the same through the respective time 
course studies (same animal facility, same diets), however, the experiments were 
performed at different times of about a year apart (this study and the long-term study).  
We are more in favour of there being a genetic difference between the two mouse 
strains, as genetic drift is known to occur in NOD mice (Simecek et al., 2015). The 
original NOD mice strains from Japan were dispensed to various laboratories around 
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the world in the 1980s. The NODk used in this study were originally from a gift of the 
Wicker laboratory from mice received by Taconic Laboratories. Taconic received their 
strain from Japan in 1985 (Podolin et al., 1993). The NOD.ShiLtJArc mice used to 
refresh our NODk colony creating the NODk-REF mice originate from a NOD 
substrain sent to the Joslin Diabetes Centre in 1984 and from there set up at Jackson 
Laboratories from where ARC obtain their NOD mice (Laboratory, 2014). 
The question arises as to what implications these findings have on the original 
hypothesis and objectives of this thesis. If for example a mutation has come into the 
NODk mice, that is not present in the NODk-REF mice, then this additional mutation is 
not required by NOD mice for type 1 diabetes pathogenesis, as NOD.ShiLtJArc (which 
will not have this mutation) do develop type 1 diabetes. However, it was apparent in 
NODk-REF mice, which they do have abnormal glucose tolerance on HF-feeding and 
the insulin responses of these mice to ip glucose is not normal. It could be that there is 
an important islet -cell non-immune susceptibility factor in both strains of NODk 
mice, but that both ( others) susceptibility factors interact to cause a more profound 
islet  -cell phenotype. 
The interpretation of the results of the published NODk.insHEL study also needs to be 
interpreted in the light of the findings of the NODk and NODk-REF findings of this 
thesis for the same reasons (Dooley et al., 2016), as a specific genetic defect in the 
NODk background of the T2D diabetes prone NODk.insHEL mice, may not be present 
in the they NOD . 
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Directions 
 
 
 
 
 
 
 
207 
 
 
7.1. Final discussion 
 
The majority of research into preventing type 1 diabetes is focused on modulating 
immunological aspects of the disease. The main hypothesis of this thesis underlying the 
objectives, however, was that non-immune -cell susceptibility factors contribute to the 
initiation of islet -cell damage, followed by immune attack, in the pathogenesis of type 
1 diabetes in NOD mice. If correct, the importance would be that alternative or 
“adjuvant” non-immunological approaches to type 1 diabetes prevention could also be 
developed.  
The main research tool used to explore the main aim was the NODk mouse model, 
which is congenic for H2k, a low risk MHC allele for type 1 diabetes. On a chow diet, 
NODk mice have excellent glucose tolerance and clearly are resistant to the 
development of insulitis and type 1 diabetes, as has previously been reported and was 
confirmed in experiments within this thesis (Podolin et al., 1993, Dooley et al., 2016). 
This on its own would suggest that islet -cells of NODk are completely normal within 
non-immune diabetes susceptibility factors.  However, this is not the case as stressing 
their islet -cells by (i) overexpressing the HEL gene specifically in the -cells (from 
previous work from our laboratory) or (ii) by feeding the mice a HF-diet does induce 
diabetes, at least in males, with clear evidence of -cell failure (Dooley et al., 2016). In 
the study of HEL overexpression, the potential role for islet autoimmune attack as the 
cause of the diabetes within male NODk.insHEL mice was excluded through extensive 
experimentation, including experiments with immune-incompetent mice (Dooley et al., 
2016). The histological experiments in this thesis are also supportive of this conclusion, 
however, the presence of some peri-islet inflammatory collections in HF-fed NODk 
does not permit a strong conclusion with respect to absence of autoimmune attack as 
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was possible from the previous work (Dooley et al., 2016). Thus, taken together, the 
previous work on male NODk.insHEL mice and the current work on male HF-fed NODk 
mice are supportive of the hypothesis. 
The most striking feature of diabetic male HF-fed NODk mice was how well they 
resemble the phenotype of human type 2 diabetes (DeFronzo, 2009, Nolan et al., 2011). 
These mice developed diet-induced obesity, profound hyperinsulinemia, dyslipidemia 
and became frankly diabetic. Thus, this mouse model is closely related to the NOD 
mouse model of type 1 diabetes, with just a change in its MHC such that it is resistant to 
autoimmune islet attack, develops type 2 diabetes when challenged with a poor diet. 
Thus, this work is also supportive of the hypothesis of there being overlap in islet -cell 
susceptibility to type 1 and type 2 diabetes (Nolan and Delghingaro-Augusto, 2014, 
Tuomi et al., 2014). 
The studies of the NODk-REF strain of mice, however, showed a very different 
phenotype with HF-feeding. These mice were resistant to the development of diabetes, 
even though they had many of the same features of the NODk mice. The NODk-REF 
mice did develop diet-induced obesity, hyperinsulinemia and at least moderately severe 
glucose intolerance, albeit, not to the same degree and as quickly as the NODk mice. 
The pattern of insulin response to intraperitoneal glucose in male HF-fed NODk-REF 
mice was very similar to that of the NODk mice consistent with an abnormal response of 
islet -cells. The major difference between NODk mice and NODk-REF mice was that, 
with HF-feeding, the latter maintain perfectly normal fed-state blood glucose levels out 
to 24 weeks of age (i.e. after 20 weeks of HF-feeding).  
This hints that the NODk mice have at least one additional diabetes susceptibility factor 
compared to NODk-REF mice. Obviously, this creates an opportunity to explore this 
extra factor through further experiments, but it also clouds the interpretation of the main 
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objective of the thesis. Considering that NOD.ShiLtJArc, that were used to refresh our 
NODk mice, do develop type 1 diabetes, then the additional susceptibility factor in 
NODk mice cannot be necessary for type 1 diabetes development. This also illustrates 
the challenges in interpreting results from murine models of diabetes due to the marked 
interactions between genome and environment, with an indication that the gut 
microbiome in particular is a significant component in these interactions (Ussar et al., 
2015). Also, the pathophysiology of all forms of diabetes, other than the infrequent 
monogenic forms, is invariably a consequence of the interaction of multiple genetic risk 
factors (Tuomi et al., 2014). It is certainly possible that in NODk mice, there are 
multiple non-immune islet -cell susceptibility factors, and that one additional factor (or 
other environmental factor) interacts making this particular mouse more susceptible to 
-cell failure. 
The histological analyses of the NODk mice provide some clues to why diabetes 
develops. As in the NODk.insHEL studies in which increased -cell apoptosis was seen, 
the HF-fed NODk mice had evidence of islet endocrine cell apoptosis (Dooley et al., 
2016). This was seen on the H&E sections, such that it is not proven that it was in -
cells, however, the  reduction in islet -cell mass seen in the insulin immuno-stained 
sections of the HF-fed NODk mice pancreases from the long-term study is consistent 
with it being -cell apoptosis. Further investigation of the apoptosis with immuno-
staining for activated caspase-3 is planned. The mechanisms underlying this increased 
likelihood of -cell apoptosis in NODk mice is of importance, but was beyond the scope 
of this thesis. 
The results of the B10k mice were also much unexpected, but extremely interesting. 
They had very poor glucose tolerance, even on chow diet. For this reason we included 
Balb/c mice in the work of the thesis, as a more normal comparator strain. The B10k 
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mice developed much worse glucose tolerance when stressed with the HF-diet, but the 
remarkable finding was they did not develop diabetes as determined by the 9 AM 
fasting blood glucose level. As glucose tolerance was so severe after 10 weeks of HF-
feeding, the long-term study was performed to determine if they would be still non-
diabetic after 20 weeks of HF-feeding. The results were the same, the B10k mice have 
poor glucose tolerance, but are very diabetes resistant. The B10k mice did not seem to 
have a reduction in -cell mass, but they failed to secrete insulin well. In fact, they 
showed a minimal compensatory response to HF-feeding. It is almost as if this poor -
cell response is protective of the mice developing complete islet -cell failure. It is 
reasonable to conclude that this strain is a insulin hypo-secreting strain compared to the 
NODk mice which insulin hyper-secrete. The islet -cell has been described as being 
fuel responsive and vulnerable (Nolan and Prentki, 2008). As the islet -cells of the 
B10k mice are poorly fuel responsive, they may be less vulnerable. There has been 
much interest in the hypothesis that insulin hyper-secretion is a risk factor for islet -
cell failure (Andrikopoulos, 2010). The B10k mouse could be used in future to further 
evaluate this hypothesis. 
Another peculiarity of the B10k mice, was their propensity to develop fasting 
hyperglycaemia (as on the day of the ipGTT), when fed-state glycaemia was normal. 
This could have been due to different effects of stress or perhaps an effect on the 
insulin/glucagon ratio.  
The Balb/c mice were remarkable in their maintenance of normal glucose tolerance 
even after 20 weeks of HF-feeding. In comparing the three mice strains, it is of interest 
to see the differences in sites of fat accumulation. The Balb/c mice were less likely to 
accumulate subcutaneous fat, but avidly developed intra-pancreatic fat deposits. There 
has been recent interest in the potential pathogenic effects of intra-pancreatic fat, but 
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these results suggest that it could be much more benign (van der Zijl et al., 2010, Chen 
et al., 2015, Heni et al., 2010, Della Corte et al., 2015). The reason Balb/c mice are 
diabetes resistant compared to many other mouse strains is also of interest and warrants 
further research. 
7.2. Limitations  
The completed work of thesis includes detailed physiological phenotyping of the three 
strains of mice on chow and high fat diet. With respect to determining mechanisms 
between the strains, we did demonstrate differences in pancreatic islet histological 
features and -cell mass. Of particular interest was the increased rates of islet endocrine 
cell apoptosis in HF-fed NODk mice. Unfortunately, due to lack of time, mechanistic 
experiments on isolated pancreatic islets, that were originally planned, could not be 
performed. The experiments we did plan are included in the future directions section. 
In the physiological studies, some limitations in interpretation come from the ipGTT 
and ipITT assessments that were performed. The ipGTT, as compared to the oGTT, 
does not assess the effects of the incretin hormone system on glucose-stimulated insulin 
secretion. Furthermore, we did not measure incretin hormones due to an inability to 
sample more blood volume. An advantage of the ipGTT, however, was consistency in 
testing compared to variable glucose absorption rates and animal stress with the oGTT. 
The intravenous GTT would also provide additional information of islet -cell function. 
Also the hyperinsulinemia euglycaemic clamp, if performed, would have given a more 
gold standard assessment of insulin sensitivity. Again, this test was not performed 
because of the technical challenges associated with this test and the large number of 
experimental groups. 
One of the unexpected findings was the very abnormal glucose tolerance of the B10k 
mice, but their resistance to the development of diabetes, as determined by the morning 
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fed glucose. We hypothesize that this is due to resistance of the -cells to failure. We 
would have liked to age these mice further to determine if they do eventually develop 
diabetes. 
7.3. Future directions 
There is more work to be performed to determine the mechanisms of the findings of this 
thesis. Islets were harvested for the assessment of islet gene expression at the mRNA 
level, including genes of islet differentiation, islet function, endoplasmic reticulum 
stress, mitochondrial stress and inflammation. This work needs to be completed. The 
dual immunohistochemistry for insulin and activated caspase-3 needs to be performed. 
The pancreases of the NODk-REF need to be assessed histologically to determine if the 
difference between this strain and the NODk is on islet -cell mass. 
All the insulin secretion data of this thesis is from in vivo experiments using the ipGTT. 
It is important that the differences in insulin secretion of the three strains is investigated 
in freshly isolated islets in vitro. Particular interest will need to focus on whether the 
islet -cell of the NODk mice are hyper-secretors as opposed to the B10k mice being 
hypo-secretors. At which part of the nutrient sensing, insulin secretion coupling 
processes and insulin exocytosis pathways of -cell function will need to be explored. 
The very unexpected finding of the B10k resistance to diabetes development is of 
particular interest. If the reason for this resistance can be determined, this may lead to 
quite novel approaches to the prevention of type 2 diabetes in particular. 
The NODk-REF findings were also very unexpected. This provides a real opportunity to 
determine what must be a very strong diabetogenic factor in NODk mice. It is likely to 
be related to an increased propensity for -cell apoptosis. As the genetic background of 
NODk-REF and NODk should be fairly similar, an approach to determine the potential 
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genetic factor causing this difference should not be too difficult with modern gene 
sequencing approaches. 
Finally, the work of this thesis is supportive of the NODk mice having perhaps multiple 
non-immune susceptibility factors. This is really exciting for future research into type 1 
diabetes, as combining therapies to modulate immunological and non-immunological 
factors for diabetes prevention are clearly possible. More focus on the non-immune 
mechanisms of -cell susceptibility in mouse models and importantly also in humans is 
a very worthy direction for future research. 
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Appendix I 
The constituents and preparation of solution mentioned in the Materials and Methods 
Chapter are shown.  
General Solutions 
Phosphate Buffered Saline (PBS) 
For preparation of 1 L, the following was added: 
1 L of MilliQH2O 
2 PBS tablets                 (Medicago AB, Uppsala, Sweden) 
Solution was sterile-filtered using 0.22µm filter and stored at 4°C. 
 
HEPES 1M 
HEPES               238.4g       (Sigma Aldrich, CA, USA)    
 
dH2O                  1000ml 
 
Phosphate buffer 
Final volume                       (1 litre) 
9.3 g of EDTA                     (Sigma Aldrich, CA, USA) 
6.9 g of NaH2PO4                (Cat# S5011, Sigma Aldrich, St.Leus,, USA) 
 0.1g   Thimerosal (0.01%)  (Cat# T5125, Sigma Aldrich, St.Leus,, USA) 
(Light sensitive product) 
 
Solution was pH adjusted to 7.5 using NaOH 10mmol/L to 1 L using dH2O then was 
sterile-filtered using 20µm filter. The bottle containing the solution was wrapped in 
aluminium foil and stored at 4°C. 
PEG phosphate buffer     (Phosphate buffer + PEG 3%) 
30g of PEG 8000 (polyethylene glycol)   (Cat #P2139, Sigma Aldrich, CA, USA)  
1000 ml phosphate buffer 
Keep at 4°C. 
BSA phosphate buffer (Phosphate buffer + 1% BSA) 
10 g BSA- RIA grade (Sigma: A-7888) 
1000 ml phosphate buffer 
Keep at 4
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Appendix 2 
H& E Scoring sheet 
 
mouse ID Diet Blinded  ID Scoring parameter
pancreas (0=normal 1= abnormal)
pancreas (0 =none;1= acute inflammation ;2 - saponification and acute 
inflammation 3= chronic inflammation; 4=1 and 3)
pancreas - severity of acute inflammation  ( 1= minimal 2=mild 3= moderate 4= 
severe)
pancreas - severity of chronic inflammation ( 1= minimal 2=mild 3= moderate 4= 
severe)
location of inflammation (1-lobule; 2= periductal; 3= perislet; 4=1 and 2; 5= 2 and 
3; 6= all
periductal inflammation (1=<10% of ducts affects ; 2=10=50%; 3= >50%)
pancreas fat (0= absent 1= present) 
fat in exocrine pancreas ( 1= infrequent 2 = mild (some) 3= moderate 4=severe)
islets (0=normal; 1= abnormal)
H&E Islet structure (1 normal, 2 some islets mildly dysmorphic, 3 some islets 
moderately dysmorphic, 4 some islets severely dysmorphic 5= small)
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Appendix 3 
Calculation of beta-cell mass: 
1. % β-cell area per pancreas= Islet Sum Area x 100 
                                                               Pancreas Area 
2. Average number of the % β-cell area per pancreas (L1,L2 and L3) 
 
3. % β-cell (average from all levels) X weight of the pancreas (mg) 
                    100 
 
